{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import sys\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "ourdata = pd.read_csv('data/drug_riskscores.csv')\n",
    "ourdata['drug'] = ourdata['drug'].str.lower()\n",
    "drugs = list(ourdata['drug'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from calc_relative_risks_drugs import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug target 1,25(oh)2d3 not found. Exiting ...\n",
      "\n",
      "Drug target 17-hydroxyprogesterone not found. Exiting ...\n",
      "\n",
      "Drug target 18f-flutemetamol not found. Exiting ...\n",
      "\n",
      "Drug target 2-hydroxysuccinaldehyde not found. Exiting ...\n",
      "\n",
      "Drug target 4-ap not found. Exiting ...\n",
      "\n",
      "Drug target 4-methylpyrazole not found. Exiting ...\n",
      "\n",
      "Drug target 5-asa not found. Exiting ...\n",
      "\n",
      "Drug target 5-fu not found. Exiting ...\n",
      "\n",
      "Drug target 5-aminolevulinic not found. Exiting ...\n",
      "\n",
      "Drug target 5-aza-2'-deoxycytidine not found. Exiting ...\n",
      "\n",
      "Drug target 5-azacytidine not found. Exiting ...\n",
      "\n",
      "Drug target a77 not found. Exiting ...\n",
      "\n",
      "Drug target acth(1-39 not found. Exiting ...\n",
      "\n",
      "Drug target amd3100 not found. Exiting ...\n",
      "\n",
      "Drug target an2690 not found. Exiting ...\n",
      "\n",
      "Drug target abarelix not found. Exiting ...\n",
      "\n",
      "Drug target anidulafungin not found. Exiting ...\n",
      "\n",
      "Drug target bcnu not found. Exiting ...\n",
      "\n",
      "Drug target benicar-hct not found. Exiting ...\n",
      "\n",
      "Drug target bivalirudin not found. Exiting ...\n",
      "\n",
      "Drug target cas not found. Exiting ...\n",
      "\n",
      "Drug target cgp not found. Exiting ...\n",
      "\n",
      "Drug target cancidas not found. Exiting ...\n",
      "\n",
      "Drug target carfilzomib not found. Exiting ...\n",
      "\n",
      "Drug target colimycin not found. Exiting ...\n",
      "\n",
      "Drug target d-penicillamine not found. Exiting ...\n",
      "\n",
      "Drug target dfmo not found. Exiting ...\n",
      "\n",
      "Drug target enfuvirtide not found. Exiting ...\n",
      "\n",
      "Drug target eptifibatide not found. Exiting ...\n",
      "\n",
      "Drug target famp not found. Exiting ...\n",
      "\n",
      "Drug target fk463 not found. Exiting ...\n",
      "\n",
      "Drug target fty720 not found. Exiting ...\n",
      "\n",
      "Drug target fe(iii not found. Exiting ...\n",
      "\n",
      "Drug target forteo not found. Exiting ...\n",
      "\n",
      "Drug target ge-132 not found. Exiting ...\n",
      "\n",
      "Drug target goserelin not found. Exiting ...\n",
      "\n",
      "Drug target histrelin not found. Exiting ...\n",
      "\n",
      "Drug target hoe not found. Exiting ...\n",
      "\n",
      "Drug target humalog not found. Exiting ...\n",
      "\n",
      "Drug target ici not found. Exiting ...\n",
      "\n",
      "Drug target implanon not found. Exiting ...\n",
      "\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "Drug target k779 not found. Exiting ...\n",
      "\n",
      "Drug target l-dmp not found. Exiting ...\n",
      "\n",
      "Drug target l-threo-dops not found. Exiting ...\n",
      "\n",
      "Drug target lmwh not found. Exiting ...\n",
      "\n",
      "Drug target ly146032 not found. Exiting ...\n",
      "\n",
      "Drug target lantus not found. Exiting ...\n",
      "\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "Drug target lisinopril not found. Exiting ...\n",
      "\n",
      "Drug target lovaza not found. Exiting ...\n",
      "\n",
      "Drug target lu not found. Exiting ...\n",
      "\n",
      "Drug target lyxumia not found. Exiting ...\n",
      "\n",
      "Drug target mdv3100 not found. Exiting ...\n",
      "\n",
      "Drug target meropenem not found. Exiting ...\n",
      "\n",
      "Drug target metrodin not found. Exiting ...\n",
      "\n",
      "Drug target mndpdp not found. Exiting ...\n",
      "\n",
      "Drug target n-acetylcysteine not found. Exiting ...\n",
      "\n",
      "Drug target nafarelin not found. Exiting ...\n",
      "\n",
      "Drug target novolog not found. Exiting ...\n",
      "\n",
      "Drug target nuvocid not found. Exiting ...\n",
      "\n",
      "Drug target octreotide not found. Exiting ...\n",
      "\n",
      "Drug target oestrogen not found. Exiting ...\n",
      "\n",
      "Drug target optison not found. Exiting ...\n",
      "\n",
      "Drug target org not found. Exiting ...\n",
      "\n",
      "Drug target pci-32765 not found. Exiting ...\n",
      "\n",
      "Drug target pep005 not found. Exiting ...\n",
      "\n",
      "Drug target pge1 not found. Exiting ...\n",
      "\n",
      "Drug target pge2 not found. Exiting ...\n",
      "\n",
      "Drug target photofrin not found. Exiting ...\n",
      "\n",
      "Drug target promacta not found. Exiting ...\n",
      "\n",
      "Drug target refludan not found. Exiting ...\n",
      "\n",
      "Drug target revasc not found. Exiting ...\n",
      "\n",
      "Drug target romidepsin not found. Exiting ...\n",
      "\n",
      "Drug target som230 not found. Exiting ...\n",
      "\n",
      "Drug target su5416 not found. Exiting ...\n",
      "\n",
      "Drug target saxagliptin not found. Exiting ...\n",
      "\n",
      "Drug target signifor not found. Exiting ...\n",
      "\n",
      "Drug target stalevo not found. Exiting ...\n",
      "\n",
      "Drug target supremon not found. Exiting ...\n",
      "\n",
      "Drug target tmc207 not found. Exiting ...\n",
      "\n",
      "Drug target tmc435 not found. Exiting ...\n",
      "\n",
      "Drug target tr-700 not found. Exiting ...\n",
      "\n",
      "Drug target tadenan not found. Exiting ...\n",
      "\n",
      "Drug target triptorelin not found. Exiting ...\n",
      "\n",
      "Drug target udca not found. Exiting ...\n",
      "\n",
      "Drug target vacv not found. Exiting ...\n",
      "\n",
      "Drug target vancocine not found. Exiting ...\n",
      "\n",
      "Drug target vitrum not found. Exiting ...\n",
      "\n",
      "Drug target westcort not found. Exiting ...\n",
      "\n",
      "Drug target abacavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó abiraterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -9.371 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: quinaprilat with relative risk of -13.197 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: prazosin with relative risk of -17.075 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nimodipine with relative risk of -27.638 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acamprosate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pemetrexed with relative risk of -9.932 of acamprosate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vinorelbine with relative risk of -10.020 of acamprosate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: treprostinil with relative risk of -10.301 of acamprosate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gabapentin with relative risk of -10.853 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: sertraline with relative risk of -11.014 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acebutolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -6.516 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: nilotinib with relative risk of -6.857 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etoposide with relative risk of -7.383 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Admin\\OneDrive\\Masa√ºst√º\\SYSBIO\\p\\459-drug-proj\\calc_relative_risks_drugs.py:24: RuntimeWarning: divide by zero encountered in log\n",
      "  drug_df['scaled_risk_score_log'] = np.log(drug_df.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rank 4: posaconazole with relative risk of -7.626 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: trimethoprim with relative risk of -7.724 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ribavirin with relative risk of -7.776 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: brinzolamide with relative risk of -7.817 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentoxifylline with relative risk of -7.823 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: aripiprazole with relative risk of -7.835 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: adenosine with relative risk of -8.023 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: tazarotene with relative risk of -8.192 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: brimonidine with relative risk of -8.310 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: amlexanox with relative risk of -8.704 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: lapatinib with relative risk of -8.720 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: granisetron with relative risk of -8.808 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: carbamazepine with relative risk of -8.905 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: meloxicam with relative risk of -8.953 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ondansetron with relative risk of -8.979 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rabeprazole with relative risk of -8.999 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ranolazine with relative risk of -9.040 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: labetalol with relative risk of -9.081 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 22: triamcinolone with relative risk of -9.122 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: nalbuphine with relative risk of -9.287 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: darunavir with relative risk of -9.390 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: oxybutynin with relative risk of -9.434 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: betaxolol with relative risk of -9.492 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 27: fluconazole with relative risk of -9.530 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: tropisetron with relative risk of -9.583 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pravastatin with relative risk of -9.713 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 30: tolterodine with relative risk of -9.880 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tolcapone with relative risk of -9.917 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fenofibrate with relative risk of -9.926 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: diltiazem with relative risk of -9.968 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 34: ziprasidone with relative risk of -10.061 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: eletriptan with relative risk of -10.218 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: estramustine with relative risk of -11.883 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: erlotinib with relative risk of -13.171 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: gefitinib with relative risk of -13.637 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: metronidazole with relative risk of -13.646 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: duloxetine with relative risk of -14.187 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: dabrafenib with relative risk of -14.274 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: milnacipran with relative risk of -14.382 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: everolimus with relative risk of -14.600 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: eliglustat with relative risk of -14.744 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: conivaptan with relative risk of -14.911 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: umeclidinium with relative risk of -14.915 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cilostazol with relative risk of -14.941 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: famotidine with relative risk of -15.053 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: glipizide with relative risk of -15.157 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: propafenone with relative risk of -16.003 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: fluocinonide with relative risk of -16.140 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: terazosin with relative risk of -16.256 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 53: dutasteride with relative risk of -16.324 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: risedronate with relative risk of -17.829 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: rivastigmine with relative risk of -18.254 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: varenicline with relative risk of -18.580 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ropinirole with relative risk of -18.754 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: fluoxetine with relative risk of -19.844 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: metoprolol with relative risk of -20.307 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 60: flutamide with relative risk of -20.482 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: omeprazole with relative risk of -20.577 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: disopyramide with relative risk of -20.593 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: sulfasalazine with relative risk of -21.098 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: flecainide with relative risk of -21.453 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 65: rofecoxib with relative risk of -21.876 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: bisoprolol with relative risk of -22.169 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 67: ramipril with relative risk of -22.328 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 68: candesartan with relative risk of -22.454 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 69: rocuronium with relative risk of -22.464 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: quinapril with relative risk of -23.100 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: raloxifene with relative risk of -24.774 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: felbamate with relative risk of -27.617 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: terbutaline with relative risk of -27.702 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: dexmedetomidine with relative risk of -29.424 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: nateglinide with relative risk of -29.640 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: axitinib with relative risk of -31.637 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: idarubicin with relative risk of -31.647 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: mifepristone with relative risk of -32.675 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: trandolapril with relative risk of -32.882 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 80: pitavastatin with relative risk of -33.010 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: delavirdine with relative risk of -33.359 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: bromocriptine with relative risk of -33.849 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: nedocromil with relative risk of -34.022 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: glimepiride with relative risk of -34.063 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: frovatriptan with relative risk of -34.546 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: vilazodone with relative risk of -34.615 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: montelukast with relative risk of -34.664 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: fesoterodine with relative risk of -34.968 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: dapagliflozin with relative risk of -35.117 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: apixaban with relative risk of -36.115 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 91: pioglitazone with relative risk of -37.056 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -37.217 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: raltitrexed with relative risk of -40.651 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: leflunomide with relative risk of -44.384 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: silodosin with relative risk of -47.047 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: gemfibrozil with relative risk of -47.087 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 97: dalbavancin with relative risk of -47.115 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: capsaicin with relative risk of -47.438 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: flumazenil with relative risk of -52.114 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: telithromycin with relative risk of -53.519 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: rosuvastatin with relative risk of -72.114 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 102: indomethacin with relative risk of -79.812 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: belinostat with relative risk of -90.590 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: mirtazapine with relative risk of -91.131 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: lansoprazole with relative risk of -91.316 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: rosiglitazone with relative risk of -101.388 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: mafenide with relative risk of -104.577 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: nelarabine with relative risk of -114.307 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: teniposide with relative risk of -119.595 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: budesonide with relative risk of -121.085 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: azathioprine with relative risk of -162.045 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: pinaverium with relative risk of -167.361 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: fosinoprilat with relative risk of -168.654 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 114: tasimelteon with relative risk of -183.691 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: mometasone with relative risk of -185.827 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: sparfloxacin with relative risk of -269.962 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: efinaconazole with relative risk of -inf of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.308\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target acetaminophen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acitretin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: deferasirox with relative risk of -12.436 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nifedipine with relative risk of -12.919 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: scopolamine with relative risk of -13.221 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: propranolol with relative risk of -13.246 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicotine with relative risk of -13.313 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: avanafil with relative risk of -13.329 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aclidinium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -9.493 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: desloratadine with relative risk of -11.458 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: salmeterol with relative risk of -11.597 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 4: dabigatran with relative risk of -11.929 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.16\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target actinomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acyclovir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: milrinone with relative risk of -11.540 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: imatinib with relative risk of -16.251 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adapalene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -11.380 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -11.672 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trospium with relative risk of -12.809 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rotigotine with relative risk of -13.343 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target adefovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adenosine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: belinostat with relative risk of -9.670 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -9.764 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: nelarabine with relative risk of -9.851 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sparfloxacin with relative risk of -9.864 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: budesonide with relative risk of -10.009 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rosiglitazone with relative risk of -10.079 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirtazapine with relative risk of -10.211 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: azathioprine with relative risk of -10.518 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rosuvastatin with relative risk of -10.766 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: leflunomide with relative risk of -10.847 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -10.933 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dalbavancin with relative risk of -10.975 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pioglitazone with relative risk of -11.064 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromocriptine with relative risk of -11.269 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ropinirole with relative risk of -11.456 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: gemfibrozil with relative risk of -11.606 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: everolimus with relative risk of -11.615 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: raltitrexed with relative risk of -11.617 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: apixaban with relative risk of -11.911 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: omeprazole with relative risk of -12.079 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: dapagliflozin with relative risk of -12.537 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pinaverium with relative risk of -12.617 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fosinoprilat with relative risk of -12.853 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.109\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó afatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.108 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -8.322 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: cyclophosphamide with relative risk of -8.391 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: danazol with relative risk of -9.425 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: glycopyrrolate with relative risk of -9.598 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: desloratadine with relative risk of -10.073 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: topotecan with relative risk of -10.141 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: telmisartan with relative risk of -10.171 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: salmeterol with relative risk of -10.211 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ritonavir with relative risk of -11.098 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: torasemide with relative risk of -11.290 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bromfenac with relative risk of -23.260 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.315\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó albendazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.810 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilutamide with relative risk of -11.672 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: fluvoxamine with relative risk of -12.779 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azilsartan with relative risk of -13.967 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alendronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -10.479 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: macitentan with relative risk of -11.639 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -11.664 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metolazone with relative risk of -11.959 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phenytoin with relative risk of -12.213 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atomoxetine with relative risk of -12.414 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: empagliflozin with relative risk of -12.449 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lamotrigine with relative risk of -12.487 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sumatriptan with relative risk of -12.661 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pimozide with relative risk of -12.759 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cytarabine with relative risk of -21.487 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ketorolac with relative risk of -23.105 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target alfentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alfuzosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.118 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -10.979 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: carvedilol with relative risk of -11.310 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lovastatin with relative risk of -13.425 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paliperidone with relative risk of -18.570 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: indapamide with relative risk of -20.166 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paroxetine with relative risk of -20.798 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: alosetron with relative risk of -21.838 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target aliskiren not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó allopurinol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -8.364 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: clonidine with relative risk of -8.937 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bupivacaine with relative risk of -10.330 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: didanosine with relative risk of -10.854 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nelfinavir with relative risk of -11.248 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: tofacitinib with relative risk of -11.299 of allopurinol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 7: perindopril with relative risk of -18.294 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: verapamil with relative risk of -21.531 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pindolol with relative risk of -22.077 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amiodarone with relative risk of -29.463 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.057\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó almotriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pergolide with relative risk of -11.215 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: citalopram with relative risk of -11.586 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dapsone with relative risk of -12.342 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -12.394 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -17.246 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -19.210 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -19.532 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxapine with relative risk of -20.494 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: salmeterol with relative risk of -20.553 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -21.267 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -21.507 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: emedastine with relative risk of -21.624 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: estradiol with relative risk of -22.393 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pramipexole with relative risk of -22.677 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: tegaserod with relative risk of -23.025 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.217\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alogliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: oxcarbazepine with relative risk of -10.063 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -13.242 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lidocaine with relative risk of -18.870 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etravirine with relative risk of -24.388 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loperamide with relative risk of -25.860 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentostatin with relative risk of -38.330 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paclitaxel with relative risk of -41.454 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: doxercalciferol with relative risk of -57.029 of alogliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: tizanidine with relative risk of -61.731 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ruxolitinib with relative risk of -63.170 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.043\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alosetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target alprazolam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ambrisentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -10.417 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -11.382 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vernakalant with relative risk of -11.588 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indinavir with relative risk of -11.986 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -12.361 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nisoldipine with relative risk of -12.372 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: iloprost with relative risk of -12.393 of ambrisentan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 9: valdecoxib with relative risk of -12.749 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: degarelix with relative risk of -12.858 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: reboxetine with relative risk of -13.131 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.041\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amiloride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zileuton with relative risk of -9.714 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: doxorubicin with relative risk of -10.163 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: letrozole with relative risk of -11.417 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tafluprost with relative risk of -11.436 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: prazosin with relative risk of -17.075 of amiloride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: clozapine with relative risk of -17.634 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nimodipine with relative risk of -18.564 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.077\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aminophylline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 3: bosentan with relative risk of -10.044 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -11.054 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: paricalcitol with relative risk of -11.871 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ramelteon with relative risk of -11.876 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pergolide with relative risk of -11.908 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: apixaban with relative risk of -11.911 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: palonosetron with relative risk of -12.264 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sorafenib with relative risk of -12.311 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: esomeprazole with relative risk of -12.574 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clomipramine with relative risk of -12.701 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rilpivirine with relative risk of -13.450 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dihydroergotamine with relative risk of -13.714 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: canagliflozin with relative risk of -13.715 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.235\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amiodarone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -8.872 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: clonidine with relative risk of -9.447 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: bupivacaine with relative risk of -10.841 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: didanosine with relative risk of -11.365 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tofacitinib with relative risk of -11.810 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: verapamil with relative risk of -23.832 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: pindolol with relative risk of -24.377 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: allopurinol with relative risk of -29.426 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.298\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amisulpride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -10.839 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: guanfacine with relative risk of -12.067 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amlexanox *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -8.146 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.345 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indomethacin with relative risk of -8.549 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -8.669 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -8.769 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lubiprostone with relative risk of -8.874 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azathioprine with relative risk of -9.422 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: cyclobenzaprine with relative risk of -9.582 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nilotinib with relative risk of -9.642 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: gefitinib with relative risk of -10.245 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: simvastatin with relative risk of -10.493 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: trimethoprim with relative risk of -10.507 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: amlodipine with relative risk of -10.762 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tazarotene with relative risk of -10.983 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -11.520 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fosinoprilat with relative risk of -11.757 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: triamcinolone with relative risk of -11.915 of amlexanox | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Aphthous Stomatitis\n",
      "Rank 18: tolterodine with relative risk of -12.673 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: diltiazem with relative risk of -12.761 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ziprasidone with relative risk of -12.854 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.016\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amlodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indapamide with relative risk of -9.553 of amlodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: citalopram with relative risk of -10.334 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amlexanox with relative risk of -10.647 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pilocarpine with relative risk of -10.752 of amlodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: isradipine with relative risk of -11.141 of amlodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: indomethacin with relative risk of -25.346 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cyclobenzaprine with relative risk of -33.196 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lubiprostone with relative risk of -33.350 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: simvastatin with relative risk of -33.413 of amlodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Cerebrovascular accident,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.552\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amoxapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.522 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pergolide with relative risk of -10.810 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -10.986 of amoxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: citalopram with relative risk of -11.181 of amoxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 5: dapsone with relative risk of -11.937 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -11.988 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -16.147 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -18.112 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -18.433 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: salmeterol with relative risk of -19.455 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: regadenoson with relative risk of -20.168 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capecitabine with relative risk of -20.408 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: emedastine with relative risk of -20.525 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: estradiol with relative risk of -21.295 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pramipexole with relative risk of -21.578 of amoxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: tegaserod with relative risk of -21.926 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -22.346 of amoxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.206\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amoxicillin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ketoprofen with relative risk of -11.547 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -11.672 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: flunisolide with relative risk of -13.237 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target amphotericin not found. Exiting ...\n",
      "\n",
      "Drug target amprenavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amsacrine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cladribine with relative risk of -27.819 of amsacrine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: apremilast with relative risk of -38.036 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: losartan with relative risk of -53.373 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.545\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó anagrelide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -7.127 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -9.058 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -9.159 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -9.234 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: miglustat with relative risk of -9.524 of anagrelide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 7: atosiban with relative risk of -9.718 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gonadorelin with relative risk of -9.926 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -10.045 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: halofantrine with relative risk of -10.767 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: hydrochlorothiazide with relative risk of -11.205 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: norfloxacin with relative risk of -18.600 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fondaparinux with relative risk of -19.194 of anagrelide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 14: iloperidone with relative risk of -25.715 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: indomethacin with relative risk of -68.164 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lubiprostone with relative risk of -70.193 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: penbutolol with relative risk of -81.272 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: estramustine with relative risk of -83.658 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cabergoline with relative risk of -86.227 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mirabegron with relative risk of -89.143 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: moxifloxacin with relative risk of -89.589 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nabumetone with relative risk of -89.786 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.066\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó anastrozole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.235 of anastrozole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: bosentan with relative risk of -8.659 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dronedarone with relative risk of -9.669 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: balsalazide with relative risk of -9.995 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paricalcitol with relative risk of -10.485 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pergolide with relative risk of -10.522 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: palonosetron with relative risk of -10.878 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.386\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target anthracycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apixaban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -7.321 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bosentan with relative risk of -7.745 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: flumazenil with relative risk of -7.883 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ixabepilone with relative risk of -8.430 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -8.755 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: fludarabine with relative risk of -8.974 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: fluoxetine with relative risk of -9.044 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: balsalazide with relative risk of -9.081 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: orlistat with relative risk of -9.121 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nedocromil with relative risk of -9.140 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: glimepiride with relative risk of -9.182 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: felbamate with relative risk of -9.206 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: silodosin with relative risk of -9.266 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: telithromycin with relative risk of -9.288 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: everolimus with relative risk of -9.313 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of -9.421 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: aminophylline with relative risk of -9.523 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: paricalcitol with relative risk of -9.570 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ramelteon with relative risk of -9.576 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: pergolide with relative risk of -9.607 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: adenosine with relative risk of -9.612 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: capsaicin with relative risk of -9.657 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: vilazodone with relative risk of -9.733 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: glipizide with relative risk of -9.870 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: palonosetron with relative risk of -9.962 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rofecoxib with relative risk of -9.979 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sorafenib with relative risk of -10.008 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: esomeprazole with relative risk of -10.272 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: clomipramine with relative risk of -10.399 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: ramipril with relative risk of -10.431 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 31: rocuronium with relative risk of -10.567 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: nevirapine with relative risk of -10.934 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: rilpivirine with relative risk of -11.147 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: quinapril with relative risk of -11.203 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 35: dihydroergotamine with relative risk of -11.411 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 36: canagliflozin with relative risk of -11.412 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: loteprednol with relative risk of -11.738 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: trametinib with relative risk of -12.111 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fosinopril with relative risk of -12.203 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 40: dalbavancin with relative risk of -14.829 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: estramustine with relative risk of -15.128 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: raloxifene with relative risk of -15.604 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: gemfibrozil with relative risk of -16.064 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: bromocriptine with relative risk of -16.132 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: terbutaline with relative risk of -16.744 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: omeprazole with relative risk of -17.229 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: duloxetine with relative risk of -17.449 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: milnacipran with relative risk of -17.644 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: naproxen with relative risk of -17.893 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: conivaptan with relative risk of -18.173 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: umeclidinium with relative risk of -18.177 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: meloxicam with relative risk of -18.396 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: desvenlafaxine with relative risk of -18.669 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 54: topiramate with relative risk of -18.799 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: dexmedetomidine with relative risk of -19.026 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: domperidone with relative risk of -20.189 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: rosuvastatin with relative risk of -21.591 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 58: dexamethasone with relative risk of -21.628 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology,neurology/psychiatry\n",
      "Rank 59: nateglinide with relative risk of -22.600 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: pioglitazone with relative risk of -22.650 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: axitinib with relative risk of -22.992 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: raltitrexed with relative risk of -23.945 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: trandolapril with relative risk of -24.237 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 64: dapagliflozin with relative risk of -25.375 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: crizotinib with relative risk of -25.698 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: belinostat with relative risk of -27.043 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: mirtazapine with relative risk of -27.584 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 68: varenicline with relative risk of -32.005 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 69: acebutolol with relative risk of -35.557 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 70: mometasone with relative risk of -37.518 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: teniposide with relative risk of -39.300 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: risedronate with relative risk of -39.738 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: budesonide with relative risk of -40.790 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: nelarabine with relative risk of -40.937 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ropinirole with relative risk of -41.358 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: rosiglitazone with relative risk of -41.838 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pinaverium with relative risk of -42.102 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: azathioprine with relative risk of -47.398 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: leflunomide with relative risk of -47.942 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: fosinoprilat with relative risk of -49.220 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 81: sparfloxacin with relative risk of -58.403 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: tasimelteon with relative risk of -61.092 of apixaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.328\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target apomorphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apraclonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -8.576 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lubiprostone with relative risk of -9.278 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nizatidine with relative risk of -9.838 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ciprofloxacin with relative risk of -11.646 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apremilast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cladribine with relative risk of -10.012 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: losartan with relative risk of -35.748 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amsacrine with relative risk of -35.908 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target aprepitant not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó argatroban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -8.975 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cabazitaxel with relative risk of -9.706 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topotecan with relative risk of -10.429 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mitoxantrone with relative risk of -10.761 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ponatinib with relative risk of -10.877 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: piroxicam with relative risk of -12.392 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aripiprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -8.146 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -8.345 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: belinostat with relative risk of -8.573 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -8.669 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nelarabine with relative risk of -8.754 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -8.913 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rosiglitazone with relative risk of -8.982 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: flumazenil with relative risk of -9.085 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: mirtazapine with relative risk of -9.114 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: azathioprine with relative risk of -9.422 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dexamethasone with relative risk of -9.482 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: raloxifene with relative risk of -9.865 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pioglitazone with relative risk of -9.966 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: crizotinib with relative risk of -9.970 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bromocriptine with relative risk of -10.170 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: varenicline with relative risk of -10.183 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: ropinirole with relative risk of -10.358 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: apixaban with relative risk of -10.813 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: capsaicin with relative risk of -10.859 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: omeprazole with relative risk of -10.980 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: desvenlafaxine with relative risk of -11.323 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: topiramate with relative risk of -11.453 of aripiprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: meloxicam with relative risk of -11.742 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: domperidone with relative risk of -12.842 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fosinopril with relative risk of -13.406 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sparfloxacin with relative risk of -15.037 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: leflunomide with relative risk of -17.858 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: risedronate with relative risk of -18.098 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.251\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó asenapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vemurafenib with relative risk of -21.369 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rivaroxaban with relative risk of -23.182 of asenapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target atazanavir not found. Exiting ...\n",
      "\n",
      "Drug target atenolol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atomoxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etodolac with relative risk of -12.358 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ketorolac with relative risk of -13.050 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: empagliflozin with relative risk of -13.142 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lamotrigine with relative risk of -13.180 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pimozide with relative risk of -13.452 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: alendronate with relative risk of -13.888 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atorvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -8.465 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dabigatran with relative risk of -10.320 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tamsulosin with relative risk of -20.618 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.273\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atosiban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -9.645 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -9.970 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anagrelide with relative risk of -10.246 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cabergoline with relative risk of -10.838 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: penbutolol with relative risk of -11.183 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: rivastigmine with relative risk of -11.359 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: estramustine with relative risk of -11.361 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mirabegron with relative risk of -11.452 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -11.533 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: moxifloxacin with relative risk of -11.898 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -12.095 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: iloperidone with relative risk of -12.184 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: ranitidine with relative risk of -12.347 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: norfloxacin with relative risk of -13.045 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.177\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target atovaquone not found. Exiting ...\n",
      "\n",
      "Drug target atracurium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atropine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -10.789 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cabozantinib with relative risk of -12.382 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pantoprazole with relative risk of -13.521 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: calcipotriol with relative risk of -inf of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó auranofin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibutilide with relative risk of -12.655 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó avanafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: scopolamine with relative risk of -13.221 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: propranolol with relative risk of -13.246 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nicotine with relative risk of -13.313 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó axitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.393 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -8.564 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: erlotinib with relative risk of -9.086 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: varenicline with relative risk of -9.491 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -9.776 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rosuvastatin with relative risk of -15.812 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: leflunomide with relative risk of -16.249 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: raltitrexed with relative risk of -17.355 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 9: belinostat with relative risk of -21.736 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirtazapine with relative risk of -22.277 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: estramustine with relative risk of -23.593 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 12: apixaban with relative risk of -24.749 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluoxetine with relative risk of -26.668 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dapagliflozin with relative risk of -27.166 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: duloxetine with relative risk of -28.314 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: milnacipran with relative risk of -28.509 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rofecoxib with relative risk of -28.702 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: conivaptan with relative risk of -29.038 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: umeclidinium with relative risk of -29.042 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramipril with relative risk of -29.154 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: quinapril with relative risk of -29.925 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -32.837 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tasimelteon with relative risk of -34.335 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: azathioprine with relative risk of -36.323 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terbutaline with relative risk of -37.258 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: pinaverium with relative risk of -38.596 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sparfloxacin with relative risk of -41.452 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: mometasone with relative risk of -42.861 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: teniposide with relative risk of -44.645 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dexmedetomidine with relative risk of -45.854 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: budesonide with relative risk of -46.135 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: nelarabine with relative risk of -46.282 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fosinoprilat with relative risk of -47.041 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: rosiglitazone with relative risk of -47.184 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: nateglinide with relative risk of -52.762 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: trandolapril with relative risk of -57.396 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.132\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azathioprine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -5.615 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -7.122 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -7.332 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 4: nilotinib with relative risk of -7.487 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: crizotinib with relative risk of -7.812 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trimethoprim with relative risk of -8.352 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pentoxifylline with relative risk of -8.451 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: aripiprazole with relative risk of -8.467 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: adenosine with relative risk of -8.657 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tazarotene with relative risk of -8.825 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brimonidine with relative risk of -8.944 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: desvenlafaxine with relative risk of -9.164 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: topiramate with relative risk of -9.294 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: amlexanox with relative risk of -9.336 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: granisetron with relative risk of -9.441 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: carbamazepine with relative risk of -9.539 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ranolazine with relative risk of -9.672 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: labetalol with relative risk of -9.715 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: triamcinolone with relative risk of -9.755 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 20: nalbuphine with relative risk of -9.921 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: oxybutynin with relative risk of -10.068 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: betaxolol with relative risk of -10.126 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tolterodine with relative risk of -10.513 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: diltiazem with relative risk of -10.601 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: domperidone with relative risk of -10.683 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ziprasidone with relative risk of -10.695 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: eletriptan with relative risk of -10.851 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinopril with relative risk of -11.247 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: estramustine with relative risk of -13.158 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: bromocriptine with relative risk of -14.156 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: felbamate with relative risk of -14.682 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: gefitinib with relative risk of -14.922 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: omeprazole with relative risk of -15.253 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: duloxetine with relative risk of -15.473 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: milnacipran with relative risk of -15.667 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 36: everolimus with relative risk of -15.886 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: eliglustat with relative risk of -16.030 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: conivaptan with relative risk of -16.197 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: umeclidinium with relative risk of -16.200 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: meloxicam with relative risk of -16.420 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 41: glipizide with relative risk of -16.443 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: dutasteride with relative risk of -17.610 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: risedronate with relative risk of -19.783 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: rivastigmine with relative risk of -20.208 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: fluoxetine with relative risk of -21.801 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: disopyramide with relative risk of -22.551 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: sulfasalazine with relative risk of -23.056 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 48: flecainide with relative risk of -23.411 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: rofecoxib with relative risk of -23.834 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ramipril with relative risk of -24.286 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: candesartan with relative risk of -24.412 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: rocuronium with relative risk of -24.422 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: quinapril with relative risk of -25.058 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dexmedetomidine with relative risk of -27.357 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: varenicline with relative risk of -27.741 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ropinirole with relative risk of -27.915 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: nedocromil with relative risk of -28.816 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: glimepiride with relative risk of -28.858 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: vilazodone with relative risk of -29.409 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: terbutaline with relative risk of -30.354 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: nateglinide with relative risk of -33.003 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: axitinib with relative risk of -35.003 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: idarubicin with relative risk of -35.014 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: capsaicin with relative risk of -35.198 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 65: raloxifene with relative risk of -35.302 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: mifepristone with relative risk of -36.042 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: trandolapril with relative risk of -36.248 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: pitavastatin with relative risk of -36.376 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: delavirdine with relative risk of -36.726 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: frovatriptan with relative risk of -37.913 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: montelukast with relative risk of -38.031 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: fesoterodine with relative risk of -38.335 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: dapagliflozin with relative risk of -38.484 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: flumazenil with relative risk of -40.280 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: cisatracurium with relative risk of -40.584 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: telithromycin with relative risk of -41.684 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: raltitrexed with relative risk of -44.757 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: apixaban with relative risk of -47.835 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: leflunomide with relative risk of -49.255 of azathioprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 80: pioglitazone with relative risk of -49.472 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: silodosin with relative risk of -51.920 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: gemfibrozil with relative risk of -51.959 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dalbavancin with relative risk of -52.776 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: rosuvastatin with relative risk of -80.349 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: belinostat with relative risk of -91.618 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: mirtazapine with relative risk of -92.158 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: rosiglitazone with relative risk of -105.006 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: budesonide with relative risk of -109.183 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: nelarabine with relative risk of -120.068 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: teniposide with relative risk of -126.540 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: sparfloxacin with relative risk of -155.397 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: acebutolol with relative risk of -161.924 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: mometasone with relative risk of -179.211 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: fosinoprilat with relative risk of -188.136 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tasimelteon with relative risk of -189.288 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: pinaverium with relative risk of -195.880 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: efinaconazole with relative risk of -inf of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.095\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target azelaic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azelastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: imatinib with relative risk of -9.029 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bumetanide with relative risk of -10.400 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: gefitinib with relative risk of -11.343 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ipratropium with relative risk of -12.574 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azilsartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.810 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: colchicine with relative risk of -11.380 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilutamide with relative risk of -11.672 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: fluvoxamine with relative risk of -12.779 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: albendazole with relative risk of -13.428 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.438\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target azithromycin not found. Exiting ...\n",
      "\n",
      "Drug target aztreonam not found. Exiting ...\n",
      "\n",
      "Drug target baclofen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó balsalazide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.911 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: anastrozole with relative risk of -9.402 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: aminophylline with relative risk of -9.880 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: apixaban with relative risk of -9.967 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sorafenib with relative risk of -10.365 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clomipramine with relative risk of -10.755 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rilpivirine with relative risk of -11.504 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dihydroergotamine with relative risk of -11.768 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: canagliflozin with relative risk of -11.769 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ixabepilone with relative risk of -16.356 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: orlistat with relative risk of -17.741 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: esomeprazole with relative risk of -19.585 of balsalazide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 13: pergolide with relative risk of -25.978 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: palonosetron with relative risk of -28.125 of balsalazide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 15: fludarabine with relative risk of -34.706 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gemcitabine with relative risk of -38.781 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ramelteon with relative risk of -43.165 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dronedarone with relative risk of -49.759 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paricalcitol with relative risk of -55.411 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bosentan with relative risk of -59.363 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.043\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó beclomethasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zonisamide with relative risk of -13.285 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó belinostat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.726 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pioglitazone with relative risk of -8.429 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: aripiprazole with relative risk of -9.085 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: adenosine with relative risk of -9.276 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: carbamazepine with relative risk of -10.158 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ropinirole with relative risk of -15.392 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: felbamate with relative risk of -15.954 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: everolimus with relative risk of -17.159 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: eliglustat with relative risk of -17.303 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: glipizide with relative risk of -17.716 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dexmedetomidine with relative risk of -17.920 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dutasteride with relative risk of -18.883 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nateglinide with relative risk of -21.491 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -21.747 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: axitinib with relative risk of -21.882 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: telithromycin with relative risk of -22.065 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: raloxifene with relative risk of -22.182 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bromocriptine with relative risk of -22.997 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trandolapril with relative risk of -23.128 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nedocromil with relative risk of -23.170 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: glimepiride with relative risk of -23.212 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vilazodone with relative risk of -23.763 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fluoxetine with relative risk of -23.767 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: terbutaline with relative risk of -24.015 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: omeprazole with relative risk of -24.500 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rofecoxib with relative risk of -25.800 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ramipril with relative risk of -26.252 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rocuronium with relative risk of -26.388 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinapril with relative risk of -27.024 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: apixaban with relative risk of -28.947 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: capsaicin with relative risk of -30.427 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: flumazenil with relative risk of -36.068 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: leflunomide with relative risk of -36.732 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: gemfibrozil with relative risk of -38.338 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: raltitrexed with relative risk of -39.448 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dapagliflozin with relative risk of -41.976 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dalbavancin with relative risk of -50.450 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: rosuvastatin with relative risk of -51.029 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: silodosin with relative risk of -57.175 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: sparfloxacin with relative risk of -84.123 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: teniposide with relative risk of -85.876 of belinostat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 42: tasimelteon with relative risk of -88.706 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: acebutolol with relative risk of -91.936 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azathioprine with relative risk of -93.085 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: fosinoprilat with relative risk of -94.213 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: pinaverium with relative risk of -95.837 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -98.799 of belinostat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Lymphoma, T-Cell, Cutaneous\n",
      "Rank 48: budesonide with relative risk of -107.959 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: nelarabine with relative risk of -108.954 of belinostat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 50: rosiglitazone with relative risk of -111.909 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: mirtazapine with relative risk of -118.370 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.015\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó benazepril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: thalidomide with relative risk of -11.722 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: doxepin with relative risk of -16.467 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: verapamil with relative risk of -17.072 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: pindolol with relative risk of -17.458 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: clonidine with relative risk of -18.202 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: bupivacaine with relative risk of -20.895 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.32\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target benazeprilat not found. Exiting ...\n",
      "\n",
      "Drug target bendamustine not found. Exiting ...\n",
      "\n",
      "Drug target benzydamine not found. Exiting ...\n",
      "\n",
      "Drug target bepridil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó betaxolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: leflunomide with relative risk of -10.847 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: brimonidine with relative risk of -12.202 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Glaucoma, Open-Angle,Ocular Hypertension,ophthalmology\n",
      "Rank 15: pinaverium with relative risk of -12.617 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.841 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.853 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ranolazine with relative risk of -12.929 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: labetalol with relative risk of -12.973 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 20: oxybutynin with relative risk of -13.326 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eletriptan with relative risk of -14.109 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.101\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bexarotene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: iloperidone with relative risk of -11.086 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia\n",
      "Rank 2: lercanidipine with relative risk of -13.231 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cilazapril with relative risk of -13.532 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pamidronate with relative risk of -20.306 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 5: loperamide with relative risk of -24.282 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.547\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bezafibrate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.984 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lurasidone with relative risk of -12.638 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loxapine with relative risk of -12.863 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ivermectin with relative risk of -12.960 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -13.238 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: nicardipine with relative risk of -13.348 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: rasagiline with relative risk of -13.589 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.141\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bicalutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -6.573 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: lubiprostone with relative risk of -7.281 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levetiracetam with relative risk of -7.753 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nizatidine with relative risk of -7.834 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: afatinib with relative risk of -7.881 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: dalbavancin with relative risk of -8.274 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: colchicine with relative risk of -8.673 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indapamide with relative risk of -8.792 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: darifenacin with relative risk of -8.809 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -8.830 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -8.995 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -9.049 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: miglustat with relative risk of -9.118 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: caffeine with relative risk of -9.562 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: quetiapine with relative risk of -9.582 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ranitidine with relative risk of -9.640 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: exemestane with relative risk of -9.850 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 18: donepezil with relative risk of -10.563 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: hydrochlorothiazide with relative risk of -10.800 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nebivolol with relative risk of -11.637 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cilazapril with relative risk of -11.923 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: bromfenac with relative risk of -12.289 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: nilotinib with relative risk of -14.757 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: repaglinide with relative risk of -25.331 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: trametinib with relative risk of -29.407 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 26: trimethoprim with relative risk of -30.457 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: linagliptin with relative risk of -33.231 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dexmedetomidine with relative risk of -37.341 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sunitinib with relative risk of -40.416 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 30: olmesartan with relative risk of -41.880 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.334\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bimatoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: atorvastatin with relative risk of -9.736 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: argatroban with relative risk of -10.003 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tolmetin with relative risk of -10.183 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -10.971 of bimatoprost | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 5: misoprostol with relative risk of -12.414 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: olopatadine with relative risk of -27.229 of bimatoprost | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 7: cabazitaxel with relative risk of -34.929 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.161\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bisoprolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.326 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.345 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.569 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -10.603 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.513 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -11.772 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -11.792 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.183 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.323 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.376 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -12.710 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: budesonide with relative risk of -16.022 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bromocriptine with relative risk of -18.839 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: erlotinib with relative risk of -19.141 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: felbamate with relative risk of -19.365 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: metronidazole with relative risk of -19.613 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dabrafenib with relative risk of -20.245 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cilostazol with relative risk of -20.912 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: famotidine with relative risk of -21.022 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: propafenone with relative risk of -21.974 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: fluocinonide with relative risk of -22.111 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -22.152 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 23: terazosin with relative risk of -22.228 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 24: metoprolol with relative risk of -30.129 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 25: flutamide with relative risk of -30.303 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.062\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target bleomycin not found. Exiting ...\n",
      "\n",
      "Drug target boceprevir not found. Exiting ...\n",
      "\n",
      "Drug target bortezomib not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bosentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: anastrozole with relative risk of -9.045 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: aminophylline with relative risk of -9.523 of bosentan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 4: apixaban with relative risk of -9.612 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sorafenib with relative risk of -10.008 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clomipramine with relative risk of -10.399 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rilpivirine with relative risk of -11.147 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dihydroergotamine with relative risk of -11.411 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: canagliflozin with relative risk of -11.412 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: esomeprazole with relative risk of -18.823 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ixabepilone with relative risk of -23.569 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: orlistat with relative risk of -26.052 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: palonosetron with relative risk of -26.893 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -33.548 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fludarabine with relative risk of -42.787 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ramelteon with relative risk of -50.224 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: paricalcitol with relative risk of -52.010 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: gemcitabine with relative risk of -54.152 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: balsalazide with relative risk of -60.343 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dronedarone with relative risk of -65.522 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.093\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bosutinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: naratriptan with relative risk of -23.376 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó brimonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: leflunomide with relative risk of -10.847 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pinaverium with relative risk of -12.617 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: meloxicam with relative risk of -12.841 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fosinoprilat with relative risk of -12.853 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ranolazine with relative risk of -12.929 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: labetalol with relative risk of -12.973 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: oxybutynin with relative risk of -13.326 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -13.384 of brimonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 21: eletriptan with relative risk of -14.109 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.014\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó brinzolamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -7.837 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -8.099 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -8.162 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -8.366 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: budesonide with relative risk of -8.403 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metoprolol with relative risk of -9.103 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: erlotinib with relative risk of -9.268 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flutamide with relative risk of -9.278 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dalbavancin with relative risk of -9.368 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: bromocriptine with relative risk of -9.660 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dabrafenib with relative risk of -9.679 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nateglinide with relative risk of -9.693 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rivastigmine with relative risk of -9.750 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: felbamate with relative risk of -9.899 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dolutegravir with relative risk of -10.216 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: cilostazol with relative risk of -10.347 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: quetiapine with relative risk of -10.680 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ranitidine with relative risk of -10.738 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bisoprolol with relative risk of -10.965 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: metolazone with relative risk of -11.042 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ondansetron with relative risk of -11.262 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rabeprazole with relative risk of -11.281 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: propafenone with relative risk of -11.409 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: fluocinonide with relative risk of -11.545 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terazosin with relative risk of -11.662 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: darunavir with relative risk of -11.672 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fluconazole with relative risk of -11.812 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: trametinib with relative risk of -13.611 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dexmedetomidine with relative risk of -14.287 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: olmesartan with relative risk of -15.068 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: linezolid with relative risk of -17.207 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: metronidazole with relative risk of -18.410 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: famotidine with relative risk of -19.818 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target bromazepam not found. Exiting ...\n",
      "\n",
      "Drug target bromcresol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bromfenac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bromocriptine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -7.817 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: flumazenil with relative risk of -8.575 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: raloxifene with relative risk of -9.355 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pioglitazone with relative risk of -9.455 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: nedocromil with relative risk of -9.833 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of -9.847 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: glimepiride with relative risk of -9.874 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: silodosin with relative risk of -9.958 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telithromycin with relative risk of -9.979 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: everolimus with relative risk of -10.006 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ribavirin with relative risk of -10.058 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: brinzolamide with relative risk of -10.092 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aripiprazole with relative risk of -10.114 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: adenosine with relative risk of -10.306 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: vilazodone with relative risk of -10.426 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: glipizide with relative risk of -10.563 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: dapagliflozin with relative risk of -10.928 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 18: lapatinib with relative risk of -11.002 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rocuronium with relative risk of -11.259 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: ondansetron with relative risk of -11.262 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rabeprazole with relative risk of -11.281 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: darunavir with relative risk of -11.672 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fluconazole with relative risk of -11.812 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: tropisetron with relative risk of -11.865 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: tolcapone with relative risk of -12.199 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Parkinson Disease\n",
      "Rank 26: teniposide with relative risk of -13.330 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: azathioprine with relative risk of -15.055 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rosuvastatin with relative risk of -16.217 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 29: dalbavancin with relative risk of -16.331 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: risedronate with relative risk of -16.895 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 31: pinaverium with relative risk of -17.194 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fosinoprilat with relative risk of -17.313 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: apixaban with relative risk of -17.467 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: gemfibrozil with relative risk of -17.567 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 35: raltitrexed with relative risk of -17.761 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: metoprolol with relative risk of -17.771 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: capsaicin with relative risk of -17.919 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: erlotinib with relative risk of -17.937 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: flutamide with relative risk of -17.946 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: metronidazole with relative risk of -18.410 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: omeprazole with relative risk of -18.733 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: dabrafenib with relative risk of -19.041 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: bisoprolol with relative risk of -19.633 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: cilostazol with relative risk of -19.708 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: famotidine with relative risk of -19.818 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: sparfloxacin with relative risk of -20.129 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -20.283 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: tasimelteon with relative risk of -20.415 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: propafenone with relative risk of -20.770 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: fluocinonide with relative risk of -20.907 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: terazosin with relative risk of -21.024 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: nelarabine with relative risk of -21.936 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: rosiglitazone with relative risk of -22.407 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: belinostat with relative risk of -22.429 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: mirtazapine with relative risk of -22.969 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: leflunomide with relative risk of -24.917 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: felbamate with relative risk of -27.523 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: acebutolol with relative risk of -34.626 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: budesonide with relative risk of -38.788 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.628\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó budesonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.377 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pioglitazone with relative risk of -8.074 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: varenicline with relative risk of -8.290 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -8.672 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: brinzolamide with relative risk of -8.708 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: aripiprazole with relative risk of -8.729 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: adenosine with relative risk of -8.919 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lapatinib with relative risk of -9.616 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: carbamazepine with relative risk of -9.801 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ondansetron with relative risk of -9.875 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 11: rabeprazole with relative risk of -9.895 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 12: darunavir with relative risk of -10.286 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluconazole with relative risk of -10.426 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tropisetron with relative risk of -10.479 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 15: tolcapone with relative risk of -10.813 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ropinirole with relative risk of -14.657 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: metoprolol with relative risk of -14.828 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: flutamide with relative risk of -15.002 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -15.466 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dabrafenib with relative risk of -16.097 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: everolimus with relative risk of -16.423 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: eliglustat with relative risk of -16.567 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bisoprolol with relative risk of -16.689 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cilostazol with relative risk of -16.764 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: famotidine with relative risk of -16.875 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 26: glipizide with relative risk of -16.980 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: propafenone with relative risk of -17.826 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fluocinonide with relative risk of -17.962 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: terazosin with relative risk of -18.079 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dutasteride with relative risk of -18.147 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: estramustine with relative risk of -19.556 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: risedronate with relative risk of -20.606 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: raloxifene with relative risk of -21.041 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: nedocromil with relative risk of -22.029 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 35: glimepiride with relative risk of -22.071 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: vilazodone with relative risk of -22.622 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fluoxetine with relative risk of -22.625 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: erlotinib with relative risk of -23.255 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: omeprazole with relative risk of -23.359 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 40: duloxetine with relative risk of -24.271 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: milnacipran with relative risk of -24.466 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: rofecoxib with relative risk of -24.659 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: conivaptan with relative risk of -24.995 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: umeclidinium with relative risk of -24.999 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ramipril with relative risk of -25.111 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: rocuronium with relative risk of -25.246 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: quinapril with relative risk of -25.882 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: telithromycin with relative risk of -27.922 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: felbamate with relative risk of -31.395 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: terbutaline with relative risk of -31.480 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 51: gemfibrozil with relative risk of -36.291 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: capsaicin with relative risk of -36.643 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: bromocriptine with relative risk of -38.661 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dapagliflozin with relative risk of -39.929 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: apixaban with relative risk of -41.998 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: flumazenil with relative risk of -42.061 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dexmedetomidine with relative risk of -42.092 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: nateglinide with relative risk of -42.199 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: leflunomide with relative risk of -42.725 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: axitinib with relative risk of -45.586 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: raltitrexed with relative risk of -46.539 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: trandolapril with relative risk of -46.831 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dalbavancin with relative risk of -47.334 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: silodosin with relative risk of -54.058 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: rosuvastatin with relative risk of -64.763 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: sparfloxacin with relative risk of -106.274 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: belinostat with relative risk of -107.264 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: mirtazapine with relative risk of -107.804 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: azathioprine with relative risk of -109.954 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: pinaverium with relative risk of -112.969 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 71: tasimelteon with relative risk of -113.085 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: teniposide with relative risk of -114.692 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: fosinoprilat with relative risk of -119.634 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: acebutolol with relative risk of -121.735 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: mometasone with relative risk of -122.817 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 76: rosiglitazone with relative risk of -133.242 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: nelarabine with relative risk of -139.137 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.082\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bumetanide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -6.791 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: gefitinib with relative risk of -8.636 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mivacurium with relative risk of -9.179 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mexiletine with relative risk of -9.542 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: esmolol with relative risk of -9.799 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: ipratropium with relative risk of -9.866 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: roflumilast with relative risk of -10.211 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: azelastine with relative risk of -10.834 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: clopidogrel with relative risk of -12.291 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: ciclesonide with relative risk of -33.459 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: imatinib with relative risk of -77.379 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.517\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bupivacaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: allopurinol with relative risk of -10.415 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiodarone with relative risk of -10.963 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: thalidomide with relative risk of -11.028 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: didanosine with relative risk of -11.077 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tofacitinib with relative risk of -11.522 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: benazepril with relative risk of -20.749 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clonidine with relative risk of -24.568 of bupivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: doxepin with relative risk of -29.554 of bupivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pruritus,neurology/psychiatry\n",
      "Rank 9: verapamil with relative risk of -30.628 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pindolol with relative risk of -31.341 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.091\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target buprenorphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bupropion *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -10.350 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ivacaftor with relative risk of -12.188 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó buspirone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: naltrexone with relative risk of -20.988 of buspirone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: lenalidomide with relative risk of -21.607 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.667\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target busulfan not found. Exiting ...\n",
      "\n",
      "Drug target butorphanol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabazitaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: argatroban with relative risk of -10.696 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olopatadine with relative risk of -11.550 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bimatoprost with relative risk of -34.891 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabergoline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.463 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -7.033 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lansoprazole with relative risk of -7.939 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rivastigmine with relative risk of -8.963 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -9.064 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: linezolid with relative risk of -9.139 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: miglustat with relative risk of -9.428 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atosiban with relative risk of -9.623 of cabergoline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: gonadorelin with relative risk of -9.830 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ranitidine with relative risk of -9.950 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: halofantrine with relative risk of -10.672 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: hydrochlorothiazide with relative risk of -11.110 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: norfloxacin with relative risk of -18.400 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fondaparinux with relative risk of -18.994 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: iloperidone with relative risk of -25.397 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: indomethacin with relative risk of -65.767 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: lubiprostone with relative risk of -67.796 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: penbutolol with relative risk of -78.874 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: estramustine with relative risk of -81.260 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: anagrelide with relative risk of -85.539 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mirabegron with relative risk of -86.745 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: moxifloxacin with relative risk of -87.191 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: nabumetone with relative risk of -87.388 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.033\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabozantinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -10.789 of cabozantinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: atropine with relative risk of -11.531 of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pantoprazole with relative risk of -13.521 of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: calcipotriol with relative risk of -inf of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó caffeine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.065 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -7.917 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -9.021 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -9.023 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dalbavancin with relative risk of -9.186 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: zafirlukast with relative risk of -27.456 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: vardenafil with relative risk of -28.615 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: temsirolimus with relative risk of -29.052 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó calcipotriol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -10.096 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atropine with relative risk of -10.837 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cabozantinib with relative risk of -11.689 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pantoprazole with relative risk of -12.828 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target calcium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó canagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bosentan with relative risk of -10.044 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -11.054 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of canagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: aminophylline with relative risk of -11.826 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paricalcitol with relative risk of -11.871 of canagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: ramelteon with relative risk of -11.876 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pergolide with relative risk of -11.908 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apixaban with relative risk of -11.911 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: palonosetron with relative risk of -12.264 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sorafenib with relative risk of -12.311 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: esomeprazole with relative risk of -12.574 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clomipramine with relative risk of -12.701 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rilpivirine with relative risk of -13.450 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dihydroergotamine with relative risk of -13.714 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.063\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó candesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -10.183 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -10.245 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.601 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -12.081 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -22.152 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: sparfloxacin with relative risk of -22.428 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mometasone with relative risk of -22.583 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tasimelteon with relative risk of -22.715 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: azathioprine with relative risk of -24.231 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: fosinoprilat with relative risk of -26.409 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: pinaverium with relative risk of -26.413 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: idarubicin with relative risk of -26.692 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pioglitazone with relative risk of -27.436 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mifepristone with relative risk of -27.720 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rivastigmine with relative risk of -28.067 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: delavirdine with relative risk of -28.404 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pitavastatin with relative risk of -29.151 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: frovatriptan with relative risk of -29.591 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: montelukast with relative risk of -29.709 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fesoterodine with relative risk of -30.012 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: disopyramide with relative risk of -30.415 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: sulfasalazine with relative risk of -30.920 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: flecainide with relative risk of -31.274 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: cisatracurium with relative risk of -32.261 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.104\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó capecitabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "Rank 2: pergolide with relative risk of -11.215 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: citalopram with relative risk of -11.586 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dapsone with relative risk of -12.342 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -12.394 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -17.246 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -19.210 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -19.532 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxapine with relative risk of -20.494 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: salmeterol with relative risk of -20.553 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -21.267 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: emedastine with relative risk of -21.624 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: estradiol with relative risk of -22.393 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV\n",
      "Rank 15: pramipexole with relative risk of -22.677 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tegaserod with relative risk of -23.025 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -23.445 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.312\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó capsaicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: risedronate with relative risk of -8.989 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: raloxifene with relative risk of -9.019 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -9.032 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -9.622 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: aripiprazole with relative risk of -9.777 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: apixaban with relative risk of -9.967 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: omeprazole with relative risk of -10.134 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: glipizide with relative risk of -10.227 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rosuvastatin with relative risk of -15.476 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: leflunomide with relative risk of -15.913 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 11: bromocriptine with relative risk of -16.893 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: raltitrexed with relative risk of -17.019 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: felbamate with relative risk of -17.420 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: eliglustat with relative risk of -18.770 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sparfloxacin with relative risk of -25.195 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rosiglitazone with relative risk of -28.570 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rocuronium with relative risk of -28.730 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: belinostat with relative risk of -28.833 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mirtazapine with relative risk of -29.374 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: tasimelteon with relative risk of -33.083 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: gemfibrozil with relative risk of -33.428 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azathioprine with relative risk of -35.072 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 23: budesonide with relative risk of -35.745 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nelarabine with relative risk of -35.823 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pinaverium with relative risk of -37.344 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: teniposide with relative risk of -42.700 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -45.096 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: nedocromil with relative risk of -45.438 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: glimepiride with relative risk of -45.480 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: vilazodone with relative risk of -46.031 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: acebutolol with relative risk of -47.190 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -49.697 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: flumazenil with relative risk of -50.679 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: telithromycin with relative risk of -52.084 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.228\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó captopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -7.226 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -7.381 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bumetanide with relative risk of -8.009 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: podophyllotoxin with relative risk of -8.020 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: afatinib with relative risk of -8.191 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: glycopyrrolate with relative risk of -8.587 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: penbutolol with relative risk of -8.791 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: topotecan with relative risk of -9.130 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vernakalant with relative risk of -9.191 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: pergolide with relative risk of -9.512 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dabigatran with relative risk of -9.531 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: venlafaxine with relative risk of -9.687 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: mexiletine with relative risk of -9.852 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: citalopram with relative risk of -9.882 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ritonavir with relative risk of -10.087 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: torasemide with relative risk of -10.279 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 17: dapsone with relative risk of -10.637 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: isradipine with relative risk of -10.689 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 19: aclidinium with relative risk of -11.165 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bromfenac with relative risk of -12.599 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: amoxapine with relative risk of -16.487 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: regadenoson with relative risk of -17.259 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: capecitabine with relative risk of -17.500 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: emedastine with relative risk of -17.617 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: estradiol with relative risk of -18.386 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 26: pramipexole with relative risk of -18.670 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tegaserod with relative risk of -19.018 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: almotriptan with relative risk of -19.438 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: desloratadine with relative risk of -29.246 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: telmisartan with relative risk of -30.106 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 31: salmeterol with relative risk of -34.171 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.212\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó carbamazepine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: belinostat with relative risk of -9.670 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -9.764 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nelarabine with relative risk of -9.851 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sparfloxacin with relative risk of -9.864 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: budesonide with relative risk of -10.009 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rosiglitazone with relative risk of -10.079 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: flumazenil with relative risk of -10.183 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: mirtazapine with relative risk of -10.211 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: azathioprine with relative risk of -10.518 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rosuvastatin with relative risk of -10.766 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: raloxifene with relative risk of -10.964 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dalbavancin with relative risk of -10.975 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: silodosin with relative risk of -11.567 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gemfibrozil with relative risk of -11.606 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: everolimus with relative risk of -11.615 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: raltitrexed with relative risk of -11.617 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: glipizide with relative risk of -12.172 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pinaverium with relative risk of -12.617 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fosinoprilat with relative risk of -12.853 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: dutasteride with relative risk of -13.339 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.155\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target carbidopa not found. Exiting ...\n",
      "\n",
      "Drug target carboplatin not found. Exiting ...\n",
      "\n",
      "Drug target carisoprodol not found. Exiting ...\n",
      "\n",
      "Drug target carnitine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó carvedilol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -9.713 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: paliperidone with relative risk of -9.816 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indapamide with relative risk of -10.399 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: nilutamide with relative risk of -10.574 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: alosetron with relative risk of -10.684 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -10.743 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nadolol with relative risk of -12.274 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: alfuzosin with relative risk of -12.428 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lovastatin with relative risk of -13.019 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.561\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cefaclor not found. Exiting ...\n",
      "\n",
      "Drug target cefepime not found. Exiting ...\n",
      "\n",
      "Drug target cefixime not found. Exiting ...\n",
      "\n",
      "Drug target cefotaxime not found. Exiting ...\n",
      "\n",
      "Drug target cefprozil not found. Exiting ...\n",
      "\n",
      "Drug target ceftaroline not found. Exiting ...\n",
      "\n",
      "Drug target ceftazidime not found. Exiting ...\n",
      "\n",
      "Drug target ceftobiprole not found. Exiting ...\n",
      "\n",
      "Drug target ceftriaxone not found. Exiting ...\n",
      "\n",
      "Drug target cefuroxime not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó celecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cetirizine with relative risk of -13.255 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cerivastatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cetirizine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: celecoxib with relative risk of -13.459 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cetrorelix *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: darifenacin with relative risk of -11.515 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.786 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dantrolene with relative risk of -12.590 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: nelfinavir with relative risk of -12.857 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: riluzole with relative risk of -13.110 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: toremifene with relative risk of -13.932 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.136\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cevimeline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: desonide with relative risk of -13.368 of cevimeline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target chlorhexidine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ciclesonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: roflumilast with relative risk of -11.533 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: imatinib with relative risk of -30.880 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bumetanide with relative risk of -32.876 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cidofovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cilazapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -8.576 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -9.013 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nizatidine with relative risk of -9.838 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loperamide with relative risk of -9.877 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bexarotene with relative risk of -10.123 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pamidronate with relative risk of -10.656 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: colchicine with relative risk of -10.687 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indapamide with relative risk of -10.805 of cilazapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: darifenacin with relative risk of -10.822 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: miglustat with relative risk of -11.133 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: iloperidone with relative risk of -11.491 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: lercanidipine with relative risk of -13.636 of cilazapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.067\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cilostazol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.974 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -11.008 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.918 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -12.178 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -12.198 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.588 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.728 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.781 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -13.115 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acebutolol with relative risk of -15.947 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: budesonide with relative risk of -17.120 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bromocriptine with relative risk of -19.937 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: metoprolol with relative risk of -20.074 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: erlotinib with relative risk of -20.239 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -20.248 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felbamate with relative risk of -20.464 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -20.712 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dabrafenib with relative risk of -21.344 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bisoprolol with relative risk of -21.935 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: famotidine with relative risk of -22.121 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: propafenone with relative risk of -23.073 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: fluocinonide with relative risk of -23.209 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terazosin with relative risk of -23.326 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cimetidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olanzapine with relative risk of -13.044 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: felodipine with relative risk of -inf of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cinacalcet not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ciprofloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: apraclonidine with relative risk of -11.470 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lubiprostone with relative risk of -16.528 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cisatracurium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: gefitinib with relative risk of -9.734 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: disopyramide with relative risk of -28.112 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: azathioprine with relative risk of -38.114 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: idarubicin with relative risk of -46.108 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -47.136 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pitavastatin with relative risk of -47.469 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: delavirdine with relative risk of -47.820 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: frovatriptan with relative risk of -49.007 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: montelukast with relative risk of -49.125 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: fesoterodine with relative risk of -49.429 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.416\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cisplatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó citalopram *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.395 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -8.549 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -8.874 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cyclobenzaprine with relative risk of -9.582 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: amoxapine with relative risk of -10.034 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 6: regadenoson with relative risk of -10.113 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: capecitabine with relative risk of -10.353 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Malignant neoplasm of stomach\n",
      "Rank 8: desloratadine with relative risk of -10.360 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -10.458 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: emedastine with relative risk of -10.471 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: simvastatin with relative risk of -10.493 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: salmeterol with relative risk of -10.499 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: amlodipine with relative risk of -10.762 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: venlafaxine with relative risk of -10.986 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,neurology/psychiatry\n",
      "Rank 15: estradiol with relative risk of -11.240 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pramipexole with relative risk of -11.524 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: tegaserod with relative risk of -11.871 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dapsone with relative risk of -11.937 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: almotriptan with relative risk of -12.292 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: isradipine with relative risk of -22.043 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.242\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cladribine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: apremilast with relative risk of -11.273 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amsacrine with relative risk of -26.952 of cladribine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: losartan with relative risk of -27.303 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.273\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clarithromycin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -10.073 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: zolmitriptan with relative risk of -12.122 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nefazodone with relative risk of -13.092 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pazopanib with relative risk of -23.338 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nizatidine with relative risk of -24.700 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: maprotiline with relative risk of -24.944 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: levetiracetam with relative risk of -24.955 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nalmefene with relative risk of -25.296 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.046\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clevidipine not found. Exiting ...\n",
      "\n",
      "Drug target clindamycin not found. Exiting ...\n",
      "\n",
      "Drug target clobazam not found. Exiting ...\n",
      "\n",
      "Drug target clobetasol not found. Exiting ...\n",
      "\n",
      "Drug target clodronate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clofarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trimetrexate with relative risk of -11.786 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: quinidine with relative risk of -12.264 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: finasteride with relative risk of -13.400 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clomiphene not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clomipramine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bosentan with relative risk of -10.044 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -11.054 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aminophylline with relative risk of -11.826 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paricalcitol with relative risk of -11.871 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ramelteon with relative risk of -11.876 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pergolide with relative risk of -11.908 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apixaban with relative risk of -11.911 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: palonosetron with relative risk of -12.264 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sorafenib with relative risk of -12.311 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: esomeprazole with relative risk of -12.574 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rilpivirine with relative risk of -13.450 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dihydroergotamine with relative risk of -13.714 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: canagliflozin with relative risk of -13.715 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.063\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clonazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: levonorgestrel with relative risk of -7.344 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olmesartan with relative risk of -8.339 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: darifenacin with relative risk of -9.031 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: allopurinol with relative risk of -9.318 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amiodarone with relative risk of -9.865 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: thalidomide with relative risk of -9.930 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -9.978 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tofacitinib with relative risk of -10.424 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: risperidone with relative risk of -10.482 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: benazepril with relative risk of -18.351 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: bupivacaine with relative risk of -24.864 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ifosfamide with relative risk of -28.623 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sildenafil with relative risk of -29.981 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dasatinib with relative risk of -33.160 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dofetilide with relative risk of -33.719 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: loratadine with relative risk of -33.947 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pindolol with relative risk of -45.850 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 18: verapamil with relative risk of -68.105 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 19: doxepin with relative risk of -73.898 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.347\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clopidogrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bumetanide with relative risk of -10.400 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: mivacurium with relative risk of -11.888 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: esmolol with relative risk of -12.507 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clozapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pindolol with relative risk of -8.976 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: abiraterone with relative risk of -10.114 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sitagliptin with relative risk of -12.009 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinaprilat with relative risk of -12.973 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amiloride with relative risk of -18.055 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nimodipine with relative risk of -26.722 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: prazosin with relative risk of -33.341 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó colchicine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -7.885 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -8.322 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: podophyllotoxin with relative risk of -9.031 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nizatidine with relative risk of -9.147 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: danazol with relative risk of -9.425 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: saquinavir with relative risk of -9.996 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: indapamide with relative risk of -10.112 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darifenacin with relative risk of -10.129 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vernakalant with relative risk of -10.202 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: miglustat with relative risk of -10.440 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: indinavir with relative risk of -10.601 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: travoprost with relative risk of -10.975 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nisoldipine with relative risk of -10.986 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: iloprost with relative risk of -11.007 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: valdecoxib with relative risk of -11.363 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluvoxamine with relative risk of -11.393 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: trospium with relative risk of -11.423 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: degarelix with relative risk of -11.471 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ambrisentan with relative risk of -11.602 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: reboxetine with relative risk of -11.745 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: adapalene with relative risk of -11.815 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rotigotine with relative risk of -11.957 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: albendazole with relative risk of -12.042 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: azilsartan with relative risk of -12.581 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: cilazapril with relative risk of -13.245 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: nilutamide with relative risk of -18.326 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target colesevelam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó conivaptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.668 of conivaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: leflunomide with relative risk of -9.749 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: erlotinib with relative risk of -9.779 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -10.183 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: terbutaline with relative risk of -10.495 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acebutolol with relative risk of -14.851 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tasimelteon with relative risk of -14.964 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: azathioprine with relative risk of -16.257 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pinaverium with relative risk of -18.396 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -18.670 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -22.428 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -22.583 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: teniposide with relative risk of -22.794 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexmedetomidine with relative risk of -23.809 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -24.237 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -26.409 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: estramustine with relative risk of -26.588 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nateglinide with relative risk of -27.385 of conivaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 21: axitinib with relative risk of -27.778 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trandolapril with relative risk of -29.023 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: duloxetine with relative risk of -31.310 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: milnacipran with relative risk of -31.505 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: umeclidinium with relative risk of -32.038 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.275\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target conjugated not found. Exiting ...\n",
      "\n",
      "Drug target copolymer not found. Exiting ...\n",
      "\n",
      "Drug target copper not found. Exiting ...\n",
      "\n",
      "Drug target cortisol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó crizotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of crizotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: azathioprine with relative risk of -9.422 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: leflunomide with relative risk of -9.749 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -9.865 of crizotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: aripiprazole with relative risk of -10.624 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fosinoprilat with relative risk of -11.757 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nevirapine with relative risk of -12.138 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loteprednol with relative risk of -12.942 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fosinopril with relative risk of -13.406 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pioglitazone with relative risk of -18.074 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: naproxen with relative risk of -20.601 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: meloxicam with relative risk of -21.104 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: desvenlafaxine with relative risk of -21.377 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: topiramate with relative risk of -21.507 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sparfloxacin with relative risk of -22.428 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tasimelteon with relative risk of -22.715 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: domperidone with relative risk of -22.897 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dexamethasone with relative risk of -26.413 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: risedronate with relative risk of -27.642 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: apixaban with relative risk of -27.744 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: varenicline with relative risk of -28.396 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ropinirole with relative risk of -28.570 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.339\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cyclobenzaprine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: citalopram with relative risk of -10.488 of cyclobenzaprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: amlexanox with relative risk of -10.801 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: isradipine with relative risk of -11.295 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indomethacin with relative risk of -19.462 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: simvastatin with relative risk of -34.261 of cyclobenzaprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: amlodipine with relative risk of -34.529 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lubiprostone with relative risk of -43.079 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.463\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cyclophosphamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: captopril with relative risk of -8.108 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: afatinib with relative risk of -9.201 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: glycopyrrolate with relative risk of -9.598 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.073 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: topotecan with relative risk of -10.141 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: telmisartan with relative risk of -10.171 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: salmeterol with relative risk of -10.211 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bromfenac with relative risk of -13.611 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ospemifene with relative risk of -20.203 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ritonavir with relative risk of -30.515 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: torasemide with relative risk of -41.049 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.483\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cyproterone not found. Exiting ...\n",
      "\n",
      "Drug target cysteamine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cytarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -10.479 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: macitentan with relative risk of -11.639 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -11.664 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metolazone with relative risk of -11.959 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phenytoin with relative risk of -12.213 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atomoxetine with relative risk of -12.414 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: empagliflozin with relative risk of -12.449 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lamotrigine with relative risk of -12.487 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sumatriptan with relative risk of -12.661 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pimozide with relative risk of -12.759 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ketorolac with relative risk of -23.105 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alendronate with relative risk of -23.943 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target d-telaprevir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dabigatran *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: desloratadine with relative risk of -10.765 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: salmeterol with relative risk of -10.904 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atorvastatin with relative risk of -11.121 of dabigatran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: tamsulosin with relative risk of -12.173 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: aclidinium with relative risk of -12.870 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dabrafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.974 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -11.008 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.918 of dabrafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: ondansetron with relative risk of -12.178 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -12.198 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.588 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.728 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.781 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -13.115 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acebutolol with relative risk of -15.947 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: budesonide with relative risk of -17.120 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bromocriptine with relative risk of -19.937 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: metoprolol with relative risk of -20.074 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: erlotinib with relative risk of -20.239 of dabrafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 17: flutamide with relative risk of -20.248 of dabrafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 18: felbamate with relative risk of -20.464 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -20.712 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bisoprolol with relative risk of -21.935 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cilostazol with relative risk of -22.011 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: famotidine with relative risk of -22.121 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: propafenone with relative risk of -23.073 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: fluocinonide with relative risk of -23.209 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terazosin with relative risk of -23.326 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.084\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dacarbazine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dalbavancin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -6.946 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -7.228 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -7.500 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: flumazenil with relative risk of -7.701 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: olmesartan with relative risk of -8.339 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: risedronate with relative risk of -8.451 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pioglitazone with relative risk of -8.582 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: varenicline with relative risk of -8.799 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nateglinide with relative risk of -8.820 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rivastigmine with relative risk of -8.876 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nedocromil with relative risk of -8.958 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ropinirole with relative risk of -8.973 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: glimepiride with relative risk of -9.000 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: felbamate with relative risk of -9.024 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: linezolid with relative risk of -9.052 of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 16: telithromycin with relative risk of -9.106 of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 17: brinzolamide with relative risk of -9.218 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -9.222 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -9.272 of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 20: dolutegravir with relative risk of -9.342 of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 21: adenosine with relative risk of -9.430 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: capsaicin with relative risk of -9.475 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: vilazodone with relative risk of -9.551 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: omeprazole with relative risk of -9.595 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: brimonidine with relative risk of -9.717 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: caffeine with relative risk of -9.784 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: quetiapine with relative risk of -9.805 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dapagliflozin with relative risk of -10.054 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: metolazone with relative risk of -10.167 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: famotidine with relative risk of -10.275 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: carbamazepine with relative risk of -10.312 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -10.357 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: rocuronium with relative risk of -10.384 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ranolazine with relative risk of -10.445 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: labetalol with relative risk of -10.488 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: oxybutynin with relative risk of -10.841 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: betaxolol with relative risk of -10.899 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: trovafloxacin with relative risk of -11.279 of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 39: eletriptan with relative risk of -11.625 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: apixaban with relative risk of -15.582 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: bromocriptine with relative risk of -15.749 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: everolimus with relative risk of -17.480 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: trametinib with relative risk of -17.635 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: glipizide with relative risk of -18.038 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: dutasteride with relative risk of -19.204 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: leflunomide with relative risk of -21.827 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: raltitrexed with relative risk of -23.339 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: gemfibrozil with relative risk of -30.779 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: raloxifene with relative risk of -30.830 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: teniposide with relative risk of -45.389 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: budesonide with relative risk of -46.879 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: nelarabine with relative risk of -47.100 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: acebutolol with relative risk of -47.310 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sparfloxacin with relative risk of -48.062 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: rosiglitazone with relative risk of -48.168 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: silodosin with relative risk of -48.433 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: belinostat with relative risk of -49.299 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mirtazapine with relative risk of -49.840 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: tasimelteon with relative risk of -50.316 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: mometasone with relative risk of -50.373 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: rosuvastatin with relative risk of -52.495 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: azathioprine with relative risk of -53.092 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: fosinoprilat with relative risk of -54.814 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: pinaverium with relative risk of -55.519 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: efinaconazole with relative risk of -inf of dalbavancin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.057\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dalteparin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó danazol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: afatinib with relative risk of -8.286 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paliperidone with relative risk of -8.615 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: colchicine with relative risk of -9.078 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indapamide with relative risk of -9.197 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: pemetrexed with relative risk of -9.422 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: alosetron with relative risk of -9.480 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paroxetine with relative risk of -9.540 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indinavir with relative risk of -9.685 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: carvedilol with relative risk of -9.701 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: zafirlukast with relative risk of -9.832 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vardenafil with relative risk of -9.892 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: caffeine with relative risk of -9.966 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: temsirolimus with relative risk of -10.329 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fluvoxamine with relative risk of -10.476 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: vandetanib with relative risk of -10.829 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nadolol with relative risk of -11.070 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: albendazole with relative risk of -11.125 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: alfuzosin with relative risk of -11.225 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azilsartan with relative risk of -11.664 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: lovastatin with relative risk of -11.815 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: nilutamide with relative risk of -16.312 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.144\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dantrolene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: darifenacin with relative risk of -11.515 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.786 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nelfinavir with relative risk of -12.857 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: riluzole with relative risk of -13.110 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: cetrorelix with relative risk of -13.236 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: toremifene with relative risk of -13.932 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.184\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dapagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.575 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -8.745 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -9.368 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pioglitazone with relative risk of -9.455 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 5: bromocriptine with relative risk of -9.660 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: silodosin with relative risk of -9.958 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gemfibrozil with relative risk of -9.997 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: everolimus with relative risk of -10.006 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: adenosine with relative risk of -10.306 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rosuvastatin with relative risk of -16.217 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: risedronate with relative risk of -16.895 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: ropinirole with relative risk of -17.599 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: omeprazole with relative risk of -18.733 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexmedetomidine with relative risk of -21.508 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: leflunomide with relative risk of -24.917 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nateglinide with relative risk of -25.083 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 17: apixaban with relative risk of -25.442 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: axitinib with relative risk of -25.476 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: raltitrexed with relative risk of -26.429 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: trandolapril with relative risk of -26.721 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluoxetine with relative risk of -27.361 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: terbutaline with relative risk of -27.609 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rofecoxib with relative risk of -29.395 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ramipril with relative risk of -29.847 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: quinapril with relative risk of -30.619 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: acebutolol with relative risk of -34.626 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sparfloxacin with relative risk of -35.086 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tasimelteon with relative risk of -36.125 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: teniposide with relative risk of -37.298 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: azathioprine with relative risk of -38.114 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: budesonide with relative risk of -38.788 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nelarabine with relative risk of -38.866 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: rosiglitazone with relative risk of -39.614 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: fosinoprilat with relative risk of -40.122 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: belinostat with relative risk of -40.139 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: pinaverium with relative risk of -40.387 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: mirtazapine with relative risk of -40.680 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.2\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dapsone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -9.493 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amoxapine with relative risk of -11.132 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: regadenoson with relative risk of -11.212 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: capecitabine with relative risk of -11.452 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -11.458 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: telmisartan with relative risk of -11.556 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: emedastine with relative risk of -11.569 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: salmeterol with relative risk of -11.597 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: venlafaxine with relative risk of -12.085 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: citalopram with relative risk of -12.279 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: estradiol with relative risk of -12.338 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris\n",
      "Rank 12: pramipexole with relative risk of -12.622 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tegaserod with relative risk of -12.970 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: isradipine with relative risk of -13.087 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: almotriptan with relative risk of -13.390 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.027\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó darifenacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -7.885 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -8.322 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levonorgestrel with relative risk of -8.439 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nizatidine with relative risk of -9.147 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: clonidine with relative risk of -9.160 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: colchicine with relative risk of -9.994 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: indapamide with relative risk of -10.112 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimetrexate with relative risk of -10.400 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: miglustat with relative risk of -10.440 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dantrolene with relative risk of -11.204 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nelfinavir with relative risk of -11.471 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: riluzole with relative risk of -11.723 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cetrorelix with relative risk of -11.849 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: toremifene with relative risk of -12.546 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cilazapril with relative risk of -13.245 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó darunavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -9.423 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: budesonide with relative risk of -10.009 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metoprolol with relative risk of -10.712 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: erlotinib with relative risk of -10.878 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: flutamide with relative risk of -10.887 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bromocriptine with relative risk of -11.269 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dabrafenib with relative risk of -11.289 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: felbamate with relative risk of -11.508 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -11.701 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -11.756 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cilostazol with relative risk of -11.956 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bisoprolol with relative risk of -12.574 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -12.759 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ondansetron with relative risk of -12.871 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rabeprazole with relative risk of -12.891 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: propafenone with relative risk of -13.018 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fluocinonide with relative risk of -13.154 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: terazosin with relative risk of -13.271 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluconazole with relative risk of -13.421 of darunavir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.013\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dasatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -29.554 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -30.628 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pindolol with relative risk of -31.341 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clonidine with relative risk of -33.811 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ifosfamide with relative risk of -34.826 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -40.151 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó deferasirox *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nifedipine with relative risk of -12.919 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: scopolamine with relative risk of -13.221 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: propranolol with relative risk of -13.246 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicotine with relative risk of -13.313 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: avanafil with relative risk of -13.329 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó degarelix *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -10.417 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -11.382 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vernakalant with relative risk of -11.588 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indinavir with relative risk of -11.986 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -12.361 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nisoldipine with relative risk of -12.372 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: iloprost with relative risk of -12.393 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -12.749 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ambrisentan with relative risk of -12.988 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: reboxetine with relative risk of -13.131 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target delamanid not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó delavirdine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.734 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -28.112 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -38.114 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: idarubicin with relative risk of -46.108 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -47.136 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pitavastatin with relative risk of -47.469 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: frovatriptan with relative risk of -49.007 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: montelukast with relative risk of -49.125 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -49.429 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target deprenyl not found. Exiting ...\n",
      "\n",
      "Drug target desflurane not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desloratadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -7.226 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -7.263 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cyclophosphamide with relative risk of -7.381 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -7.586 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -7.852 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: afatinib with relative risk of -8.191 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cabergoline with relative risk of -8.445 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: glycopyrrolate with relative risk of -8.587 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: penbutolol with relative risk of -8.791 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: estramustine with relative risk of -8.968 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mirabegron with relative risk of -9.058 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: topotecan with relative risk of -9.130 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: moxifloxacin with relative risk of -9.504 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -9.512 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dabigatran with relative risk of -9.531 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: venlafaxine with relative risk of -9.687 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nabumetone with relative risk of -9.701 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: citalopram with relative risk of -9.882 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ritonavir with relative risk of -10.087 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: torasemide with relative risk of -10.279 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: olopatadine with relative risk of -10.540 of desloratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Hay fever,Allergic Conjunctivitis\n",
      "Rank 22: dapsone with relative risk of -10.637 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: norfloxacin with relative risk of -10.648 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: isradipine with relative risk of -10.689 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: aclidinium with relative risk of -11.165 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: bromfenac with relative risk of -12.599 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fexofenadine with relative risk of -14.529 of desloratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic idiopathic urticaria,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder),Sneezing,allergy\n",
      "Rank 28: amoxapine with relative risk of -16.487 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: regadenoson with relative risk of -17.259 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: capecitabine with relative risk of -17.500 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: emedastine with relative risk of -17.617 of desloratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 32: estradiol with relative risk of -18.386 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: pramipexole with relative risk of -18.670 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tegaserod with relative risk of -19.018 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: almotriptan with relative risk of -19.438 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: captopril with relative risk of -27.282 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: telmisartan with relative risk of -30.106 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: salmeterol with relative risk of -34.171 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.028\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target desmopressin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cevimeline with relative risk of -13.174 of desonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desoximetasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: prasugrel with relative risk of -17.873 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desvenlafaxine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.160 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azathioprine with relative risk of -9.826 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: leflunomide with relative risk of -10.154 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -10.271 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: naproxen with relative risk of -10.952 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: aripiprazole with relative risk of -11.030 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: fosinoprilat with relative risk of -12.161 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -12.543 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: domperidone with relative risk of -13.247 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: loteprednol with relative risk of -13.347 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fosinopril with relative risk of -13.812 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tasimelteon with relative risk of -16.062 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sparfloxacin with relative risk of -16.134 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexamethasone with relative risk of -18.438 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: pioglitazone with relative risk of -19.173 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -19.197 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: varenicline with relative risk of -19.727 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: apixaban with relative risk of -19.769 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of -19.901 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: crizotinib with relative risk of -20.430 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: meloxicam with relative risk of -22.202 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: topiramate with relative risk of -22.606 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.199\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexamethasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azathioprine with relative risk of -8.225 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 3: leflunomide with relative risk of -8.547 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Arthritis, Psoriatic,rheumatology\n",
      "Rank 4: raloxifene with relative risk of -8.663 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: aripiprazole with relative risk of -9.421 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: fosinoprilat with relative risk of -10.561 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nevirapine with relative risk of -10.934 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loteprednol with relative risk of -11.738 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Iritis,Corneal abrasion,Corneal Perforation,Punctate keratitis,Rosacea,Herpes zoster keratitis,Iridocyclitis,Anterior uveitis,Allergic Conjunctivitis\n",
      "Rank 9: fosinopril with relative risk of -12.203 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pioglitazone with relative risk of -15.368 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: sparfloxacin with relative risk of -17.653 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: naproxen with relative risk of -17.893 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Bursitis,Ankylosing spondylitis,neurology/psychiatry,rheumatology,endocrinology\n",
      "Rank 13: tasimelteon with relative risk of -17.937 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: meloxicam with relative risk of -18.396 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 15: desvenlafaxine with relative risk of -18.669 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: topiramate with relative risk of -18.799 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: domperidone with relative risk of -20.189 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Nausea and vomiting\n",
      "Rank 18: risedronate with relative risk of -22.856 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 19: apixaban with relative risk of -22.959 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry,hematology\n",
      "Rank 20: varenicline with relative risk of -23.609 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: ropinirole with relative risk of -23.783 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: crizotinib with relative risk of -25.698 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: olmesartan with relative risk of -45.856 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: lansoprazole with relative risk of -47.769 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 25: formoterol with relative risk of -60.429 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.505\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexmedetomidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indomethacin with relative risk of -6.730 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lubiprostone with relative risk of -7.051 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: flumazenil with relative risk of -7.244 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: anagrelide with relative risk of -7.309 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: verapamil with relative risk of -7.427 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metoprolol with relative risk of -7.769 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cabergoline with relative risk of -7.901 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flutamide with relative risk of -7.944 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dalbavancin with relative risk of -8.039 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: bromocriptine with relative risk of -8.327 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: varenicline with relative risk of -8.341 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dabrafenib with relative risk of -8.345 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rivastigmine with relative risk of -8.419 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: mirabegron with relative risk of -8.515 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: felbamate with relative risk of -8.566 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: silodosin with relative risk of -8.627 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: moxifloxacin with relative risk of -8.960 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cilostazol with relative risk of -9.012 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nabumetone with relative risk of -9.157 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: gonadorelin with relative risk of -9.285 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ranitidine with relative risk of -9.404 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: exemestane with relative risk of -9.614 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bisoprolol with relative risk of -9.631 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: metolazone with relative risk of -9.708 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ondansetron with relative risk of -9.927 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rabeprazole with relative risk of -9.946 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: propafenone with relative risk of -10.074 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fluocinonide with relative risk of -10.211 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: donepezil with relative risk of -10.327 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: terazosin with relative risk of -10.328 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: darunavir with relative risk of -10.337 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fluconazole with relative risk of -10.477 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: hydrochlorothiazide with relative risk of -10.564 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: rosuvastatin with relative risk of -13.383 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: penbutolol with relative risk of -13.467 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: leflunomide with relative risk of -13.819 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: linezolid with relative risk of -14.372 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: raltitrexed with relative risk of -14.924 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: erlotinib with relative risk of -15.098 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: brinzolamide with relative risk of -15.230 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: dolutegravir with relative risk of -15.641 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: repaglinide with relative risk of -16.256 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: famotidine with relative risk of -16.980 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: quetiapine with relative risk of -17.203 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: belinostat with relative risk of -17.862 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: mirtazapine with relative risk of -18.402 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 47: apixaban with relative risk of -20.873 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: trimethoprim with relative risk of -21.845 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: fluoxetine with relative risk of -22.788 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: metronidazole with relative risk of -23.198 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dapagliflozin with relative risk of -23.287 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: duloxetine with relative risk of -24.434 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 53: milnacipran with relative risk of -24.629 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: rofecoxib with relative risk of -24.821 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: conivaptan with relative risk of -25.158 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: umeclidinium with relative risk of -25.162 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ramipril with relative risk of -25.273 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: quinapril with relative risk of -26.045 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: estramustine with relative risk of -26.083 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: azathioprine with relative risk of -28.766 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: sunitinib with relative risk of -30.107 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: acebutolol with relative risk of -30.713 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: pinaverium with relative risk of -31.038 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: sparfloxacin with relative risk of -31.266 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: terbutaline with relative risk of -31.704 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: linagliptin with relative risk of -32.187 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: mometasone with relative risk of -32.667 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tasimelteon with relative risk of -32.690 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 69: teniposide with relative risk of -34.444 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: nelarabine with relative risk of -36.081 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: fosinoprilat with relative risk of -36.845 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: rosiglitazone with relative risk of -36.981 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: bicalutamide with relative risk of -37.387 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: budesonide with relative risk of -42.730 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: axitinib with relative risk of -45.942 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: olmesartan with relative risk of -46.178 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: trandolapril with relative risk of -47.187 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: nateglinide with relative risk of -50.892 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: trametinib with relative risk of -55.513 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.166\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexrazoxane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: guanfacine with relative risk of -12.067 of dexrazoxane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: amisulpride with relative risk of -14.174 of dexrazoxane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.667\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target diazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó diclofenac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dolasetron with relative risk of -22.093 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dicyclomine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó didanosine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -9.967 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -10.350 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clonidine with relative risk of -10.545 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pindolol with relative risk of -10.581 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: allopurinol with relative risk of -11.801 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -11.939 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amiodarone with relative risk of -12.349 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tofacitinib with relative risk of -12.908 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target digoxin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dihydroergotamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bosentan with relative risk of -10.044 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -11.054 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aminophylline with relative risk of -11.826 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paricalcitol with relative risk of -11.871 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ramelteon with relative risk of -11.876 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pergolide with relative risk of -11.908 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apixaban with relative risk of -11.911 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: palonosetron with relative risk of -12.264 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sorafenib with relative risk of -12.311 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: esomeprazole with relative risk of -12.574 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clomipramine with relative risk of -12.701 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rilpivirine with relative risk of -13.450 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: canagliflozin with relative risk of -13.715 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.064\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó diltiazem *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -9.242 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: sparfloxacin with relative risk of -9.864 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -10.518 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nilotinib with relative risk of -10.740 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -11.343 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -11.605 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tazarotene with relative risk of -12.082 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amlexanox with relative risk of -12.592 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pinaverium with relative risk of -12.617 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fosinoprilat with relative risk of -12.853 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: triamcinolone with relative risk of -13.013 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tolterodine with relative risk of -13.771 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ziprasidone with relative risk of -13.953 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.126\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dipyridamole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of dipyridamole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: scopolamine with relative risk of -13.221 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: propranolol with relative risk of -13.246 of dipyridamole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Atrial Fibrillation,cardiology\n",
      "Rank 7: nicotine with relative risk of -13.313 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: avanafil with relative risk of -13.329 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rufinamide with relative risk of -13.344 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.147\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó disopyramide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -10.183 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -10.245 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.601 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -12.081 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -22.152 of disopyramide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: sparfloxacin with relative risk of -22.428 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mometasone with relative risk of -22.583 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tasimelteon with relative risk of -22.715 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: azathioprine with relative risk of -24.231 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: fosinoprilat with relative risk of -26.409 of disopyramide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: pinaverium with relative risk of -26.413 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: idarubicin with relative risk of -26.692 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pioglitazone with relative risk of -27.436 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mifepristone with relative risk of -27.720 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rivastigmine with relative risk of -28.067 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: delavirdine with relative risk of -28.404 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pitavastatin with relative risk of -29.151 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: frovatriptan with relative risk of -29.591 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: montelukast with relative risk of -29.709 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fesoterodine with relative risk of -30.012 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sulfasalazine with relative risk of -30.920 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flecainide with relative risk of -31.274 of disopyramide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: cisatracurium with relative risk of -32.261 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: candesartan with relative risk of -32.275 of disopyramide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.103\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó docetaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tadalafil with relative risk of -13.249 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dofetilide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dolasetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: diclofenac with relative risk of -22.172 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dolutegravir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dalbavancin with relative risk of -9.590 of dolutegravir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 3: penbutolol with relative risk of -9.799 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nateglinide with relative risk of -9.916 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -9.973 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: brinzolamide with relative risk of -10.315 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: metronidazole with relative risk of -10.370 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: quetiapine with relative risk of -10.903 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: metolazone with relative risk of -11.265 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: famotidine with relative risk of -11.373 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dexmedetomidine with relative risk of -14.797 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: linezolid with relative risk of -17.718 of dolutegravir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.188\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó domperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.160 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azathioprine with relative risk of -9.826 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: leflunomide with relative risk of -10.154 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -10.271 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pioglitazone with relative risk of -10.371 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: naproxen with relative risk of -10.952 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: aripiprazole with relative risk of -11.030 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desvenlafaxine with relative risk of -11.728 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: topiramate with relative risk of -11.858 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: meloxicam with relative risk of -12.148 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fosinopril with relative risk of -13.812 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tasimelteon with relative risk of -16.062 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sparfloxacin with relative risk of -16.134 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexamethasone with relative risk of -18.438 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -19.197 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: varenicline with relative risk of -19.727 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: apixaban with relative risk of -19.769 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ropinirole with relative risk of -19.901 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: crizotinib with relative risk of -20.430 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó donepezil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -9.423 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: bicalutamide with relative risk of -9.706 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -10.808 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sunitinib with relative risk of -11.382 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trimethoprim with relative risk of -11.605 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: linagliptin with relative risk of -12.077 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: quetiapine with relative risk of -12.289 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.23\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target doripenem not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -16.467 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxepin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olmesartan with relative risk of -7.274 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: allopurinol with relative risk of -8.224 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amiodarone with relative risk of -8.769 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: thalidomide with relative risk of -8.831 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: didanosine with relative risk of -8.880 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: risperidone with relative risk of -9.383 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: benazepril with relative risk of -16.095 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: doxazosin with relative risk of -16.227 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tofacitinib with relative risk of -16.517 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ifosfamide with relative risk of -23.848 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sildenafil with relative risk of -25.205 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dasatinib with relative risk of -28.381 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dofetilide with relative risk of -28.940 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: loratadine with relative risk of -29.168 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bupivacaine with relative risk of -29.328 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pruritus,neurology/psychiatry\n",
      "Rank 16: clonidine with relative risk of -73.377 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pindolol with relative risk of -128.911 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: verapamil with relative risk of -148.680 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.105\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxercalciferol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: prasugrel with relative risk of -12.855 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: progesterone with relative risk of -14.631 of doxercalciferol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: regorafenib with relative risk of -15.724 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: oxcarbazepine with relative risk of -17.389 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lidocaine with relative risk of -17.647 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: etravirine with relative risk of -22.472 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ropivacaine with relative risk of -30.470 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loperamide with relative risk of -35.356 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pentostatin with relative risk of -42.987 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tizanidine with relative risk of -46.726 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: paclitaxel with relative risk of -51.949 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alogliptin with relative risk of -58.581 of doxercalciferol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: ruxolitinib with relative risk of -74.608 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.183\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxorubicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zileuton with relative risk of -10.407 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiloride with relative risk of -10.708 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: letrozole with relative risk of -12.110 of doxorubicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: tafluprost with relative risk of -12.129 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.16\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target doxycycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dronedarone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: anastrozole with relative risk of -9.045 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: aminophylline with relative risk of -9.523 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: apixaban with relative risk of -9.612 of dronedarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: sorafenib with relative risk of -10.008 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clomipramine with relative risk of -10.399 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rilpivirine with relative risk of -11.147 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dihydroergotamine with relative risk of -11.411 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: canagliflozin with relative risk of -11.412 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: esomeprazole with relative risk of -18.823 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ixabepilone with relative risk of -23.569 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: orlistat with relative risk of -26.052 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: palonosetron with relative risk of -26.893 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fludarabine with relative risk of -32.915 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pergolide with relative risk of -33.548 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paricalcitol with relative risk of -41.773 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: balsalazide with relative risk of -49.729 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramelteon with relative risk of -50.224 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bosentan with relative risk of -64.513 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: gemcitabine with relative risk of -74.954 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.069\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó duloxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.668 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.749 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: erlotinib with relative risk of -9.779 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -10.183 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: terbutaline with relative risk of -10.495 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acebutolol with relative risk of -14.851 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tasimelteon with relative risk of -14.964 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: azathioprine with relative risk of -16.257 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pinaverium with relative risk of -18.396 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -18.670 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: sparfloxacin with relative risk of -22.428 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -22.583 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: teniposide with relative risk of -22.794 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexmedetomidine with relative risk of -23.809 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: nelarabine with relative risk of -24.237 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -26.409 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: estramustine with relative risk of -26.588 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nateglinide with relative risk of -27.385 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: axitinib with relative risk of -27.778 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trandolapril with relative risk of -29.023 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: milnacipran with relative risk of -31.505 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Fibromyalgia\n",
      "Rank 24: conivaptan with relative risk of -32.034 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: umeclidinium with relative risk of -32.038 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.159\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dutasteride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -9.490 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemfibrozil with relative risk of -10.913 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: everolimus with relative risk of -10.922 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 4: raltitrexed with relative risk of -10.924 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: glipizide with relative risk of -11.479 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: carbamazepine with relative risk of -12.104 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: teniposide with relative risk of -15.630 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mometasone with relative risk of -15.895 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: acebutolol with relative risk of -15.947 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tasimelteon with relative risk of -16.062 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -16.134 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nelarabine with relative risk of -17.016 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: budesonide with relative risk of -17.120 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: belinostat with relative risk of -17.160 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azathioprine with relative risk of -17.354 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rosiglitazone with relative risk of -17.361 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mirtazapine with relative risk of -17.701 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rosuvastatin with relative risk of -18.519 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dalbavancin with relative risk of -18.632 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: raloxifene with relative risk of -19.409 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pinaverium with relative risk of -19.494 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fosinoprilat with relative risk of -19.613 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: silodosin with relative risk of -19.830 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.101\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ecallantide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó efavirenz *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -13.237 of efavirenz | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó efinaconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: leflunomide with relative risk of -10.847 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of efinaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 11: varenicline with relative risk of -11.282 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: brimonidine with relative risk of -12.202 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -12.617 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.841 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.853 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ranolazine with relative risk of -12.929 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: labetalol with relative risk of -12.973 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: oxybutynin with relative risk of -13.326 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: betaxolol with relative risk of -13.384 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: eletriptan with relative risk of -14.109 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.027\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eletriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of eletriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: acebutolol with relative risk of -9.764 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: leflunomide with relative risk of -10.847 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of eletriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: brimonidine with relative risk of -12.202 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -12.617 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.841 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.853 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ranolazine with relative risk of -12.929 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: labetalol with relative risk of -12.973 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: oxybutynin with relative risk of -13.326 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: betaxolol with relative risk of -13.384 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.115\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eliglustat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sparfloxacin with relative risk of -9.172 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: felbamate with relative risk of -10.815 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: teniposide with relative risk of -15.630 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mometasone with relative risk of -15.895 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -15.947 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: tasimelteon with relative risk of -16.062 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nelarabine with relative risk of -17.016 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: budesonide with relative risk of -17.120 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: belinostat with relative risk of -17.160 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: azathioprine with relative risk of -17.354 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rosiglitazone with relative risk of -17.361 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mirtazapine with relative risk of -17.701 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: flumazenil with relative risk of -18.292 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pinaverium with relative risk of -19.494 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -19.613 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: telithromycin with relative risk of -19.696 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gemfibrozil with relative risk of -19.869 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nedocromil with relative risk of -20.110 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: glimepiride with relative risk of -20.152 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: capsaicin with relative risk of -20.221 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -20.703 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rocuronium with relative risk of -22.230 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target eltrombopag not found. Exiting ...\n",
      "\n",
      "Drug target elvitegravir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó emedastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pergolide with relative risk of -11.215 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: citalopram with relative risk of -11.586 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dapsone with relative risk of -12.342 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -12.394 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -17.246 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -19.210 of emedastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 9: telmisartan with relative risk of -19.532 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxapine with relative risk of -20.494 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: salmeterol with relative risk of -20.553 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -21.267 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -21.507 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: estradiol with relative risk of -22.393 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pramipexole with relative risk of -22.677 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tegaserod with relative risk of -23.025 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -23.445 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.036\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó empagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of empagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: cytarabine with relative risk of -11.432 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of empagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: etodolac with relative risk of -12.358 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -13.050 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atomoxetine with relative risk of -13.107 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lamotrigine with relative risk of -13.180 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pimozide with relative risk of -13.452 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alendronate with relative risk of -13.888 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.43\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target emtricitabine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó entacapone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: travoprost with relative risk of -12.361 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target entecavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eplerenone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sotalol with relative risk of -20.493 of eplerenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eprosartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.291 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -11.564 of eprosartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: lurasidone with relative risk of -11.944 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loxapine with relative risk of -12.169 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ivermectin with relative risk of -12.267 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicardipine with relative risk of -12.655 of eprosartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: rasagiline with relative risk of -12.896 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.257\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target eribulin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó erlotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -7.422 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -8.146 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -8.345 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nelarabine with relative risk of -8.754 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -8.769 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rosiglitazone with relative risk of -8.982 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: axitinib with relative risk of -9.566 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: nateglinide with relative risk of -10.203 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -10.263 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: ribavirin with relative risk of -10.569 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -10.603 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: duloxetine with relative risk of -10.795 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: trandolapril with relative risk of -10.811 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: milnacipran with relative risk of -10.990 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lapatinib with relative risk of -11.513 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 16: conivaptan with relative risk of -11.519 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: umeclidinium with relative risk of -11.523 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -11.757 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ondansetron with relative risk of -11.772 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rabeprazole with relative risk of -11.792 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Endocrine Neoplasia\n",
      "Rank 21: darunavir with relative risk of -12.183 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections\n",
      "Rank 22: fluconazole with relative risk of -12.323 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tropisetron with relative risk of -12.376 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: tolcapone with relative risk of -12.710 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: acebutolol with relative risk of -14.851 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: dexmedetomidine with relative risk of -15.490 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: bromocriptine with relative risk of -18.839 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: metoprolol with relative risk of -18.975 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: flutamide with relative risk of -19.150 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 30: felbamate with relative risk of -19.365 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: metronidazole with relative risk of -19.613 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: dabrafenib with relative risk of -20.245 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 33: bisoprolol with relative risk of -20.837 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: cilostazol with relative risk of -20.912 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: famotidine with relative risk of -21.022 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: propafenone with relative risk of -21.974 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fluocinonide with relative risk of -22.111 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: terazosin with relative risk of -22.228 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: budesonide with relative risk of -24.284 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.114\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ertapenem not found. Exiting ...\n",
      "\n",
      "Drug target eslicarbazepine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó esmolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bumetanide with relative risk of -10.400 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: mivacurium with relative risk of -11.888 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clopidogrel with relative risk of -15.000 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.727\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó esomeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.160 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ixabepilone with relative risk of -10.038 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fludarabine with relative risk of -10.582 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: orlistat with relative risk of -10.730 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: aminophylline with relative risk of -11.133 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -11.218 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sorafenib with relative risk of -11.618 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clomipramine with relative risk of -12.008 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rilpivirine with relative risk of -12.757 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dihydroergotamine with relative risk of -13.020 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: canagliflozin with relative risk of -13.022 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemcitabine with relative risk of -17.478 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bosentan with relative risk of -17.902 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dronedarone with relative risk of -18.912 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: balsalazide with relative risk of -19.644 of esomeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 16: ramelteon with relative risk of -20.140 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: paricalcitol with relative risk of -20.316 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pergolide with relative risk of -20.577 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: palonosetron with relative risk of -21.625 of esomeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.034\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target estazolam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó estradiol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV\n",
      "Rank 2: pergolide with relative risk of -11.215 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: citalopram with relative risk of -11.586 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dapsone with relative risk of -12.342 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris\n",
      "Rank 6: isradipine with relative risk of -12.394 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 7: captopril with relative risk of -17.246 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,endocrinology\n",
      "Rank 8: desloratadine with relative risk of -19.210 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -19.532 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 10: amoxapine with relative risk of -20.494 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: salmeterol with relative risk of -20.553 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -21.267 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -21.507 of estradiol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV\n",
      "Rank 14: emedastine with relative risk of -21.624 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pramipexole with relative risk of -22.677 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tegaserod with relative risk of -23.025 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -23.445 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.494\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó estramustine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.297 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: rosuvastatin with relative risk of -8.206 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: leflunomide with relative risk of -8.286 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -8.314 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: varenicline with relative risk of -8.719 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rivastigmine with relative risk of -8.797 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: desloratadine with relative risk of -8.898 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: linezolid with relative risk of -8.972 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: terbutaline with relative risk of -9.030 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: miglustat with relative risk of -9.261 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: atosiban with relative risk of -9.456 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gonadorelin with relative risk of -9.664 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ranitidine with relative risk of -9.783 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: halofantrine with relative risk of -10.505 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: hydrochlorothiazide with relative risk of -10.943 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: acebutolol with relative risk of -11.613 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tasimelteon with relative risk of -11.719 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azathioprine with relative risk of -13.009 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pinaverium with relative risk of -15.148 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: apixaban with relative risk of -15.416 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sparfloxacin with relative risk of -16.790 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: mometasone with relative risk of -16.939 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: teniposide with relative risk of -17.146 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: norfloxacin with relative risk of -18.050 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: nelarabine with relative risk of -18.588 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: budesonide with relative risk of -18.636 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fondaparinux with relative risk of -18.644 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rosiglitazone with relative risk of -19.058 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: fosinoprilat with relative risk of -20.764 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: nateglinide with relative risk of -21.732 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: axitinib with relative risk of -22.123 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 32: trandolapril with relative risk of -23.369 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: dexmedetomidine with relative risk of -24.525 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: iloperidone with relative risk of -24.847 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: duloxetine with relative risk of -25.654 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: milnacipran with relative risk of -25.849 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: conivaptan with relative risk of -26.378 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: umeclidinium with relative risk of -26.382 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: indomethacin with relative risk of -62.512 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lubiprostone with relative risk of -64.540 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: penbutolol with relative risk of -75.617 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: cabergoline with relative risk of -80.571 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: anagrelide with relative risk of -82.281 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: mirabegron with relative risk of -83.487 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: moxifloxacin with relative risk of -83.933 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: nabumetone with relative risk of -84.130 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.29\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etodolac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metolazone with relative risk of -12.652 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phenytoin with relative risk of -12.906 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -13.050 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atomoxetine with relative risk of -13.107 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: empagliflozin with relative risk of -13.142 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lamotrigine with relative risk of -13.180 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pimozide with relative risk of -13.452 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alendronate with relative risk of -13.888 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etoposide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -9.441 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acebutolol with relative risk of -9.764 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: posaconazole with relative risk of -11.512 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pravastatin with relative risk of -13.605 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fenofibrate with relative risk of -13.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etravirine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paclitaxel with relative risk of -7.308 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lidocaine with relative risk of -11.705 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: doxercalciferol with relative risk of -21.055 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loperamide with relative risk of -21.981 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tizanidine with relative risk of -22.585 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ruxolitinib with relative risk of -23.214 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: alogliptin with relative risk of -24.523 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó everolimus *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -9.490 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: leflunomide with relative risk of -10.154 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 3: risedronate with relative risk of -10.241 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -10.271 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: pioglitazone with relative risk of -10.371 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bromocriptine with relative risk of -10.576 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of -10.763 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: silodosin with relative risk of -10.874 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 9: apixaban with relative risk of -11.218 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: adenosine with relative risk of -11.222 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: omeprazole with relative risk of -11.386 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: glipizide with relative risk of -11.479 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dapagliflozin with relative risk of -11.844 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: carbamazepine with relative risk of -12.104 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: dutasteride with relative risk of -12.646 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 16: teniposide with relative risk of -15.630 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mometasone with relative risk of -15.895 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: acebutolol with relative risk of -15.947 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tasimelteon with relative risk of -16.062 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: sparfloxacin with relative risk of -16.134 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nelarabine with relative risk of -17.016 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: budesonide with relative risk of -17.120 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: belinostat with relative risk of -17.160 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: azathioprine with relative risk of -17.354 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 25: rosiglitazone with relative risk of -17.361 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: mirtazapine with relative risk of -17.701 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: rosuvastatin with relative risk of -18.519 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dalbavancin with relative risk of -18.632 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pinaverium with relative risk of -19.494 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fosinoprilat with relative risk of -19.613 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: gemfibrozil with relative risk of -19.869 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: raltitrexed with relative risk of -20.063 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.64\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó exemestane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -9.423 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -9.706 of exemestane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: linezolid with relative risk of -11.533 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trimethoprim with relative risk of -11.605 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metronidazole with relative risk of -11.756 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ranitidine with relative risk of -12.347 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: hydrochlorothiazide with relative risk of -13.508 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.193\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó exenatide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: prazosin with relative risk of -11.008 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tolvaptan with relative risk of -12.970 of exenatide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ezetimibe not found. Exiting ...\n",
      "\n",
      "Drug target famciclovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó famotidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.345 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -9.877 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nateglinide with relative risk of -10.203 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -10.260 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: linezolid with relative risk of -10.435 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ribavirin with relative risk of -10.569 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dolutegravir with relative risk of -10.727 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: quetiapine with relative risk of -11.191 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lapatinib with relative risk of -11.513 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: metolazone with relative risk of -11.553 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ondansetron with relative risk of -11.772 of famotidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 13: rabeprazole with relative risk of -11.792 of famotidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Zollinger-Ellison syndrome,Gastroesophageal reflux disease,Duodenal Ulcer,gastroenterology\n",
      "Rank 14: darunavir with relative risk of -12.183 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fluconazole with relative risk of -12.323 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tropisetron with relative risk of -12.376 of famotidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 17: tolcapone with relative risk of -12.710 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: acebutolol with relative risk of -14.851 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dexmedetomidine with relative risk of -15.490 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: budesonide with relative risk of -16.022 of famotidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 21: bromocriptine with relative risk of -18.839 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: metoprolol with relative risk of -18.975 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: erlotinib with relative risk of -19.141 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: flutamide with relative risk of -19.150 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: brinzolamide with relative risk of -19.271 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: felbamate with relative risk of -19.365 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dabrafenib with relative risk of -20.245 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: bisoprolol with relative risk of -20.837 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: cilostazol with relative risk of -20.912 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: propafenone with relative risk of -21.974 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fluocinonide with relative risk of -22.111 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: terazosin with relative risk of -22.228 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: metronidazole with relative risk of -30.074 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.067\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó febuxostat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indacaterol with relative risk of -10.132 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó felbamate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.039 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: flumazenil with relative risk of -8.797 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rosuvastatin with relative risk of -9.381 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: leflunomide with relative risk of -9.462 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: raloxifene with relative risk of -9.578 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dalbavancin with relative risk of -9.590 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: silodosin with relative risk of -10.181 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: raltitrexed with relative risk of -10.232 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ribavirin with relative risk of -10.281 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: brinzolamide with relative risk of -10.315 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: eliglustat with relative risk of -10.373 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: apixaban with relative risk of -10.526 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: glipizide with relative risk of -10.786 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: lapatinib with relative risk of -11.225 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ondansetron with relative risk of -11.485 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rabeprazole with relative risk of -11.504 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: darunavir with relative risk of -11.895 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluconazole with relative risk of -12.035 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tropisetron with relative risk of -12.088 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tolcapone with relative risk of -12.422 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: teniposide with relative risk of -13.840 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: mometasone with relative risk of -14.106 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sparfloxacin with relative risk of -14.346 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nelarabine with relative risk of -15.225 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: belinostat with relative risk of -15.370 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: azathioprine with relative risk of -15.565 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: rosiglitazone with relative risk of -15.571 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: mirtazapine with relative risk of -15.910 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: pinaverium with relative risk of -17.704 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fosinoprilat with relative risk of -17.823 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: telithromycin with relative risk of -17.905 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: gemfibrozil with relative risk of -18.077 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: metoprolol with relative risk of -18.282 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: nedocromil with relative risk of -18.318 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: glimepiride with relative risk of -18.360 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: capsaicin with relative risk of -18.429 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 37: erlotinib with relative risk of -18.448 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: flutamide with relative risk of -18.457 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: vilazodone with relative risk of -18.912 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: metronidazole with relative risk of -18.920 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: dabrafenib with relative risk of -19.552 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: bisoprolol with relative risk of -20.144 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: cilostazol with relative risk of -20.219 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: famotidine with relative risk of -20.329 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: rocuronium with relative risk of -20.438 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: propafenone with relative risk of -21.281 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: tasimelteon with relative risk of -21.330 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: fluocinonide with relative risk of -21.418 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: terazosin with relative risk of -21.534 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: bromocriptine with relative risk of -27.507 of felbamate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: acebutolol with relative risk of -28.378 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: budesonide with relative risk of -31.506 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.389\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó felodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olanzapine with relative risk of -13.044 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cimetidine with relative risk of -14.309 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fenofibrate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -9.441 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acebutolol with relative risk of -9.764 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etoposide with relative risk of -11.275 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -11.512 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pravastatin with relative risk of -13.605 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Familial hypercholesterolemia - heterozygous,Hypercholesterolemia,Hypertriglyceridemia,Hyperlipidemia, Familial Combined,endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fenofibric not found. Exiting ...\n",
      "\n",
      "Drug target fentanyl not found. Exiting ...\n",
      "\n",
      "Drug target ferumoxytol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fesoterodine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.734 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -28.112 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -38.114 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: idarubicin with relative risk of -46.108 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -47.136 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pitavastatin with relative risk of -47.469 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: delavirdine with relative risk of -47.820 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: frovatriptan with relative risk of -49.007 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: montelukast with relative risk of -49.125 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fexofenadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: norfloxacin with relative risk of -10.407 of fexofenadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: desloratadine with relative risk of -14.704 of fexofenadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic idiopathic urticaria,Hay fever,Sneezing,Allergic Conjunctivitis,Allergic rhinitis (disorder),allergy\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fidaxomicin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó finasteride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clofarabine with relative risk of -11.059 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.786 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: quinidine with relative risk of -12.264 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flecainide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -10.183 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -10.245 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.601 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -12.081 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -22.152 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: sparfloxacin with relative risk of -22.428 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mometasone with relative risk of -22.583 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tasimelteon with relative risk of -22.715 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: azathioprine with relative risk of -24.231 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: fosinoprilat with relative risk of -26.409 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: pinaverium with relative risk of -26.413 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: idarubicin with relative risk of -26.692 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pioglitazone with relative risk of -27.436 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mifepristone with relative risk of -27.720 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rivastigmine with relative risk of -28.067 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: delavirdine with relative risk of -28.404 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pitavastatin with relative risk of -29.151 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: frovatriptan with relative risk of -29.591 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: montelukast with relative risk of -29.709 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fesoterodine with relative risk of -30.012 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: disopyramide with relative risk of -30.415 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: sulfasalazine with relative risk of -30.920 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: cisatracurium with relative risk of -32.261 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: candesartan with relative risk of -32.275 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.103\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target florbetapir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -9.423 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: budesonide with relative risk of -10.009 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metoprolol with relative risk of -10.712 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: erlotinib with relative risk of -10.878 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: flutamide with relative risk of -10.887 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bromocriptine with relative risk of -11.269 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dabrafenib with relative risk of -11.289 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: felbamate with relative risk of -11.508 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -11.701 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -11.756 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cilostazol with relative risk of -11.956 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bisoprolol with relative risk of -12.574 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -12.759 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ondansetron with relative risk of -12.871 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rabeprazole with relative risk of -12.891 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: propafenone with relative risk of -13.018 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fluocinonide with relative risk of -13.154 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: terazosin with relative risk of -13.271 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: darunavir with relative risk of -13.281 of fluconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.013\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fludarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.246 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: aminophylline with relative risk of -10.216 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: apixaban with relative risk of -10.303 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: palonosetron with relative risk of -10.654 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sorafenib with relative risk of -10.701 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: esomeprazole with relative risk of -10.965 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clomipramine with relative risk of -11.092 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rilpivirine with relative risk of -11.840 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dihydroergotamine with relative risk of -12.104 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: canagliflozin with relative risk of -12.106 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pergolide with relative risk of -18.274 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemcitabine with relative risk of -23.151 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ixabepilone with relative risk of -26.053 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: paricalcitol with relative risk of -26.682 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: orlistat with relative risk of -28.537 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dronedarone with relative risk of -33.387 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: balsalazide with relative risk of -35.149 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramelteon with relative risk of -35.644 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bosentan with relative risk of -42.249 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flumazenil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -7.349 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: axitinib with relative risk of -8.586 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: risedronate with relative risk of -8.856 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -8.886 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dalbavancin with relative risk of -8.899 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bromocriptine with relative risk of -9.190 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nateglinide with relative risk of -9.224 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fluoxetine with relative risk of -9.267 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: felbamate with relative risk of -9.429 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: silodosin with relative risk of -9.489 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: terbutaline with relative risk of -9.515 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: everolimus with relative risk of -9.536 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: aripiprazole with relative risk of -9.644 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trandolapril with relative risk of -9.831 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: apixaban with relative risk of -9.834 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: omeprazole with relative risk of -10.000 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: glipizide with relative risk of -10.093 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rofecoxib with relative risk of -10.202 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dapagliflozin with relative risk of -10.459 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramipril with relative risk of -10.654 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: carbamazepine with relative risk of -10.717 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: dutasteride with relative risk of -11.260 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: quinapril with relative risk of -11.426 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rosuvastatin with relative risk of -15.189 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: leflunomide with relative risk of -15.625 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: eliglustat with relative risk of -18.482 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: rocuronium with relative risk of -18.898 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: raltitrexed with relative risk of -24.707 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sparfloxacin with relative risk of -31.066 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: gemfibrozil with relative risk of -32.735 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: nedocromil with relative risk of -34.180 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: glimepiride with relative risk of -34.221 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: vilazodone with relative risk of -34.773 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: rosiglitazone with relative risk of -35.590 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: belinostat with relative risk of -36.115 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: mirtazapine with relative risk of -36.656 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 37: tasimelteon with relative risk of -39.554 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: telithromycin with relative risk of -41.048 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: azathioprine with relative risk of -41.794 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: budesonide with relative risk of -42.804 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: nelarabine with relative risk of -42.951 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pinaverium with relative risk of -44.115 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: teniposide with relative risk of -49.982 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: fosinoprilat with relative risk of -51.926 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: capsaicin with relative risk of -52.320 of flumazenil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: acebutolol with relative risk of -53.507 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -56.574 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.418\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flunisolide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ketoprofen with relative risk of -11.547 of flunisolide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -11.672 of flunisolide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amoxicillin with relative risk of -13.617 of flunisolide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fluocinolone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluocinonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.974 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -11.008 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.918 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -12.178 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -12.198 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.588 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.728 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.781 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -13.115 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acebutolol with relative risk of -15.947 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: budesonide with relative risk of -17.120 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bromocriptine with relative risk of -19.937 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: metoprolol with relative risk of -20.074 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: erlotinib with relative risk of -20.239 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -20.248 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felbamate with relative risk of -20.464 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -20.712 of fluocinonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 20: dabrafenib with relative risk of -21.344 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bisoprolol with relative risk of -21.935 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cilostazol with relative risk of -22.011 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: famotidine with relative risk of -22.121 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: propafenone with relative risk of -23.073 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terazosin with relative risk of -23.326 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.014\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluoxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.797 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: verapamil with relative risk of -8.967 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rosuvastatin with relative risk of -9.381 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: leflunomide with relative risk of -9.462 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -10.181 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -10.526 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: raltitrexed with relative risk of -18.271 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: acebutolol with relative risk of -20.768 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sparfloxacin with relative risk of -21.043 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mometasone with relative risk of -21.198 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tasimelteon with relative risk of -21.330 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: teniposide with relative risk of -21.409 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dexmedetomidine with relative risk of -22.423 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: azathioprine with relative risk of -22.846 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -22.852 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -22.899 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -23.322 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: belinostat with relative risk of -23.344 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mirtazapine with relative risk of -23.885 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 20: fosinoprilat with relative risk of -25.024 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pinaverium with relative risk of -25.028 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nateglinide with relative risk of -25.999 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: axitinib with relative risk of -26.392 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: trandolapril with relative risk of -27.637 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terbutaline with relative risk of -28.525 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: dapagliflozin with relative risk of -28.775 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: rofecoxib with relative risk of -30.311 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ramipril with relative risk of -30.763 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinapril with relative risk of -31.535 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.35\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.326 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.345 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.569 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -10.603 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.513 of flutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: ondansetron with relative risk of -11.772 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -11.792 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.183 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.323 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.376 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -12.710 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: budesonide with relative risk of -16.022 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bromocriptine with relative risk of -18.839 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: erlotinib with relative risk of -19.141 of flutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 15: felbamate with relative risk of -19.365 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: metronidazole with relative risk of -19.613 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dabrafenib with relative risk of -20.245 of flutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 18: cilostazol with relative risk of -20.912 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: famotidine with relative risk of -21.022 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: propafenone with relative risk of -21.974 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluocinonide with relative risk of -22.111 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -22.152 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: terazosin with relative risk of -22.228 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: metoprolol with relative risk of -30.129 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: bisoprolol with relative risk of -31.990 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.087\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fluticasone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: voriconazole with relative risk of -13.558 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluvoxamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.810 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilutamide with relative risk of -11.672 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: albendazole with relative risk of -13.428 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azilsartan with relative risk of -13.967 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fondaparinux *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: miglustat with relative risk of -11.133 of fondaparinux | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 2: halofantrine with relative risk of -12.377 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: hydrochlorothiazide with relative risk of -12.814 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indomethacin with relative risk of -16.036 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lubiprostone with relative risk of -16.528 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: anagrelide with relative risk of -18.104 of fondaparinux | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 7: cabergoline with relative risk of -18.591 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: penbutolol with relative risk of -18.599 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -18.931 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirabegron with relative risk of -19.310 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: moxifloxacin with relative risk of -19.756 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -19.952 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: iloperidone with relative risk of -21.141 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.367\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó formoterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olmesartan with relative risk of -50.640 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lansoprazole with relative risk of -52.554 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -59.899 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fosaprepitant not found. Exiting ...\n",
      "\n",
      "Drug target foscarnet not found. Exiting ...\n",
      "\n",
      "Drug target fosfomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosinopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sparfloxacin with relative risk of -9.864 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: azathioprine with relative risk of -10.518 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dexamethasone with relative risk of -10.580 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: leflunomide with relative risk of -10.847 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: risedronate with relative risk of -10.933 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: raloxifene with relative risk of -10.964 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pioglitazone with relative risk of -11.064 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: crizotinib with relative risk of -11.068 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ropinirole with relative risk of -11.456 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aripiprazole with relative risk of -11.723 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: apixaban with relative risk of -11.911 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: desvenlafaxine with relative risk of -12.421 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: topiramate with relative risk of -12.551 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: meloxicam with relative risk of -12.841 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: domperidone with relative risk of -13.940 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.02\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosinoprilat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.050 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: dexamethasone with relative risk of -7.258 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilotinib with relative risk of -7.413 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -7.548 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: crizotinib with relative risk of -7.738 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trimethoprim with relative risk of -8.279 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: naproxen with relative risk of -8.314 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentoxifylline with relative risk of -8.378 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: adenosine with relative risk of -8.583 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: tazarotene with relative risk of -8.751 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brimonidine with relative risk of -8.870 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: desvenlafaxine with relative risk of -9.090 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: topiramate with relative risk of -9.220 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: amlexanox with relative risk of -9.262 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: granisetron with relative risk of -9.367 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: carbamazepine with relative risk of -9.464 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ranolazine with relative risk of -9.598 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: labetalol with relative risk of -9.641 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: triamcinolone with relative risk of -9.681 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nalbuphine with relative risk of -9.847 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nevirapine with relative risk of -9.904 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: oxybutynin with relative risk of -9.994 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: betaxolol with relative risk of -10.052 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: tolterodine with relative risk of -10.439 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: diltiazem with relative risk of -10.527 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 26: ziprasidone with relative risk of -10.621 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: loteprednol with relative risk of -10.708 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: eletriptan with relative risk of -10.777 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: bromocriptine with relative risk of -14.006 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: felbamate with relative risk of -14.531 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: gefitinib with relative risk of -14.771 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: omeprazole with relative risk of -15.102 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: everolimus with relative risk of -15.735 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: eliglustat with relative risk of -15.879 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -16.269 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: glipizide with relative risk of -16.292 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dutasteride with relative risk of -17.459 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: estramustine with relative risk of -18.504 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: risedronate with relative risk of -19.552 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: rivastigmine with relative risk of -19.977 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: fluoxetine with relative risk of -21.570 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: disopyramide with relative risk of -22.320 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: sulfasalazine with relative risk of -22.825 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: flecainide with relative risk of -23.180 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: duloxetine with relative risk of -23.216 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: milnacipran with relative risk of -23.411 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: rofecoxib with relative risk of -23.603 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: conivaptan with relative risk of -23.940 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: umeclidinium with relative risk of -23.944 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ramipril with relative risk of -24.055 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: candesartan with relative risk of -24.181 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: rocuronium with relative risk of -24.191 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: quinapril with relative risk of -24.827 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: raloxifene with relative risk of -27.109 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: varenicline with relative risk of -27.427 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ropinirole with relative risk of -27.601 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: terbutaline with relative risk of -30.039 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dexmedetomidine with relative risk of -33.027 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: idarubicin with relative risk of -34.613 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: mifepristone with relative risk of -35.641 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: pitavastatin with relative risk of -35.974 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: delavirdine with relative risk of -36.325 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: nedocromil with relative risk of -36.987 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: glimepiride with relative risk of -37.029 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: frovatriptan with relative risk of -37.512 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vilazodone with relative risk of -37.580 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: montelukast with relative risk of -37.629 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: fesoterodine with relative risk of -37.933 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: dapagliflozin with relative risk of -38.083 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: nateglinide with relative risk of -39.926 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: cisatracurium with relative risk of -40.182 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: leflunomide with relative risk of -40.452 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: capsaicin with relative risk of -42.814 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: axitinib with relative risk of -43.311 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: raltitrexed with relative risk of -44.265 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: trandolapril with relative risk of -44.557 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 77: apixaban with relative risk of -47.248 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 78: flumazenil with relative risk of -48.003 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pioglitazone with relative risk of -48.884 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: telithromycin with relative risk of -49.408 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: silodosin with relative risk of -51.332 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: gemfibrozil with relative risk of -51.371 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 83: dalbavancin with relative risk of -52.088 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: rosuvastatin with relative risk of -79.327 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 85: belinostat with relative risk of -90.337 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: mirtazapine with relative risk of -90.878 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: rosiglitazone with relative risk of -112.996 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: budesonide with relative risk of -116.454 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: nelarabine with relative risk of -127.994 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: teniposide with relative risk of -145.266 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: sparfloxacin with relative risk of -160.096 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: acebutolol with relative risk of -166.124 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: tasimelteon with relative risk of -183.353 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: azathioprine with relative risk of -185.727 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: pinaverium with relative risk of -191.044 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: mometasone with relative risk of -195.843 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: efinaconazole with relative risk of -inf of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.302\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosphenytoin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vincristine with relative risk of -10.623 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: irbesartan with relative risk of -13.619 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: phentolamine with relative risk of -13.684 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fospropofol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó frovatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: gefitinib with relative risk of -9.734 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: disopyramide with relative risk of -28.112 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: azathioprine with relative risk of -38.114 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: idarubicin with relative risk of -46.108 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -47.136 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pitavastatin with relative risk of -47.469 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: delavirdine with relative risk of -47.820 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: montelukast with relative risk of -49.125 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -49.429 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.415\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fusidic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gabapentin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acamprosate with relative risk of -10.587 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pemetrexed with relative risk of -11.031 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vinorelbine with relative risk of -11.119 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: treprostinil with relative risk of -11.400 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gadobenate not found. Exiting ...\n",
      "\n",
      "Drug target gadobutrol not found. Exiting ...\n",
      "\n",
      "Drug target gadolinium not found. Exiting ...\n",
      "\n",
      "Drug target gadopentetate not found. Exiting ...\n",
      "\n",
      "Drug target gadoteridol not found. Exiting ...\n",
      "\n",
      "Drug target gadoversetamide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó galantamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zileuton with relative risk of -11.100 of galantamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: irinotecan with relative risk of -12.010 of galantamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tafluprost with relative risk of -12.822 of galantamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ganciclovir not found. Exiting ...\n",
      "\n",
      "Drug target gatifloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gefitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: imatinib with relative risk of -7.932 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: idarubicin with relative risk of -7.969 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mifepristone with relative risk of -8.997 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bumetanide with relative risk of -9.303 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nilotinib with relative risk of -9.642 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: delavirdine with relative risk of -9.681 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: disopyramide with relative risk of -9.900 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pioglitazone with relative risk of -9.966 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rivastigmine with relative risk of -10.260 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sulfasalazine with relative risk of -10.405 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trimethoprim with relative risk of -10.507 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flecainide with relative risk of -10.759 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: frovatriptan with relative risk of -10.868 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pitavastatin with relative risk of -10.939 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tazarotene with relative risk of -10.983 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: montelukast with relative risk of -10.985 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fesoterodine with relative risk of -11.289 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ipratropium with relative risk of -11.476 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: amlexanox with relative risk of -11.494 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: candesartan with relative risk of -11.760 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: triamcinolone with relative risk of -11.915 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -12.443 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tolterodine with relative risk of -12.673 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: diltiazem with relative risk of -12.761 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ziprasidone with relative risk of -12.854 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: cisatracurium with relative risk of -13.538 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: mometasone with relative risk of -14.798 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: acebutolol with relative risk of -14.851 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tasimelteon with relative risk of -14.964 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sparfloxacin with relative risk of -15.037 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: azathioprine with relative risk of -16.257 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: pinaverium with relative risk of -18.396 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fosinoprilat with relative risk of -18.515 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.245\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gemcitabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: captopril with relative risk of -7.194 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amoxapine with relative risk of -8.830 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: regadenoson with relative risk of -8.909 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anastrozole with relative risk of -9.045 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: capecitabine with relative risk of -9.150 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "Rank 7: desloratadine with relative risk of -9.159 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: telmisartan with relative risk of -9.257 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: emedastine with relative risk of -9.267 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: salmeterol with relative risk of -9.296 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: aminophylline with relative risk of -9.523 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: apixaban with relative risk of -9.612 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sorafenib with relative risk of -10.008 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 14: estradiol with relative risk of -10.036 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV\n",
      "Rank 15: pramipexole with relative risk of -10.320 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clomipramine with relative risk of -10.399 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tegaserod with relative risk of -10.668 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: almotriptan with relative risk of -11.088 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rilpivirine with relative risk of -11.147 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dihydroergotamine with relative risk of -11.411 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: canagliflozin with relative risk of -11.412 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: esomeprazole with relative risk of -18.823 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ixabepilone with relative risk of -23.569 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "Rank 24: fludarabine with relative risk of -24.113 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: orlistat with relative risk of -26.052 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: palonosetron with relative risk of -26.893 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: paricalcitol with relative risk of -32.594 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: balsalazide with relative risk of -40.185 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ramelteon with relative risk of -40.681 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: pergolide with relative risk of -43.420 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: bosentan with relative risk of -54.576 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: dronedarone with relative risk of -76.388 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.384\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gemeprost not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gemfibrozil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: risedronate with relative risk of -8.989 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: pioglitazone with relative risk of -9.120 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: varenicline with relative risk of -9.337 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ropinirole with relative risk of -9.511 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -9.759 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: adenosine with relative risk of -9.969 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: omeprazole with relative risk of -10.134 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: brimonidine with relative risk of -10.256 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dapagliflozin with relative risk of -10.592 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 10: carbamazepine with relative risk of -10.851 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: meloxicam with relative risk of -10.895 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ranolazine with relative risk of -10.984 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: labetalol with relative risk of -11.027 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: oxybutynin with relative risk of -11.380 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dutasteride with relative risk of -11.393 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: betaxolol with relative risk of -11.438 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: eletriptan with relative risk of -12.164 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: apixaban with relative risk of -16.726 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: silodosin with relative risk of -16.786 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bromocriptine with relative risk of -16.893 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 21: felbamate with relative risk of -17.420 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: everolimus with relative risk of -18.625 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: eliglustat with relative risk of -18.770 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: glipizide with relative risk of -19.183 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 25: leflunomide with relative risk of -23.665 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: raloxifene with relative risk of -24.523 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: raltitrexed with relative risk of -25.176 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rocuronium with relative risk of -28.730 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dalbavancin with relative risk of -30.688 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: rosuvastatin with relative risk of -30.797 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertriglyceridemia,endocrinology,cardiology\n",
      "Rank 31: flumazenil with relative risk of -31.445 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sparfloxacin with relative risk of -32.045 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: telithromycin with relative risk of -32.850 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: capsaicin with relative risk of -33.780 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: nedocromil with relative risk of -34.873 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: glimepiride with relative risk of -34.914 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 37: vilazodone with relative risk of -35.466 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: budesonide with relative risk of -35.745 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nelarabine with relative risk of -35.823 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: rosiglitazone with relative risk of -36.570 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: belinostat with relative risk of -37.096 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: mirtazapine with relative risk of -37.637 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: acebutolol with relative risk of -47.190 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: tasimelteon with relative risk of -49.681 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: mometasone with relative risk of -49.697 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: teniposide with relative risk of -52.061 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azathioprine with relative risk of -52.183 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: fosinoprilat with relative risk of -54.005 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 49: pinaverium with relative risk of -54.556 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: efinaconazole with relative risk of -inf of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.531\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gemifloxacin not found. Exiting ...\n",
      "\n",
      "Drug target gliclazide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glimepiride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.158 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: leflunomide with relative risk of -9.239 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -9.355 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dalbavancin with relative risk of -9.368 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bromocriptine with relative risk of -9.660 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: silodosin with relative risk of -9.958 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: raltitrexed with relative risk of -10.009 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apixaban with relative risk of -10.303 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: glipizide with relative risk of -10.563 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 10: sparfloxacin with relative risk of -13.837 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: felbamate with relative risk of -18.162 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: eliglustat with relative risk of -19.512 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nelarabine with relative risk of -21.936 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -21.983 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rosiglitazone with relative risk of -22.407 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: belinostat with relative risk of -22.429 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mirtazapine with relative risk of -22.969 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tasimelteon with relative risk of -27.795 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azathioprine with relative risk of -29.542 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rocuronium with relative risk of -29.982 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pinaverium with relative risk of -31.768 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flumazenil with relative risk of -33.391 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: acebutolol with relative risk of -34.626 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gemfibrozil with relative risk of -35.373 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 25: mometasone with relative risk of -36.065 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: teniposide with relative risk of -37.298 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -40.122 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telithromycin with relative risk of -45.073 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: capsaicin with relative risk of -46.291 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: nedocromil with relative risk of -48.483 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vilazodone with relative risk of -49.076 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.336\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glipizide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -9.490 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -10.154 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bromocriptine with relative risk of -10.576 of glipizide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: nedocromil with relative risk of -10.748 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: glimepiride with relative risk of -10.790 of glipizide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 6: felbamate with relative risk of -10.815 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: telithromycin with relative risk of -10.895 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: everolimus with relative risk of -10.922 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: apixaban with relative risk of -11.218 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: capsaicin with relative risk of -11.264 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vilazodone with relative risk of -11.341 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: carbamazepine with relative risk of -12.104 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rocuronium with relative risk of -12.175 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dutasteride with relative risk of -12.646 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: teniposide with relative risk of -15.630 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mometasone with relative risk of -15.895 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: acebutolol with relative risk of -15.947 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tasimelteon with relative risk of -16.062 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: sparfloxacin with relative risk of -16.134 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nelarabine with relative risk of -17.016 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: budesonide with relative risk of -17.120 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: belinostat with relative risk of -17.160 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azathioprine with relative risk of -17.354 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rosiglitazone with relative risk of -17.361 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mirtazapine with relative risk of -17.701 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rosuvastatin with relative risk of -18.519 of glipizide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 27: dalbavancin with relative risk of -18.632 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: raloxifene with relative risk of -19.409 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pinaverium with relative risk of -19.494 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fosinoprilat with relative risk of -19.613 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: silodosin with relative risk of -19.830 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: gemfibrozil with relative risk of -19.869 of glipizide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 33: raltitrexed with relative risk of -20.063 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.147\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target glutamine not found. Exiting ...\n",
      "\n",
      "Drug target glycerol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glycopyrrolate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -9.084 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: afatinib with relative risk of -9.894 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -10.765 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: topotecan with relative risk of -10.834 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: telmisartan with relative risk of -10.863 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: salmeterol with relative risk of -10.904 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bezafibrate with relative risk of -11.564 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ritonavir with relative risk of -11.791 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lurasidone with relative risk of -11.944 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: torasemide with relative risk of -11.983 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loxapine with relative risk of -12.169 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ivermectin with relative risk of -12.267 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: eprosartan with relative risk of -12.545 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nicardipine with relative risk of -12.655 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rasagiline with relative risk of -12.896 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromfenac with relative risk of -14.304 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gold not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gonadorelin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -8.326 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indomethacin with relative risk of -8.549 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -8.874 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -9.148 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: olmesartan with relative risk of -9.712 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cabergoline with relative risk of -9.740 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: penbutolol with relative risk of -10.086 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -10.263 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirabegron with relative risk of -10.354 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: moxifloxacin with relative risk of -10.800 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -10.997 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó granisetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.067 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mifepristone with relative risk of -10.095 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azathioprine with relative risk of -10.518 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: delavirdine with relative risk of -10.779 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: disopyramide with relative risk of -10.998 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pioglitazone with relative risk of -11.064 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rivastigmine with relative risk of -11.359 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -11.503 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: flecainide with relative risk of -11.857 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: frovatriptan with relative risk of -11.966 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pitavastatin with relative risk of -12.037 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: montelukast with relative risk of -12.084 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fesoterodine with relative risk of -12.387 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pinaverium with relative risk of -12.617 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 20: fosinoprilat with relative risk of -12.853 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: candesartan with relative risk of -12.859 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cisatracurium with relative risk of -14.637 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.035\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó guanfacine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -10.146 of guanfacine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: amisulpride with relative risk of -13.480 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.667\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó halofantrine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indomethacin with relative risk of -9.645 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lubiprostone with relative risk of -9.970 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: anagrelide with relative risk of -10.246 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cabergoline with relative risk of -10.838 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: penbutolol with relative risk of -11.183 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -11.361 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mirabegron with relative risk of -11.452 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: miglustat with relative risk of -11.826 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: moxifloxacin with relative risk of -11.898 of halofantrine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 10: nabumetone with relative risk of -12.095 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: iloperidone with relative risk of -12.184 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fondaparinux with relative risk of -12.946 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: hydrochlorothiazide with relative risk of -13.508 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.035\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó hydrochlorothiazide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -8.953 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bicalutamide with relative risk of -9.013 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -9.278 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -9.553 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cabergoline with relative risk of -10.145 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: penbutolol with relative risk of -10.491 of hydrochlorothiazide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: estramustine with relative risk of -10.668 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mirabegron with relative risk of -10.759 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -10.840 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trimethoprim with relative risk of -10.912 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -11.063 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: miglustat with relative risk of -11.133 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: moxifloxacin with relative risk of -11.205 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nabumetone with relative risk of -11.402 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: iloperidone with relative risk of -11.491 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ranitidine with relative risk of -11.654 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: exemestane with relative risk of -11.865 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fondaparinux with relative risk of -12.253 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: halofantrine with relative risk of -12.377 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.04\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target hydrocodone not found. Exiting ...\n",
      "\n",
      "Drug target hydromorphone not found. Exiting ...\n",
      "\n",
      "Drug target hydroxocobalamin not found. Exiting ...\n",
      "\n",
      "Drug target hydroxybutyrate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ibandronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: efavirenz with relative risk of -12.600 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ibuprofen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ibutilide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: auranofin with relative risk of -10.007 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target icodextrin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó idarubicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.734 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -28.112 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -38.114 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: mifepristone with relative risk of -47.136 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pitavastatin with relative risk of -47.469 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: delavirdine with relative risk of -47.820 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: frovatriptan with relative risk of -49.007 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: montelukast with relative risk of -49.125 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -49.429 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ifosfamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tizanidine with relative risk of -7.402 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -16.818 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: doxepin with relative risk of -25.311 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: verapamil with relative risk of -26.384 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pindolol with relative risk of -27.096 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clonidine with relative risk of -29.564 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dasatinib with relative risk of -35.116 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loratadine with relative risk of -35.903 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó iloperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: loperamide with relative risk of -9.186 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -9.430 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pamidronate with relative risk of -9.963 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -9.973 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: linezolid with relative risk of -10.148 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: miglustat with relative risk of -10.440 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atosiban with relative risk of -10.635 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: ranitidine with relative risk of -10.961 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: norfloxacin with relative risk of -11.659 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: halofantrine with relative risk of -11.684 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: hydrochlorothiazide with relative risk of -12.121 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lercanidipine with relative risk of -12.943 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cilazapril with relative risk of -13.245 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: indomethacin with relative risk of -21.069 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fondaparinux with relative risk of -21.209 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: lubiprostone with relative risk of -21.732 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: anagrelide with relative risk of -24.693 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: penbutolol with relative risk of -24.703 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: cabergoline with relative risk of -25.062 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: estramustine with relative risk of -25.202 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: mirabegron with relative risk of -25.899 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: moxifloxacin with relative risk of -26.345 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nabumetone with relative risk of -26.542 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.086\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó iloprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -10.417 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -11.382 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vernakalant with relative risk of -11.588 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indinavir with relative risk of -11.986 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -12.361 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nisoldipine with relative risk of -12.372 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: valdecoxib with relative risk of -12.749 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: degarelix with relative risk of -12.858 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ambrisentan with relative risk of -12.988 of iloprost | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 11: reboxetine with relative risk of -13.131 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.033\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó imatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gefitinib with relative risk of -8.454 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: milrinone with relative risk of -9.343 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ipratropium with relative risk of -9.684 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: roflumilast with relative risk of -10.029 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azelastine with relative risk of -10.652 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acyclovir with relative risk of -16.730 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ciclesonide with relative risk of -32.651 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -78.568 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.368\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target imiquimod not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indacaterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: febuxostat with relative risk of -12.192 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indapamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -7.662 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -8.099 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nizatidine with relative risk of -8.924 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: danazol with relative risk of -9.203 of indapamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: colchicine with relative risk of -9.771 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: darifenacin with relative risk of -9.906 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nilutamide with relative risk of -10.064 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: miglustat with relative risk of -10.216 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -10.251 of indapamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 10: carvedilol with relative risk of -10.394 of indapamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: lovastatin with relative risk of -12.508 of indapamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: cilazapril with relative risk of -13.022 of indapamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: paroxetine with relative risk of -18.496 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alosetron with relative risk of -19.535 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: alfuzosin with relative risk of -21.279 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paliperidone with relative risk of -24.021 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.188\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -8.808 of indinavir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 2: danazol with relative risk of -9.203 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: colchicine with relative risk of -9.771 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: saquinavir with relative risk of -9.773 of indinavir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: vernakalant with relative risk of -9.979 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pemetrexed with relative risk of -10.114 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: travoprost with relative risk of -10.752 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nisoldipine with relative risk of -10.763 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: iloprost with relative risk of -10.784 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: valdecoxib with relative risk of -11.140 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: degarelix with relative risk of -11.248 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ambrisentan with relative risk of -11.379 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: reboxetine with relative risk of -11.522 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: vandetanib with relative risk of -11.522 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.384\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indomethacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -5.197 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -5.764 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -7.680 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -7.786 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -7.858 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: miglustat with relative risk of -8.139 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atosiban with relative risk of -8.332 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gonadorelin with relative risk of -8.542 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: citalopram with relative risk of -8.594 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ranitidine with relative risk of -8.662 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: amlexanox with relative risk of -8.907 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: halofantrine with relative risk of -9.381 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: isradipine with relative risk of -9.400 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: hydrochlorothiazide with relative risk of -9.820 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: norfloxacin with relative risk of -15.749 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fondaparinux with relative risk of -16.342 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: cyclobenzaprine with relative risk of -18.601 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: iloperidone with relative risk of -21.306 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: amlodipine with relative risk of -25.819 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: simvastatin with relative risk of -32.531 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: penbutolol with relative risk of -60.721 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: estramustine with relative risk of -63.104 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: cabergoline with relative risk of -65.670 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: anagrelide with relative risk of -67.379 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mirabegron with relative risk of -68.585 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: moxifloxacin with relative risk of -69.031 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: nabumetone with relative risk of -69.228 of indomethacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 28: acebutolol with relative risk of -80.134 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: lubiprostone with relative risk of -80.623 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sparfloxacin with relative risk of -81.788 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: lansoprazole with relative risk of -95.288 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mafenide with relative risk of -108.552 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.009\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "Drug target iodixanol not found. Exiting ...\n",
      "\n",
      "Drug target iohexol not found. Exiting ...\n",
      "\n",
      "Drug target iopamidol not found. Exiting ...\n",
      "\n",
      "Drug target iopromide not found. Exiting ...\n",
      "\n",
      "Drug target iotrolan not found. Exiting ...\n",
      "\n",
      "Drug target ioversol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ipratropium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: imatinib with relative risk of -9.029 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bumetanide with relative risk of -10.400 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: gefitinib with relative risk of -11.343 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: azelastine with relative risk of -13.542 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó irbesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vincristine with relative risk of -10.623 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fosphenytoin with relative risk of -12.906 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: phentolamine with relative risk of -13.684 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target irbesartan-hydrochlorothiazide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó irinotecan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zileuton with relative risk of -11.100 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tafluprost with relative risk of -12.822 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: galantamine with relative risk of -13.843 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target iron not found. Exiting ...\n",
      "\n",
      "Drug target isosorbide-5-mononitrate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó isradipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: indomethacin with relative risk of -8.953 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -9.278 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cyclobenzaprine with relative risk of -9.988 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amoxapine with relative risk of -10.439 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: regadenoson with relative risk of -10.518 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: capecitabine with relative risk of -10.759 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -10.765 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -10.863 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 10: emedastine with relative risk of -10.876 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: simvastatin with relative risk of -10.898 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: salmeterol with relative risk of -10.904 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: amlodipine with relative risk of -11.167 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: venlafaxine with relative risk of -11.392 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: estradiol with relative risk of -11.645 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pramipexole with relative risk of -11.929 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tegaserod with relative risk of -12.277 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dapsone with relative risk of -12.342 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: almotriptan with relative risk of -12.697 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: citalopram with relative risk of -21.641 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.355\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target itraconazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ivacaftor *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -10.350 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bupropion with relative risk of -13.123 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ivermectin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.984 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -12.257 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lurasidone with relative risk of -12.638 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loxapine with relative risk of -12.863 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -13.238 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicardipine with relative risk of -13.348 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rasagiline with relative risk of -13.589 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ixabepilone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.246 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: aminophylline with relative risk of -10.216 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: paricalcitol with relative risk of -10.262 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: apixaban with relative risk of -10.303 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: palonosetron with relative risk of -10.654 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sorafenib with relative risk of -10.701 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: esomeprazole with relative risk of -10.965 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clomipramine with relative risk of -11.092 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rilpivirine with relative risk of -11.840 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dihydroergotamine with relative risk of -12.104 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: canagliflozin with relative risk of -12.106 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: balsalazide with relative risk of -17.342 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ramelteon with relative risk of -17.838 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -18.274 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gemcitabine with relative risk of -23.151 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "Rank 16: bosentan with relative risk of -23.575 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dronedarone with relative risk of -24.585 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fludarabine with relative risk of -26.597 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: orlistat with relative risk of -28.537 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.348\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketoconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mitotane with relative risk of -21.036 of ketoconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: timolol with relative risk of -22.774 of ketoconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketoprofen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nilutamide with relative risk of -10.979 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flunisolide with relative risk of -12.544 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amoxicillin with relative risk of -12.923 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketorolac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -10.479 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: macitentan with relative risk of -11.639 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -11.664 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metolazone with relative risk of -11.959 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phenytoin with relative risk of -12.213 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: atomoxetine with relative risk of -12.414 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: empagliflozin with relative risk of -12.449 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lamotrigine with relative risk of -12.487 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: sumatriptan with relative risk of -12.661 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pimozide with relative risk of -12.759 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cytarabine with relative risk of -21.487 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alendronate with relative risk of -23.943 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.226\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó labetalol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: leflunomide with relative risk of -10.847 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: brimonidine with relative risk of -12.202 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -12.617 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.841 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.853 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: ranolazine with relative risk of -12.929 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: oxybutynin with relative risk of -13.326 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -13.384 of labetalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 21: eletriptan with relative risk of -14.109 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.194\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lacosamide not found. Exiting ...\n",
      "\n",
      "Drug target lamivudine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lamotrigine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etodolac with relative risk of -12.358 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Tonic - clonic seizures,Lennox-Gastaut syndrome,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 7: ketorolac with relative risk of -13.050 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of -13.107 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: empagliflozin with relative risk of -13.142 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pimozide with relative risk of -13.452 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: alendronate with relative risk of -13.888 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.202\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lanreotide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lansoprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabergoline with relative risk of -7.670 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olmesartan with relative risk of -37.905 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -47.147 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 4: formoterol with relative risk of -52.462 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -91.467 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sparfloxacin with relative risk of -93.124 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: indomethacin with relative risk of -95.117 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mafenide with relative risk of -119.908 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.123\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lanthanum not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lapatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acebutolol with relative risk of -9.764 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: budesonide with relative risk of -10.009 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metoprolol with relative risk of -10.712 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -10.878 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: flutamide with relative risk of -10.887 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: bromocriptine with relative risk of -11.269 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dabrafenib with relative risk of -11.289 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: felbamate with relative risk of -11.508 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ribavirin with relative risk of -11.667 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: metronidazole with relative risk of -11.756 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilostazol with relative risk of -11.956 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bisoprolol with relative risk of -12.574 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: famotidine with relative risk of -12.759 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: propafenone with relative risk of -13.018 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fluocinonide with relative risk of -13.154 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: terazosin with relative risk of -13.271 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tropisetron with relative risk of -13.475 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tolcapone with relative risk of -13.809 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.17\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó latanoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lidocaine with relative risk of -12.622 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó leflunomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.779 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexamethasone with relative risk of -8.503 of leflunomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Arthritis, Psoriatic,rheumatology\n",
      "Rank 3: crizotinib with relative risk of -8.990 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: fluoxetine with relative risk of -9.267 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -9.285 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nedocromil with relative risk of -9.363 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: glimepiride with relative risk of -9.405 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: felbamate with relative risk of -9.429 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: silodosin with relative risk of -9.489 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: telithromycin with relative risk of -9.510 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: everolimus with relative risk of -9.536 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pentoxifylline with relative risk of -9.626 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: duloxetine with relative risk of -9.815 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: adenosine with relative risk of -9.836 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: vilazodone with relative risk of -9.956 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: milnacipran with relative risk of -10.010 of leflunomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 17: glipizide with relative risk of -10.093 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: brimonidine with relative risk of -10.122 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rofecoxib with relative risk of -10.202 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desvenlafaxine with relative risk of -10.342 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: topiramate with relative risk of -10.472 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: conivaptan with relative risk of -10.539 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: umeclidinium with relative risk of -10.542 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ramipril with relative risk of -10.654 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rocuronium with relative risk of -10.790 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ranolazine with relative risk of -10.850 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: labetalol with relative risk of -10.894 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: oxybutynin with relative risk of -11.247 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: betaxolol with relative risk of -11.305 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: quinapril with relative risk of -11.426 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: domperidone with relative risk of -11.861 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: eletriptan with relative risk of -12.030 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fosinopril with relative risk of -12.426 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: dexmedetomidine with relative risk of -13.260 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: flumazenil with relative risk of -14.961 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: axitinib with relative risk of -15.778 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: pioglitazone with relative risk of -15.842 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: nateglinide with relative risk of -15.946 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: capsaicin with relative risk of -16.890 of leflunomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 40: trandolapril with relative risk of -17.024 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: terbutaline with relative risk of -17.218 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: aripiprazole with relative risk of -17.753 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: meloxicam with relative risk of -18.870 of leflunomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 44: dalbavancin with relative risk of -22.361 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: raloxifene with relative risk of -24.053 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: gemfibrozil with relative risk of -24.290 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: varenicline with relative risk of -24.371 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ropinirole with relative risk of -24.545 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: raltitrexed with relative risk of -24.707 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: bromocriptine with relative risk of -24.869 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dapagliflozin with relative risk of -26.137 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: omeprazole with relative risk of -26.372 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: rosuvastatin with relative risk of -30.104 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: risedronate with relative risk of -32.063 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: belinostat with relative risk of -36.115 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: mirtazapine with relative risk of -36.656 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: teniposide with relative risk of -41.314 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: budesonide with relative risk of -42.804 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: nelarabine with relative risk of -42.951 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: fosinoprilat with relative risk of -43.711 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: rosiglitazone with relative risk of -43.852 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: pinaverium with relative risk of -44.115 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: acebutolol with relative risk of -45.113 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: tasimelteon with relative risk of -47.603 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: mometasone with relative risk of -47.619 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: apixaban with relative risk of -49.229 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: azathioprine with relative risk of -50.105 of leflunomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 68: sparfloxacin with relative risk of -54.260 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: efinaconazole with relative risk of -inf of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.13\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lenalidomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: naltrexone with relative risk of -20.988 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: buspirone with relative risk of -23.212 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lercanidipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: loperamide with relative risk of -10.569 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bexarotene with relative risk of -10.816 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pamidronate with relative risk of -11.349 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: iloperidone with relative risk of -12.184 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cilazapril with relative risk of -14.631 of lercanidipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó letrozole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: zileuton with relative risk of -11.100 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiloride with relative risk of -11.401 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: doxorubicin with relative risk of -11.549 of letrozole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: tafluprost with relative risk of -12.822 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.16\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target leucovorin not found. Exiting ...\n",
      "\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levetiracetam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -6.826 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nefazodone with relative risk of -11.301 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilotinib with relative risk of -14.381 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: liraglutide with relative risk of -15.099 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: zolmitriptan with relative risk of -18.245 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: clarithromycin with relative risk of -25.300 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pazopanib with relative risk of -116.257 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nizatidine with relative risk of -118.771 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: maprotiline with relative risk of -128.071 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: nalmefene with relative risk of -128.423 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.106\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levocabastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -10.073 of levocabastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 2: tolmetin with relative risk of -12.262 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: olopatadine with relative risk of -12.936 of levocabastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 4: misoprostol with relative risk of -14.493 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.64\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target levodopa/carbidopa not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levonorgestrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clonidine with relative risk of -8.151 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: darifenacin with relative risk of -9.118 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lidocaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tizanidine with relative risk of -8.380 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pentostatin with relative risk of -9.275 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etravirine with relative risk of -10.452 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: latanoprost with relative risk of -12.479 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: doxercalciferol with relative risk of -14.976 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paclitaxel with relative risk of -15.233 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: loperamide with relative risk of -16.307 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -16.560 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 9: alogliptin with relative risk of -17.751 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.398\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target linaclotide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó linagliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: quetiapine with relative risk of -10.903 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: donepezil with relative risk of -11.885 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trimethoprim with relative risk of -18.259 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: repaglinide with relative risk of -19.605 of linagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 5: trametinib with relative risk of -30.186 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: olmesartan with relative risk of -30.577 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dexmedetomidine with relative risk of -31.091 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bicalutamide with relative risk of -32.182 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sunitinib with relative risk of -38.368 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó linezolid *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indomethacin with relative risk of -7.461 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -7.514 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -7.784 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anagrelide with relative risk of -8.052 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cabergoline with relative risk of -8.644 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dalbavancin with relative risk of -8.782 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 7: penbutolol with relative risk of -8.991 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nateglinide with relative risk of -9.106 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -9.168 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirabegron with relative risk of -9.258 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: posaconazole with relative risk of -9.316 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 12: trimethoprim with relative risk of -9.410 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 13: moxifloxacin with relative risk of -9.704 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Staphylococcus aureus infection,Streptococcus pyogenes infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 14: atosiban with relative risk of -9.824 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nabumetone with relative risk of -9.901 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: iloperidone with relative risk of -9.988 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: quetiapine with relative risk of -10.092 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: exemestane with relative risk of -10.361 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metolazone with relative risk of -10.455 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: famotidine with relative risk of -10.563 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: norfloxacin with relative risk of -10.848 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcal Pneumonia,Staphylococcus aureus infection,infectious disease\n",
      "Rank 22: hydrochlorothiazide with relative risk of -11.311 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: dexmedetomidine with relative risk of -13.009 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rivastigmine with relative risk of -16.040 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: brinzolamide with relative risk of -16.787 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: metronidazole with relative risk of -17.129 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dolutegravir with relative risk of -17.198 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 28: trametinib with relative risk of -25.354 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ranitidine with relative risk of -27.333 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.127\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó liraglutide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.046 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: macitentan with relative risk of -10.946 of liraglutide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: etodolac with relative risk of -10.971 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -11.202 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -11.265 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -11.520 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -11.664 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atomoxetine with relative risk of -11.720 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: empagliflozin with relative risk of -11.755 of liraglutide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 10: lamotrigine with relative risk of -11.793 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sumatriptan with relative risk of -11.968 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pimozide with relative risk of -12.066 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: alendronate with relative risk of -12.502 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nefazodone with relative risk of -12.805 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pazopanib with relative risk of -14.489 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: maprotiline with relative risk of -15.738 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nizatidine with relative risk of -15.799 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: levetiracetam with relative risk of -15.882 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nalmefene with relative risk of -16.090 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: zolmitriptan with relative risk of -21.483 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.17\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lisdexamfetamine not found. Exiting ...\n",
      "\n",
      "Drug target lodoxamide not found. Exiting ...\n",
      "\n",
      "Drug target lomefloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loperamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pentostatin with relative risk of -7.123 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: prasugrel with relative risk of -7.470 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: iloperidone with relative risk of -8.929 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lercanidipine with relative risk of -11.071 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ropivacaine with relative risk of -11.275 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cilazapril with relative risk of -11.374 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pamidronate with relative risk of -15.621 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lidocaine with relative risk of -16.894 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tizanidine with relative risk of -17.033 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: etravirine with relative risk of -21.314 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: paclitaxel with relative risk of -21.789 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bexarotene with relative risk of -22.370 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ruxolitinib with relative risk of -23.885 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alogliptin with relative risk of -25.327 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: doxercalciferol with relative risk of -33.272 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loratadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -29.554 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: verapamil with relative risk of -30.628 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pindolol with relative risk of -31.341 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clonidine with relative risk of -33.811 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: ifosfamide with relative risk of -34.826 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dasatinib with relative risk of -39.364 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.51\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lorazepam not found. Exiting ...\n",
      "\n",
      "Drug target lorcaserin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó losartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cladribine with relative risk of -26.790 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: apremilast with relative risk of -36.495 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amsacrine with relative risk of -51.993 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loteprednol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -9.441 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sparfloxacin with relative risk of -9.864 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -10.580 of loteprednol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,Corneal abrasion,Punctate keratitis,Iridocyclitis,Herpes zoster keratitis,Iritis,Keratitis,Rosacea,Anterior uveitis,Corneal Perforation\n",
      "Rank 4: risedronate with relative risk of -10.933 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pioglitazone with relative risk of -11.064 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: crizotinib with relative risk of -11.068 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: varenicline with relative risk of -11.282 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ropinirole with relative risk of -11.456 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: naproxen with relative risk of -11.645 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -11.911 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: desvenlafaxine with relative risk of -12.421 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: topiramate with relative risk of -12.551 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: meloxicam with relative risk of -12.841 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fosinoprilat with relative risk of -12.853 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nevirapine with relative risk of -13.237 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.1\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lovastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.810 of lovastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: paliperidone with relative risk of -10.913 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indapamide with relative risk of -11.498 of lovastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: nilutamide with relative risk of -11.672 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: alosetron with relative risk of -11.783 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -11.842 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: carvedilol with relative risk of -12.003 of lovastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: alfuzosin with relative risk of -13.527 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.543\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loxapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.984 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -12.257 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lurasidone with relative risk of -12.638 of loxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 4: ivermectin with relative risk of -12.960 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -13.238 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicardipine with relative risk of -13.348 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rasagiline with relative risk of -13.589 of loxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.184\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lubiprostone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -5.922 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -6.200 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -7.464 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rivastigmine with relative risk of -7.841 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -7.946 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: linezolid with relative risk of -8.018 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: brinzolamide with relative risk of -8.180 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: miglustat with relative risk of -8.301 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: atosiban with relative risk of -8.495 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apraclonidine with relative risk of -8.638 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: gonadorelin with relative risk of -8.704 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: citalopram with relative risk of -8.756 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ranitidine with relative risk of -8.824 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: amlexanox with relative risk of -9.069 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: halofantrine with relative risk of -9.544 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: isradipine with relative risk of -9.562 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: hydrochlorothiazide with relative risk of -9.983 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: trametinib with relative risk of -14.349 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: olmesartan with relative risk of -15.300 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciprofloxacin with relative risk of -16.064 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: norfloxacin with relative risk of -16.078 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fondaparinux with relative risk of -16.671 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: iloperidone with relative risk of -21.807 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: amlodipine with relative risk of -33.659 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: cyclobenzaprine with relative risk of -42.055 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: simvastatin with relative risk of -49.843 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: penbutolol with relative risk of -62.586 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: estramustine with relative risk of -64.970 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: cabergoline with relative risk of -67.536 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: anagrelide with relative risk of -69.245 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mirabegron with relative risk of -70.451 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: moxifloxacin with relative risk of -70.897 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nabumetone with relative risk of -71.094 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: indomethacin with relative risk of -80.460 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.019\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lurasidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.984 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -12.257 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loxapine with relative risk of -12.863 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 4: ivermectin with relative risk of -12.960 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -13.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicardipine with relative risk of -13.348 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rasagiline with relative risk of -13.589 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.184\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó macitentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of macitentan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: cytarabine with relative risk of -11.432 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metolazone with relative risk of -12.652 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phenytoin with relative risk of -12.906 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -13.050 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atomoxetine with relative risk of -13.107 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: empagliflozin with relative risk of -13.142 of macitentan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: lamotrigine with relative risk of -13.180 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pimozide with relative risk of -13.452 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: alendronate with relative risk of -13.888 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.363\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mafenide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acebutolol with relative risk of -104.963 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sparfloxacin with relative risk of -106.623 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indomethacin with relative risk of -108.617 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lansoprazole with relative risk of -120.144 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target malvidin not found. Exiting ...\n",
      "\n",
      "Drug target mannitol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó maprotiline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nefazodone with relative risk of -11.419 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: liraglutide with relative risk of -15.342 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: zolmitriptan with relative risk of -18.488 of maprotiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: clarithromycin with relative risk of -25.676 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pazopanib with relative risk of -121.287 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nizatidine with relative risk of -123.801 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: levetiracetam with relative risk of -128.458 of maprotiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: nalmefene with relative risk of -133.454 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target maraviroc not found. Exiting ...\n",
      "\n",
      "Drug target meclofenamate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó medroxyprogesterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tiotropium with relative risk of -12.854 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mefloquine not found. Exiting ...\n",
      "\n",
      "Drug target megestrol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó meloxicam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -7.422 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trametinib with relative risk of -7.755 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -8.146 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -8.669 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rosuvastatin with relative risk of -9.668 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dalbavancin with relative risk of -9.877 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gemfibrozil with relative risk of -10.508 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: naproxen with relative risk of -10.546 of meloxicam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 9: pentoxifylline with relative risk of -10.606 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: aripiprazole with relative risk of -10.624 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brimonidine with relative risk of -11.103 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pinaverium with relative risk of -11.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ranolazine with relative risk of -11.831 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: labetalol with relative risk of -11.875 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nevirapine with relative risk of -12.138 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: oxybutynin with relative risk of -12.227 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: betaxolol with relative risk of -12.285 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: domperidone with relative risk of -12.842 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: loteprednol with relative risk of -12.942 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: eletriptan with relative risk of -13.011 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fosinopril with relative risk of -13.406 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azathioprine with relative risk of -16.257 of meloxicam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 23: dexamethasone with relative risk of -17.340 of meloxicam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 24: leflunomide with relative risk of -17.858 of meloxicam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 25: pioglitazone with relative risk of -18.074 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: risedronate with relative risk of -18.098 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: raloxifene with relative risk of -18.311 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -18.515 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: apixaban with relative risk of -18.670 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ropinirole with relative risk of -18.803 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: crizotinib with relative risk of -19.332 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: desvenlafaxine with relative risk of -21.377 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: topiramate with relative risk of -21.507 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: sparfloxacin with relative risk of -22.428 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tasimelteon with relative risk of -22.715 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: varenicline with relative risk of -28.396 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: efinaconazole with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.061\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target melphalan not found. Exiting ...\n",
      "\n",
      "Drug target memantine not found. Exiting ...\n",
      "\n",
      "Drug target meropenem not found. Exiting ...\n",
      "\n",
      "Drug target mesna not found. Exiting ...\n",
      "\n",
      "Drug target metaiodobenzylguanidine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metaproterenol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: topotecan with relative risk of -10.834 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -10.863 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: perindopril with relative risk of -11.235 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target metformin not found. Exiting ...\n",
      "\n",
      "Drug target methyl not found. Exiting ...\n",
      "\n",
      "Drug target methylphenidate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metolazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.160 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -8.731 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -10.282 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: liraglutide with relative risk of -10.479 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nateglinide with relative risk of -10.608 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rivastigmine with relative risk of -10.666 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cytarabine with relative risk of -10.739 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: linezolid with relative risk of -10.840 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: brinzolamide with relative risk of -11.008 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: metronidazole with relative risk of -11.063 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dolutegravir with relative risk of -11.132 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: quetiapine with relative risk of -11.596 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: macitentan with relative risk of -11.639 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: etodolac with relative risk of -11.664 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -12.066 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: phenytoin with relative risk of -12.213 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ketorolac with relative risk of -12.357 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: atomoxetine with relative risk of -12.414 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: empagliflozin with relative risk of -12.449 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lamotrigine with relative risk of -12.487 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sumatriptan with relative risk of -12.661 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pimozide with relative risk of -12.759 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: alendronate with relative risk of -13.195 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metoprolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.326 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.345 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.569 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -10.603 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.513 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -11.772 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -11.792 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.183 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.323 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.376 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -12.710 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: budesonide with relative risk of -16.022 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bromocriptine with relative risk of -18.839 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: erlotinib with relative risk of -19.141 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: felbamate with relative risk of -19.365 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: metronidazole with relative risk of -19.613 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dabrafenib with relative risk of -20.245 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cilostazol with relative risk of -20.912 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: famotidine with relative risk of -21.022 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: propafenone with relative risk of -21.974 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: fluocinonide with relative risk of -22.111 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -22.152 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 23: terazosin with relative risk of -22.228 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 24: flutamide with relative risk of -30.303 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: bisoprolol with relative risk of -31.990 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.061\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metronidazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.058 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bicalutamide with relative risk of -8.322 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dalbavancin with relative risk of -9.590 of metronidazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 5: nateglinide with relative risk of -9.916 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rivastigmine with relative risk of -9.973 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimethoprim with relative risk of -10.219 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ribavirin with relative risk of -10.281 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dolutegravir with relative risk of -10.439 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: quetiapine with relative risk of -10.903 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ranitidine with relative risk of -10.961 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: exemestane with relative risk of -11.172 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lapatinib with relative risk of -11.225 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: metolazone with relative risk of -11.265 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ondansetron with relative risk of -11.485 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rabeprazole with relative risk of -11.504 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: darunavir with relative risk of -11.895 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluconazole with relative risk of -12.035 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tropisetron with relative risk of -12.088 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: hydrochlorothiazide with relative risk of -12.121 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: tolcapone with relative risk of -12.422 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -14.160 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: budesonide with relative risk of -15.330 of metronidazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Crohn Disease\n",
      "Rank 24: linezolid with relative risk of -17.718 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: bromocriptine with relative risk of -18.146 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: metoprolol with relative risk of -18.282 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: erlotinib with relative risk of -18.448 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: flutamide with relative risk of -18.457 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: brinzolamide with relative risk of -18.578 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: felbamate with relative risk of -18.672 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dabrafenib with relative risk of -19.552 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: bisoprolol with relative risk of -20.144 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: cilostazol with relative risk of -20.219 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: propafenone with relative risk of -21.281 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: fluocinonide with relative risk of -21.418 of metronidazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 36: terazosin with relative risk of -21.534 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dexmedetomidine with relative risk of -22.423 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: famotidine with relative risk of -30.789 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.076\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mexiletine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.395 of mexiletine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: bumetanide with relative risk of -9.303 of mexiletine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target miconazole not found. Exiting ...\n",
      "\n",
      "Drug target midazolam not found. Exiting ...\n",
      "\n",
      "Drug target midodrine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mifepristone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.734 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -28.112 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -38.114 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of mifepristone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 18: idarubicin with relative risk of -46.108 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pitavastatin with relative risk of -47.469 of mifepristone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 20: delavirdine with relative risk of -47.820 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: frovatriptan with relative risk of -49.007 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: montelukast with relative risk of -49.125 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -49.429 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.03\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó miglustat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -8.576 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -8.953 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bicalutamide with relative risk of -9.013 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -9.278 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -9.553 of miglustat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 6: nizatidine with relative risk of -9.838 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cabergoline with relative risk of -10.145 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: penbutolol with relative risk of -10.491 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -10.668 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: colchicine with relative risk of -10.687 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mirabegron with relative risk of -10.759 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: indapamide with relative risk of -10.805 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: darifenacin with relative risk of -10.822 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: moxifloxacin with relative risk of -11.205 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nabumetone with relative risk of -11.402 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: iloperidone with relative risk of -11.491 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fondaparinux with relative risk of -12.253 of miglustat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 18: halofantrine with relative risk of -12.377 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: hydrochlorothiazide with relative risk of -12.814 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: cilazapril with relative risk of -13.938 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.072\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó milnacipran *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.668 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.749 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 3: erlotinib with relative risk of -9.779 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -10.183 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: terbutaline with relative risk of -10.495 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acebutolol with relative risk of -14.851 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tasimelteon with relative risk of -14.964 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: azathioprine with relative risk of -16.257 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 9: pinaverium with relative risk of -18.396 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -18.670 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -22.428 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -22.583 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: teniposide with relative risk of -22.794 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexmedetomidine with relative risk of -23.809 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -24.237 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -26.409 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: estramustine with relative risk of -26.588 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nateglinide with relative risk of -27.385 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: axitinib with relative risk of -27.778 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trandolapril with relative risk of -29.023 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: duloxetine with relative risk of -31.310 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Fibromyalgia\n",
      "Rank 24: conivaptan with relative risk of -32.034 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: umeclidinium with relative risk of -32.038 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó milrinone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: imatinib with relative risk of -9.029 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acyclovir with relative risk of -11.705 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target minocycline not found. Exiting ...\n",
      "\n",
      "Drug target mipomersen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mirabegron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -7.127 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -9.058 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -9.159 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -9.234 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: miglustat with relative risk of -9.524 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atosiban with relative risk of -9.718 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gonadorelin with relative risk of -9.926 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -10.045 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: halofantrine with relative risk of -10.767 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: hydrochlorothiazide with relative risk of -11.205 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: norfloxacin with relative risk of -18.600 of mirabegron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 13: fondaparinux with relative risk of -19.194 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: iloperidone with relative risk of -25.715 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: indomethacin with relative risk of -68.164 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lubiprostone with relative risk of -70.193 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: penbutolol with relative risk of -81.272 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: estramustine with relative risk of -83.658 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cabergoline with relative risk of -86.227 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: anagrelide with relative risk of -87.937 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: moxifloxacin with relative risk of -89.589 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nabumetone with relative risk of -89.786 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.023\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mirtazapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.726 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pioglitazone with relative risk of -8.429 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: aripiprazole with relative risk of -9.085 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: adenosine with relative risk of -9.276 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: carbamazepine with relative risk of -10.158 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of -15.392 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: felbamate with relative risk of -15.954 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: everolimus with relative risk of -17.159 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: eliglustat with relative risk of -17.303 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: glipizide with relative risk of -17.716 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dexmedetomidine with relative risk of -17.920 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dutasteride with relative risk of -18.883 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nateglinide with relative risk of -21.491 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -21.747 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: axitinib with relative risk of -21.882 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: telithromycin with relative risk of -22.065 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: raloxifene with relative risk of -22.182 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bromocriptine with relative risk of -22.997 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: trandolapril with relative risk of -23.128 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nedocromil with relative risk of -23.170 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: glimepiride with relative risk of -23.212 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vilazodone with relative risk of -23.763 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 23: fluoxetine with relative risk of -23.767 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 24: terbutaline with relative risk of -24.015 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: omeprazole with relative risk of -24.500 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rofecoxib with relative risk of -25.800 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ramipril with relative risk of -26.252 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rocuronium with relative risk of -26.388 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: quinapril with relative risk of -27.024 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: apixaban with relative risk of -28.947 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: capsaicin with relative risk of -30.427 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: flumazenil with relative risk of -36.068 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: leflunomide with relative risk of -36.732 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: gemfibrozil with relative risk of -38.338 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: raltitrexed with relative risk of -39.448 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dapagliflozin with relative risk of -41.976 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dalbavancin with relative risk of -50.450 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: rosuvastatin with relative risk of -51.029 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: silodosin with relative risk of -57.175 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: sparfloxacin with relative risk of -84.123 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: teniposide with relative risk of -85.876 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tasimelteon with relative risk of -88.706 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: acebutolol with relative risk of -91.936 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azathioprine with relative risk of -93.085 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: fosinoprilat with relative risk of -94.213 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: pinaverium with relative risk of -95.837 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -98.799 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: budesonide with relative risk of -107.959 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: nelarabine with relative risk of -108.954 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: rosiglitazone with relative risk of -111.909 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: belinostat with relative risk of -117.829 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.312\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó misoprostol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -10.073 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tolmetin with relative risk of -12.262 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: olopatadine with relative risk of -12.936 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -13.051 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mitomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mitotane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ketoconazole with relative risk of -22.324 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: timolol with relative risk of -22.774 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mitoxantrone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ponatinib with relative risk of -11.976 of mitoxantrone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: argatroban with relative risk of -12.082 of mitoxantrone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: piroxicam with relative risk of -13.491 of mitoxantrone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.545\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mivacurium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bumetanide with relative risk of -10.400 of mivacurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: esmolol with relative risk of -12.507 of mivacurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clopidogrel with relative risk of -15.000 of mivacurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target modafinil not found. Exiting ...\n",
      "\n",
      "Drug target moexiprilat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mometasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -6.952 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilotinib with relative risk of -7.312 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: erlotinib with relative risk of -7.446 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trimethoprim with relative risk of -8.178 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -8.277 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: aripiprazole with relative risk of -8.291 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: adenosine with relative risk of -8.481 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tazarotene with relative risk of -8.649 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 9: brimonidine with relative risk of -8.768 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amlexanox with relative risk of -9.161 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: granisetron with relative risk of -9.265 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: carbamazepine with relative risk of -9.363 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: meloxicam with relative risk of -9.409 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ranolazine with relative risk of -9.497 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: labetalol with relative risk of -9.539 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: triamcinolone with relative risk of -9.579 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Scalp psoriasis,Granuloma Annulare,Exanthema,Contact Dermatitis,Lichen Simplex Chronicus,Chronic small plaque psoriasis,Asthma,Pruritus Ani,Allergic rhinitis (disorder),Pruritus of genital organs,Seborrheic dermatitis,Lymphoma, T-Cell, Cutaneous,Lupus Erythematosus, Discoid,dermatology\n",
      "Rank 17: nalbuphine with relative risk of -9.745 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: oxybutynin with relative risk of -9.892 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: betaxolol with relative risk of -9.950 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tolterodine with relative risk of -10.337 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: diltiazem with relative risk of -10.425 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ziprasidone with relative risk of -10.519 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: eletriptan with relative risk of -10.675 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: felbamate with relative risk of -14.324 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gefitinib with relative risk of -14.564 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: everolimus with relative risk of -15.528 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: eliglustat with relative risk of -15.672 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: glipizide with relative risk of -16.085 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dutasteride with relative risk of -17.252 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: estramustine with relative risk of -18.189 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: risedronate with relative risk of -19.236 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: rivastigmine with relative risk of -19.661 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: varenicline with relative risk of -19.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ropinirole with relative risk of -20.163 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: bromocriptine with relative risk of -20.485 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: fluoxetine with relative risk of -21.254 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: omeprazole with relative risk of -21.987 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: disopyramide with relative risk of -22.004 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: sulfasalazine with relative risk of -22.509 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: flecainide with relative risk of -22.863 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: duloxetine with relative risk of -22.899 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: milnacipran with relative risk of -23.094 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: rofecoxib with relative risk of -23.287 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: conivaptan with relative risk of -23.623 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: umeclidinium with relative risk of -23.627 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ramipril with relative risk of -23.739 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: candesartan with relative risk of -23.865 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: rocuronium with relative risk of -23.874 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: quinapril with relative risk of -24.510 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: raloxifene with relative risk of -26.680 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: terbutaline with relative risk of -29.610 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 52: dexmedetomidine with relative risk of -32.358 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: idarubicin with relative risk of -34.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: mifepristone with relative risk of -35.093 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: pitavastatin with relative risk of -35.427 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: delavirdine with relative risk of -35.777 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: nedocromil with relative risk of -36.440 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 58: glimepiride with relative risk of -36.481 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: frovatriptan with relative risk of -36.964 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: vilazodone with relative risk of -37.033 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: montelukast with relative risk of -37.082 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Allergic asthma,Intrinsic asthma\n",
      "Rank 62: fesoterodine with relative risk of -37.386 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: apixaban with relative risk of -39.056 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: nateglinide with relative risk of -39.256 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: pioglitazone with relative risk of -39.999 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: axitinib with relative risk of -42.641 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: raltitrexed with relative risk of -43.595 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: trandolapril with relative risk of -43.887 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: leflunomide with relative risk of -47.869 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: silodosin with relative risk of -50.534 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: gemfibrozil with relative risk of -50.573 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: capsaicin with relative risk of -50.925 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: dalbavancin with relative risk of -51.157 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: flumazenil with relative risk of -56.160 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: telithromycin with relative risk of -57.565 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: rosuvastatin with relative risk of -77.955 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: belinostat with relative risk of -98.433 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: mirtazapine with relative risk of -98.974 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: rosiglitazone with relative risk of -120.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: budesonide with relative risk of -123.147 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 83: nelarabine with relative risk of -135.673 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: teniposide with relative risk of -141.961 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: sparfloxacin with relative risk of -163.207 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: azathioprine with relative risk of -180.312 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pinaverium with relative risk of -185.629 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: acebutolol with relative risk of -186.807 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tasimelteon with relative risk of -187.194 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: fosinoprilat with relative risk of -199.353 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: efinaconazole with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.05\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target monoethanolamine not found. Exiting ...\n",
      "\n",
      "Drug target monomethylfumarate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó montelukast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.673 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.734 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.090 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.570 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.765 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -28.112 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -28.617 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.971 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.973 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -34.626 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -35.086 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -36.065 of montelukast | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Allergic asthma,Intrinsic asthma\n",
      "Rank 13: tasimelteon with relative risk of -36.125 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -38.114 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -40.122 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -40.387 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -44.550 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: idarubicin with relative risk of -46.108 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -47.136 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pitavastatin with relative risk of -47.469 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: delavirdine with relative risk of -47.820 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: frovatriptan with relative risk of -49.007 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -49.429 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -51.678 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.022\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target morphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó moxifloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -7.127 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -9.058 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -9.159 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -9.234 of moxifloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 6: miglustat with relative risk of -9.524 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atosiban with relative risk of -9.718 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gonadorelin with relative risk of -9.926 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -10.045 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: halofantrine with relative risk of -10.767 of moxifloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 11: hydrochlorothiazide with relative risk of -11.205 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: norfloxacin with relative risk of -18.600 of moxifloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pneumonia due to Klebsiella pneumoniae,Streptococcal pneumonia,Streptococcus pyogenes infection,Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Moraxella catarrhalis pneumonia,Pneumonia, Bacterial,Peritonitis,Rhinoscleroma,Bacterial conjunctivitis,Chlamydial pneumonia,Acute exacerbation of chronic bronchitis,Mycoplasma pneumonia,Intraabdominal Infections,Enterobacteriaceae Infections,Abdominal Abscess,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Acute bacterial sinusitis,infectious disease\n",
      "Rank 13: fondaparinux with relative risk of -19.194 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: iloperidone with relative risk of -25.715 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: indomethacin with relative risk of -68.164 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lubiprostone with relative risk of -70.193 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: penbutolol with relative risk of -81.272 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: estramustine with relative risk of -83.658 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cabergoline with relative risk of -86.227 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: anagrelide with relative risk of -87.937 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mirabegron with relative risk of -89.143 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nabumetone with relative risk of -89.786 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.104\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mupirocin not found. Exiting ...\n",
      "\n",
      "Drug target mycophenolate not found. Exiting ...\n",
      "\n",
      "Drug target mycophenolic not found. Exiting ...\n",
      "\n",
      "Drug target n-3 not found. Exiting ...\n",
      "\n",
      "Drug target nabilone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nabumetone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.557 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -7.127 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -9.058 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -9.159 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -9.234 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: miglustat with relative risk of -9.524 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atosiban with relative risk of -9.718 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gonadorelin with relative risk of -9.926 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -10.045 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: halofantrine with relative risk of -10.767 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: hydrochlorothiazide with relative risk of -11.205 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: norfloxacin with relative risk of -18.600 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fondaparinux with relative risk of -19.194 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: iloperidone with relative risk of -25.715 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: indomethacin with relative risk of -68.164 of nabumetone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 16: lubiprostone with relative risk of -70.193 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: penbutolol with relative risk of -81.272 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: estramustine with relative risk of -83.658 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cabergoline with relative risk of -86.227 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: anagrelide with relative risk of -87.937 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mirabegron with relative risk of -89.143 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: moxifloxacin with relative risk of -89.589 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.018\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nadolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.118 of nadolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: carvedilol with relative risk of -11.310 of nadolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target naftifine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nalbuphine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.067 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of nalbuphine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: acebutolol with relative risk of -9.764 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mifepristone with relative risk of -10.095 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azathioprine with relative risk of -10.518 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: delavirdine with relative risk of -10.779 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: disopyramide with relative risk of -10.998 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pioglitazone with relative risk of -11.064 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rivastigmine with relative risk of -11.359 of nalbuphine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: sulfasalazine with relative risk of -11.503 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: flecainide with relative risk of -11.857 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: frovatriptan with relative risk of -11.966 of nalbuphine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: pitavastatin with relative risk of -12.037 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: montelukast with relative risk of -12.084 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fesoterodine with relative risk of -12.387 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pinaverium with relative risk of -12.617 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fosinoprilat with relative risk of -12.853 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: candesartan with relative risk of -12.859 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cisatracurium with relative risk of -14.637 of nalbuphine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.149\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nalmefene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nefazodone with relative risk of -11.419 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: liraglutide with relative risk of -15.342 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: zolmitriptan with relative risk of -18.488 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -25.676 of nalmefene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 5: pazopanib with relative risk of -121.287 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nizatidine with relative risk of -123.801 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: levetiracetam with relative risk of -128.458 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: maprotiline with relative risk of -133.102 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.092\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naltrexone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -19.815 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: buspirone with relative risk of -21.420 of naltrexone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naproxen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pioglitazone with relative risk of -10.371 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: desvenlafaxine with relative risk of -11.728 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: topiramate with relative risk of -11.858 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: meloxicam with relative risk of -12.148 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 5: fosinoprilat with relative risk of -12.161 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nevirapine with relative risk of -12.543 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: domperidone with relative risk of -13.247 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loteprednol with relative risk of -13.347 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tasimelteon with relative risk of -16.062 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: sparfloxacin with relative risk of -16.134 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dexamethasone with relative risk of -18.438 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Ankylosing spondylitis,Rheumatoid Arthritis,Bursitis,endocrinology,rheumatology,neurology/psychiatry\n",
      "Rank 12: risedronate with relative risk of -19.197 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: varenicline with relative risk of -19.727 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: apixaban with relative risk of -19.769 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: ropinirole with relative risk of -19.901 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: crizotinib with relative risk of -20.430 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.764\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naratriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -21.068 of naratriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nateglinide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.662 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flumazenil with relative risk of -7.988 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: verapamil with relative risk of -8.162 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -8.681 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dalbavancin with relative risk of -8.782 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: varenicline with relative risk of -9.086 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rivastigmine with relative risk of -9.163 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: linezolid with relative risk of -9.339 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: silodosin with relative risk of -9.371 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: brinzolamide with relative risk of -9.505 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: metronidazole with relative risk of -9.559 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dolutegravir with relative risk of -9.629 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: quetiapine with relative risk of -10.092 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: metolazone with relative risk of -10.455 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -10.563 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rosuvastatin with relative risk of -14.938 of nateglinide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: leflunomide with relative risk of -15.374 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: raltitrexed with relative risk of -16.480 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: belinostat with relative risk of -20.302 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mirtazapine with relative risk of -20.843 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: estramustine with relative risk of -22.160 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: apixaban with relative risk of -23.315 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fluoxetine with relative risk of -25.233 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: dapagliflozin with relative risk of -25.731 of nateglinide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 25: duloxetine with relative risk of -26.879 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: milnacipran with relative risk of -27.074 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: rofecoxib with relative risk of -27.267 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: conivaptan with relative risk of -27.603 of nateglinide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 29: umeclidinium with relative risk of -27.607 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ramipril with relative risk of -27.719 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: quinapril with relative risk of -28.490 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: acebutolol with relative risk of -29.798 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tasimelteon with relative risk of -31.294 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: azathioprine with relative risk of -33.282 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: terbutaline with relative risk of -35.130 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: pinaverium with relative risk of -35.554 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: sparfloxacin with relative risk of -37.026 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: mometasone with relative risk of -38.434 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: teniposide with relative risk of -40.216 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: budesonide with relative risk of -41.706 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: nelarabine with relative risk of -41.853 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fosinoprilat with relative risk of -42.613 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: rosiglitazone with relative risk of -42.754 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: dexmedetomidine with relative risk of -49.761 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: axitinib with relative risk of -51.720 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: trandolapril with relative risk of -52.965 of nateglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.032\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nebivolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -9.706 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olmesartan with relative risk of -10.808 of nebivolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: sunitinib with relative risk of -11.382 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trimethoprim with relative risk of -11.605 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: repaglinide with relative risk of -12.035 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.219\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nedocromil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.158 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.239 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -9.355 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dalbavancin with relative risk of -9.368 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bromocriptine with relative risk of -9.660 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: silodosin with relative risk of -9.958 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: raltitrexed with relative risk of -10.009 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apixaban with relative risk of -10.303 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: glipizide with relative risk of -10.563 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sparfloxacin with relative risk of -13.837 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: felbamate with relative risk of -18.162 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: eliglustat with relative risk of -19.512 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nelarabine with relative risk of -21.936 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -21.983 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 15: rosiglitazone with relative risk of -22.407 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: belinostat with relative risk of -22.429 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mirtazapine with relative risk of -22.969 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: tasimelteon with relative risk of -27.795 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: azathioprine with relative risk of -29.542 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rocuronium with relative risk of -29.982 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: pinaverium with relative risk of -31.768 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flumazenil with relative risk of -33.391 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: acebutolol with relative risk of -34.626 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gemfibrozil with relative risk of -35.373 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mometasone with relative risk of -36.065 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 26: teniposide with relative risk of -37.298 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -40.122 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telithromycin with relative risk of -45.073 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: capsaicin with relative risk of -46.291 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: glimepiride with relative risk of -48.524 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vilazodone with relative risk of -49.076 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.2\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nefazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nelarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.427 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: erlotinib with relative risk of -7.935 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pioglitazone with relative risk of -8.125 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -8.341 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: aripiprazole with relative risk of -8.780 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: adenosine with relative risk of -8.971 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: carbamazepine with relative risk of -9.852 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: felbamate with relative risk of -15.324 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: everolimus with relative risk of -16.528 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: eliglustat with relative risk of -16.672 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: glipizide with relative risk of -17.086 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dutasteride with relative risk of -18.252 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: estramustine with relative risk of -19.719 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -20.769 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: raloxifene with relative risk of -21.203 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ropinirole with relative risk of -21.696 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromocriptine with relative risk of -22.019 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nedocromil with relative risk of -22.191 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: glimepiride with relative risk of -22.233 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vilazodone with relative risk of -22.784 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluoxetine with relative risk of -22.788 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: omeprazole with relative risk of -23.521 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: duloxetine with relative risk of -24.434 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: milnacipran with relative risk of -24.629 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rofecoxib with relative risk of -24.821 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: conivaptan with relative risk of -25.158 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: umeclidinium with relative risk of -25.162 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ramipril with relative risk of -25.273 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: rocuronium with relative risk of -25.409 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: quinapril with relative risk of -26.045 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: terbutaline with relative risk of -31.704 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: dexmedetomidine with relative risk of -35.653 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: telithromycin with relative risk of -35.714 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: gemfibrozil with relative risk of -36.579 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: capsaicin with relative risk of -36.931 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dapagliflozin with relative risk of -40.217 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: apixaban with relative risk of -42.355 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: flumazenil with relative risk of -42.418 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nateglinide with relative risk of -42.555 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: leflunomide with relative risk of -43.082 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: axitinib with relative risk of -45.942 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: raltitrexed with relative risk of -46.895 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: trandolapril with relative risk of -47.187 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: dalbavancin with relative risk of -47.764 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: silodosin with relative risk of -54.489 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: rosuvastatin with relative risk of -74.721 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: belinostat with relative risk of -108.468 of nelarabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 48: mirtazapine with relative risk of -109.008 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: tasimelteon with relative risk of -114.981 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: acebutolol with relative risk of -115.167 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: sparfloxacin with relative risk of -117.088 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: azathioprine with relative risk of -121.049 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: pinaverium with relative risk of -124.169 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: teniposide with relative risk of -126.703 of nelarabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 55: fosinoprilat with relative risk of -131.384 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: rosiglitazone with relative risk of -135.139 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: mometasone with relative risk of -135.553 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: budesonide with relative risk of -139.346 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.009\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nelfinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: darifenacin with relative risk of -10.822 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.093 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: allopurinol with relative risk of -11.108 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: perindopril with relative risk of -11.235 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dantrolene with relative risk of -11.897 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: riluzole with relative risk of -12.416 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cetrorelix with relative risk of -12.543 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: toremifene with relative risk of -13.239 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target nesiritide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nevirapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -9.441 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sparfloxacin with relative risk of -9.864 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -10.580 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: risedronate with relative risk of -10.933 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pioglitazone with relative risk of -11.064 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: crizotinib with relative risk of -11.068 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: varenicline with relative risk of -11.282 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ropinirole with relative risk of -11.456 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: naproxen with relative risk of -11.645 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -11.911 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: desvenlafaxine with relative risk of -12.421 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: topiramate with relative risk of -12.551 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: meloxicam with relative risk of -12.841 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fosinoprilat with relative risk of -12.853 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: loteprednol with relative risk of -14.040 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target niacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nicardipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -9.885 of nicardipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -11.159 of nicardipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: lurasidone with relative risk of -11.539 of nicardipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loxapine with relative risk of -11.764 of nicardipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ivermectin with relative risk of -11.861 of nicardipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: eprosartan with relative risk of -12.139 of nicardipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: rasagiline with relative risk of -12.491 of nicardipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.257\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nicotine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: scopolamine with relative risk of -13.221 of nicotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: propranolol with relative risk of -13.246 of nicotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: avanafil with relative risk of -13.329 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of nicotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.174\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nifedipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: scopolamine with relative risk of -13.221 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: propranolol with relative risk of -13.246 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Angina Pectoris,Hypertensive disease,cardiology\n",
      "Rank 6: nicotine with relative risk of -13.313 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: avanafil with relative risk of -13.329 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.11\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nilotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -7.637 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -7.837 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -8.162 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -8.262 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -8.913 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: raloxifene with relative risk of -9.355 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -9.734 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -9.997 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: omeprazole with relative risk of -10.470 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tazarotene with relative risk of -10.472 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: amlexanox with relative risk of -10.983 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pinaverium with relative risk of -11.011 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fosinoprilat with relative risk of -11.249 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: triamcinolone with relative risk of -11.404 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tolterodine with relative risk of -12.162 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: diltiazem with relative risk of -12.250 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ziprasidone with relative risk of -12.343 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bicalutamide with relative risk of -14.821 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: levetiracetam with relative risk of -15.372 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nilutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paliperidone with relative risk of -9.124 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indapamide with relative risk of -9.707 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ketoprofen with relative risk of -9.755 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: alosetron with relative risk of -9.991 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paroxetine with relative risk of -10.051 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: carvedilol with relative risk of -10.212 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: fluvoxamine with relative risk of -10.987 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -11.018 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: adapalene with relative risk of -11.409 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: flunisolide with relative risk of -11.445 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rotigotine with relative risk of -11.551 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: albendazole with relative risk of -11.636 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: alfuzosin with relative risk of -11.735 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: amoxicillin with relative risk of -11.825 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azilsartan with relative risk of -12.175 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lovastatin with relative risk of -12.326 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: danazol with relative risk of -15.961 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: colchicine with relative risk of -17.628 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nimodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: quinaprilat with relative risk of -12.791 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiloride with relative risk of -17.650 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clozapine with relative risk of -25.386 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: abiraterone with relative risk of -27.045 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: prazosin with relative risk of -41.422 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nisoldipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -10.417 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -11.382 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vernakalant with relative risk of -11.588 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: indinavir with relative risk of -11.986 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -12.361 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: iloprost with relative risk of -12.393 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: valdecoxib with relative risk of -12.749 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: degarelix with relative risk of -12.858 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ambrisentan with relative risk of -12.988 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: reboxetine with relative risk of -13.131 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.083\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target nitazoxanide not found. Exiting ...\n",
      "\n",
      "Drug target nitrofurantoin not found. Exiting ...\n",
      "\n",
      "Drug target nitrogen not found. Exiting ...\n",
      "\n",
      "Drug target nitroglycerin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nizatidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -6.674 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -8.338 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indapamide with relative risk of -8.457 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -8.473 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: miglustat with relative risk of -8.782 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -8.800 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apraclonidine with relative risk of -9.120 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nefazodone with relative risk of -11.147 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cilazapril with relative risk of -11.587 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: liraglutide with relative risk of -14.782 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: zolmitriptan with relative risk of -17.928 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clarithromycin with relative risk of -24.811 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levetiracetam with relative risk of -118.538 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: maprotiline with relative risk of -123.181 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nalmefene with relative risk of -123.533 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pazopanib with relative risk of -164.978 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó norfloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fexofenadine with relative risk of -9.945 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivastigmine with relative risk of -10.260 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -10.360 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -10.435 of norfloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 6: atosiban with relative risk of -10.922 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: iloperidone with relative risk of -11.086 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ranitidine with relative risk of -11.249 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: indomethacin with relative risk of -14.939 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lubiprostone with relative risk of -15.431 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: anagrelide with relative risk of -17.006 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: cabergoline with relative risk of -17.492 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: penbutolol with relative risk of -17.501 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: estramustine with relative risk of -17.833 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mirabegron with relative risk of -18.212 of norfloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 16: moxifloxacin with relative risk of -18.657 of norfloxacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chlamydial pneumonia,Acute bacterial sinusitis,Acute exacerbation of chronic bronchitis,Moraxella catarrhalis pneumonia,Bacterial infection due to Klebsiella pneumoniae,Mycoplasma pneumonia,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Abdominal Abscess,Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Peritonitis,Pneumonia due to Klebsiella pneumoniae,Pneumonia, Bacterial,Streptococcal pneumonia,Intraabdominal Infections,Bacterial conjunctivitis,Rhinoscleroma,infectious disease\n",
      "Rank 17: nabumetone with relative risk of -18.854 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.096\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target o291 not found. Exiting ...\n",
      "\n",
      "Drug target ofatumumab not found. Exiting ...\n",
      "\n",
      "Drug target ofloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olanzapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cimetidine with relative risk of -14.309 of olanzapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: felodipine with relative risk of -inf of olanzapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olmesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -6.490 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -6.863 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: clonidine with relative risk of -7.034 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: sildenafil with relative risk of -7.290 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dalbavancin with relative risk of -7.464 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dofetilide with relative risk of -8.029 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gonadorelin with relative risk of -8.704 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: caffeine with relative risk of -8.748 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: quetiapine with relative risk of -8.764 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: donepezil with relative risk of -9.745 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nebivolol with relative risk of -10.818 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: brinzolamide with relative risk of -14.044 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lubiprostone with relative risk of -14.462 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: repaglinide with relative risk of -22.755 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: trimethoprim with relative risk of -26.933 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: linagliptin with relative risk of -29.705 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sunitinib with relative risk of -35.887 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: lansoprazole with relative risk of -37.076 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bicalutamide with relative risk of -39.959 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dexmedetomidine with relative risk of -44.211 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: dexamethasone with relative risk of -44.404 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: formoterol with relative risk of -49.719 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: trametinib with relative risk of -69.806 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.248\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target olodaterol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olopatadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.419 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: desloratadine with relative risk of -10.073 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder)\n",
      "Rank 3: tolmetin with relative risk of -10.876 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -11.664 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 5: misoprostol with relative risk of -13.107 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bimatoprost with relative risk of -25.059 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.374\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target olsalazine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó omeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.797 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilotinib with relative risk of -9.355 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rosuvastatin with relative risk of -9.381 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -9.578 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dalbavancin with relative risk of -9.590 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pioglitazone with relative risk of -9.678 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gemfibrozil with relative risk of -10.220 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: everolimus with relative risk of -10.229 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raltitrexed with relative risk of -10.232 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: aripiprazole with relative risk of -10.337 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: adenosine with relative risk of -10.529 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capsaicin with relative risk of -10.572 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: teniposide with relative risk of -13.840 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tasimelteon with relative risk of -14.272 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azathioprine with relative risk of -15.565 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -17.704 of omeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 17: fosinoprilat with relative risk of -17.823 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: apixaban with relative risk of -17.977 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ropinirole with relative risk of -18.110 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bromocriptine with relative risk of -18.146 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: dapagliflozin with relative risk of -19.414 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -20.768 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sparfloxacin with relative risk of -21.043 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: mometasone with relative risk of -21.198 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: nelarabine with relative risk of -22.852 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: budesonide with relative risk of -22.899 of omeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 27: rosiglitazone with relative risk of -23.322 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: belinostat with relative risk of -23.344 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: mirtazapine with relative risk of -23.885 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: leflunomide with relative risk of -25.833 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: risedronate with relative risk of -26.256 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.025\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ondansetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -9.423 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: budesonide with relative risk of -10.009 of ondansetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 5: metoprolol with relative risk of -10.712 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: erlotinib with relative risk of -10.878 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: flutamide with relative risk of -10.887 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bromocriptine with relative risk of -11.269 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dabrafenib with relative risk of -11.289 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: felbamate with relative risk of -11.508 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -11.701 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -11.756 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cilostazol with relative risk of -11.956 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bisoprolol with relative risk of -12.574 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -12.759 of ondansetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 16: rabeprazole with relative risk of -12.891 of ondansetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 17: propafenone with relative risk of -13.018 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluocinonide with relative risk of -13.154 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: terazosin with relative risk of -13.271 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: darunavir with relative risk of -13.281 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluconazole with relative risk of -13.421 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.104\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó orlistat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: aminophylline with relative risk of -10.727 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: paricalcitol with relative risk of -10.772 of orlistat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: apixaban with relative risk of -10.813 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: palonosetron with relative risk of -11.165 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sorafenib with relative risk of -11.212 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: esomeprazole with relative risk of -11.476 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clomipramine with relative risk of -11.603 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rilpivirine with relative risk of -12.351 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dihydroergotamine with relative risk of -12.615 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: canagliflozin with relative risk of -12.616 of orlistat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: balsalazide with relative risk of -18.546 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ramelteon with relative risk of -19.041 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -19.478 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gemcitabine with relative risk of -25.453 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bosentan with relative risk of -25.877 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dronedarone with relative risk of -26.887 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ixabepilone with relative risk of -28.356 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fludarabine with relative risk of -28.900 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.12\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oseltamivir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ospemifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -17.635 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: torasemide with relative risk of -20.533 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ritonavir with relative risk of -20.747 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxaliplatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó oxcarbazepine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tizanidine with relative risk of -8.785 of oxcarbazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ruxolitinib with relative risk of -9.213 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: prasugrel with relative risk of -10.016 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: alogliptin with relative risk of -10.299 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: doxercalciferol with relative risk of -16.074 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paclitaxel with relative risk of -16.331 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ropivacaine with relative risk of -17.044 of oxcarbazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pentostatin with relative risk of -18.482 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.42\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxiconazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó oxybutynin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -8.519 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -9.242 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -9.441 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.764 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sparfloxacin with relative risk of -9.864 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -10.518 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.766 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: leflunomide with relative risk of -10.847 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.964 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.975 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -11.282 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.606 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -11.704 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: brimonidine with relative risk of -12.202 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -12.617 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.841 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.853 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ranolazine with relative risk of -12.929 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: labetalol with relative risk of -12.973 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -13.384 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eletriptan with relative risk of -14.109 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxycodone not found. Exiting ...\n",
      "\n",
      "Drug target oxymorphone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paclitaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etravirine with relative risk of -8.845 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: oxcarbazepine with relative risk of -17.766 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lidocaine with relative risk of -18.023 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loperamide with relative risk of -23.993 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: prasugrel with relative risk of -25.165 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentostatin with relative risk of -27.974 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ropivacaine with relative risk of -31.517 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tizanidine with relative risk of -32.716 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ruxolitinib with relative risk of -33.595 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: alogliptin with relative risk of -43.125 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: doxercalciferol with relative risk of -52.069 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paliperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -8.330 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -9.190 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: carvedilol with relative risk of -9.519 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lovastatin with relative risk of -11.633 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paroxetine with relative risk of -16.609 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: alosetron with relative risk of -17.648 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: alfuzosin with relative risk of -19.392 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indapamide with relative risk of -23.730 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó palonosetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ixabepilone with relative risk of -9.633 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fludarabine with relative risk of -10.177 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anastrozole with relative risk of -10.248 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: orlistat with relative risk of -10.325 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: aminophylline with relative risk of -10.727 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apixaban with relative risk of -10.813 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sorafenib with relative risk of -11.212 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: clomipramine with relative risk of -11.603 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rilpivirine with relative risk of -12.351 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -12.615 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: canagliflozin with relative risk of -12.616 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ramelteon with relative risk of -19.041 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: esomeprazole with relative risk of -21.531 of palonosetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 15: gemcitabine with relative risk of -25.453 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bosentan with relative risk of -25.877 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dronedarone with relative risk of -26.887 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: balsalazide with relative risk of -28.090 of palonosetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 19: paricalcitol with relative risk of -28.985 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pergolide with relative risk of -29.533 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.035\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pamidronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: iloperidone with relative risk of -11.491 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lercanidipine with relative risk of -13.636 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cilazapril with relative risk of -13.938 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loperamide with relative risk of -17.405 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bexarotene with relative risk of -20.178 of pamidronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pantoprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -10.789 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atropine with relative risk of -11.531 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cabozantinib with relative risk of -12.382 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: calcipotriol with relative risk of -inf of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paricalcitol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.065 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ixabepilone with relative risk of -8.940 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: anastrozole with relative risk of -9.556 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: orlistat with relative risk of -9.632 of paricalcitol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: aminophylline with relative risk of -10.034 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -10.121 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sorafenib with relative risk of -10.519 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clomipramine with relative risk of -10.910 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: rilpivirine with relative risk of -11.658 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dihydroergotamine with relative risk of -11.922 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: canagliflozin with relative risk of -11.923 of paricalcitol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: esomeprazole with relative risk of -19.921 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fludarabine with relative risk of -25.904 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -26.537 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: palonosetron with relative risk of -28.684 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gemcitabine with relative risk of -30.854 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dronedarone with relative risk of -41.467 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramelteon with relative risk of -44.418 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bosentan with relative risk of -50.695 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: balsalazide with relative risk of -55.076 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.095\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paroxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pazopanib with relative risk of -7.885 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nizatidine with relative risk of -9.147 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -9.425 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nilutamide with relative risk of -10.287 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: carvedilol with relative risk of -10.617 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lovastatin with relative risk of -12.732 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paliperidone with relative risk of -16.780 of paroxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: indapamide with relative risk of -18.375 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: alosetron with relative risk of -20.046 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: alfuzosin with relative risk of -21.790 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.049\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pazopanib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -6.628 of pazopanib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: colchicine with relative risk of -8.291 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indapamide with relative risk of -8.410 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -8.427 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: miglustat with relative risk of -8.736 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -8.753 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apraclonidine with relative risk of -9.073 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nefazodone with relative risk of -11.100 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cilazapril with relative risk of -11.541 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: liraglutide with relative risk of -14.687 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: zolmitriptan with relative risk of -17.833 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clarithromycin with relative risk of -24.665 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levetiracetam with relative risk of -117.239 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: maprotiline with relative risk of -121.882 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nalmefene with relative risk of -122.234 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nizatidine with relative risk of -166.194 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.296\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pemetrexed *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.118 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acamprosate with relative risk of -10.587 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vinorelbine with relative risk of -11.119 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: indinavir with relative risk of -11.293 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: treprostinil with relative risk of -11.400 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gabapentin with relative risk of -11.951 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: vandetanib with relative risk of -12.438 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.184\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó penbutolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.156 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: captopril with relative risk of -6.791 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: rivastigmine with relative risk of -8.654 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desloratadine with relative risk of -8.756 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -8.830 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: miglustat with relative risk of -9.118 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dolutegravir with relative risk of -9.119 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atosiban with relative risk of -9.313 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: gonadorelin with relative risk of -9.521 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ranitidine with relative risk of -9.640 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: halofantrine with relative risk of -10.362 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: hydrochlorothiazide with relative risk of -10.800 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: valsartan with relative risk of -11.091 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: dexmedetomidine with relative risk of -11.943 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: norfloxacin with relative risk of -17.753 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fondaparinux with relative risk of -18.347 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: iloperidone with relative risk of -24.383 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indomethacin with relative risk of -60.163 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: lubiprostone with relative risk of -62.190 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: estramustine with relative risk of -75.651 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cabergoline with relative risk of -78.219 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: anagrelide with relative risk of -79.930 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: mirabegron with relative risk of -81.136 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: moxifloxacin with relative risk of -81.582 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: nabumetone with relative risk of -81.778 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.206\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target penciclovir not found. Exiting ...\n",
      "\n",
      "Drug target pentamidine not found. Exiting ...\n",
      "\n",
      "Drug target pentosan not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pentostatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: loperamide with relative risk of -8.497 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: prasugrel with relative risk of -8.635 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lidocaine with relative risk of -11.236 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: oxcarbazepine with relative risk of -19.088 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ropivacaine with relative risk of -20.438 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ruxolitinib with relative risk of -21.492 of pentostatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 7: paclitaxel with relative risk of -27.144 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tizanidine with relative risk of -28.498 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: alogliptin with relative risk of -39.172 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: doxercalciferol with relative risk of -42.277 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.057\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pentoxifylline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -6.732 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -7.456 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -7.656 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -7.982 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: sparfloxacin with relative risk of -8.081 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -8.732 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -8.977 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: leflunomide with relative risk of -9.057 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -9.173 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -9.186 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -9.491 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -9.815 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: brimonidine with relative risk of -10.410 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pinaverium with relative risk of -10.830 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: meloxicam with relative risk of -11.049 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fosinoprilat with relative risk of -11.068 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: ranolazine with relative risk of -11.138 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: labetalol with relative risk of -11.181 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: oxybutynin with relative risk of -11.534 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -11.592 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eletriptan with relative risk of -12.318 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ifosfamide with relative risk of -15.411 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: efinaconazole with relative risk of -inf of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target perampanel not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pergolide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó perindopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: topotecan with relative risk of -9.918 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -9.948 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: metaproterenol with relative risk of -10.456 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nelfinavir with relative risk of -11.248 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: allopurinol with relative risk of -18.168 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.219\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó phentolamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vincristine with relative risk of -10.623 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fosphenytoin with relative risk of -12.906 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irbesartan with relative risk of -13.619 of phentolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target phenylbutyric not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó phenytoin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etodolac with relative risk of -12.358 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -13.050 of phenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: atomoxetine with relative risk of -13.107 of phenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: empagliflozin with relative risk of -13.142 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lamotrigine with relative risk of -13.180 of phenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 10: sumatriptan with relative risk of -13.354 of phenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pimozide with relative risk of -13.452 of phenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: alendronate with relative risk of -13.888 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target phosphate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pilocarpine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amlodipine with relative risk of -11.860 of pilocarpine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pimecrolimus not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pimozide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etodolac with relative risk of -12.358 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ketorolac with relative risk of -13.050 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of -13.107 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: empagliflozin with relative risk of -13.142 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lamotrigine with relative risk of -13.180 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: sumatriptan with relative risk of -13.354 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: alendronate with relative risk of -13.888 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.202\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pinaverium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.160 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilotinib with relative risk of -7.526 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trimethoprim with relative risk of -8.391 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 4: pentoxifylline with relative risk of -8.490 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: adenosine with relative risk of -8.696 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: tazarotene with relative risk of -8.864 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: brimonidine with relative risk of -8.983 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: amlexanox with relative risk of -9.375 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: granisetron with relative risk of -9.481 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 10: carbamazepine with relative risk of -9.578 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: meloxicam with relative risk of -9.624 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ranolazine with relative risk of -9.712 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: labetalol with relative risk of -9.754 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: triamcinolone with relative risk of -9.794 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nalbuphine with relative risk of -9.960 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: oxybutynin with relative risk of -10.107 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: betaxolol with relative risk of -10.165 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tolterodine with relative risk of -10.552 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: diltiazem with relative risk of -10.641 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ziprasidone with relative risk of -10.734 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eletriptan with relative risk of -10.891 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: estramustine with relative risk of -13.238 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: risedronate with relative risk of -13.498 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: bromocriptine with relative risk of -14.236 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: felbamate with relative risk of -14.762 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: gefitinib with relative risk of -15.002 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: omeprazole with relative risk of -15.333 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 28: duloxetine with relative risk of -15.553 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: milnacipran with relative risk of -15.747 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: everolimus with relative risk of -15.966 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: eliglustat with relative risk of -16.110 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: conivaptan with relative risk of -16.277 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: umeclidinium with relative risk of -16.280 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: glipizide with relative risk of -16.524 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: dutasteride with relative risk of -17.690 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: rivastigmine with relative risk of -20.330 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: varenicline with relative risk of -20.658 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ropinirole with relative risk of -20.832 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fluoxetine with relative risk of -21.924 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: disopyramide with relative risk of -22.674 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: sulfasalazine with relative risk of -23.179 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 42: flecainide with relative risk of -23.533 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: rofecoxib with relative risk of -23.957 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ramipril with relative risk of -24.409 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: candesartan with relative risk of -24.535 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: rocuronium with relative risk of -24.544 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: quinapril with relative risk of -25.180 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: dexmedetomidine with relative risk of -27.570 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: raloxifene with relative risk of -27.590 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: nedocromil with relative risk of -28.983 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: glimepiride with relative risk of -29.025 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: vilazodone with relative risk of -29.576 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: terbutaline with relative risk of -30.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: nateglinide with relative risk of -33.217 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: axitinib with relative risk of -35.216 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: idarubicin with relative risk of -35.228 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: capsaicin with relative risk of -35.412 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mifepristone with relative risk of -36.256 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: trandolapril with relative risk of -36.462 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: pitavastatin with relative risk of -36.589 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: delavirdine with relative risk of -36.940 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: frovatriptan with relative risk of -38.127 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: montelukast with relative risk of -38.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: fesoterodine with relative risk of -38.548 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: dapagliflozin with relative risk of -38.698 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: apixaban with relative risk of -40.480 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: flumazenil with relative risk of -40.542 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: cisatracurium with relative risk of -40.797 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: leflunomide with relative risk of -41.206 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: pioglitazone with relative risk of -41.423 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: telithromycin with relative risk of -41.947 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: raltitrexed with relative risk of -45.019 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: silodosin with relative risk of -52.233 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: gemfibrozil with relative risk of -52.272 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: dalbavancin with relative risk of -53.143 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: rosuvastatin with relative risk of -80.899 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: belinostat with relative risk of -92.311 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: mirtazapine with relative risk of -92.852 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: rosiglitazone with relative risk of -105.866 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: budesonide with relative risk of -110.139 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 81: nelarabine with relative risk of -121.129 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: teniposide with relative risk of -127.718 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: sparfloxacin with relative risk of -148.514 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: acebutolol with relative risk of -165.181 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: tasimelteon with relative risk of -181.180 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: mometasone with relative risk of -182.469 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: fosinoprilat with relative risk of -191.394 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: azathioprine with relative risk of -193.821 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: efinaconazole with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pindolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -7.542 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: prazosin with relative risk of -7.798 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: thalidomide with relative risk of -9.196 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: didanosine with relative risk of -9.244 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tofacitinib with relative risk of -9.690 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sitagliptin with relative risk of -10.399 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: benazepril with relative risk of -16.837 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: allopurinol with relative risk of -21.687 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amiodarone with relative risk of -24.025 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: ifosfamide with relative risk of -25.385 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dasatinib with relative risk of -29.919 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loratadine with relative risk of -30.706 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bupivacaine with relative risk of -30.867 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: clonidine with relative risk of -45.079 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: doxepin with relative risk of -128.662 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: verapamil with relative risk of -164.534 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.263\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pioglitazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -6.446 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trametinib with relative risk of -6.779 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: belinostat with relative risk of -7.595 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nelarabine with relative risk of -7.777 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: budesonide with relative risk of -7.936 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rosiglitazone with relative risk of -8.004 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mirtazapine with relative risk of -8.136 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rosuvastatin with relative risk of -8.690 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: raloxifene with relative risk of -8.886 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -8.899 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromocriptine with relative risk of -9.190 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: gefitinib with relative risk of -9.264 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: gemfibrozil with relative risk of -9.528 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 14: everolimus with relative risk of -9.536 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: raltitrexed with relative risk of -9.539 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: naproxen with relative risk of -9.566 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: aripiprazole with relative risk of -9.644 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: adenosine with relative risk of -9.836 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: omeprazole with relative risk of -10.000 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dapagliflozin with relative risk of -10.459 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 21: granisetron with relative risk of -10.620 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nalbuphine with relative risk of -11.100 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: nevirapine with relative risk of -11.157 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: domperidone with relative risk of -11.861 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loteprednol with relative risk of -11.961 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fosinopril with relative risk of -12.426 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dexamethasone with relative risk of -15.108 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 28: leflunomide with relative risk of -15.625 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: crizotinib with relative risk of -17.098 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -18.870 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: desvenlafaxine with relative risk of -19.144 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: topiramate with relative risk of -19.274 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: risedronate with relative risk of -23.618 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 34: apixaban with relative risk of -23.720 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: rivastigmine with relative risk of -24.043 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: varenicline with relative risk of -24.371 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ropinirole with relative risk of -24.545 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: disopyramide with relative risk of -26.389 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: sulfasalazine with relative risk of -26.894 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: flecainide with relative risk of -27.249 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: candesartan with relative risk of -28.250 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: acebutolol with relative risk of -37.568 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: mometasone with relative risk of -39.531 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: idarubicin with relative risk of -42.083 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: mifepristone with relative risk of -43.111 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 46: pitavastatin with relative risk of -43.443 of pioglitazone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 47: delavirdine with relative risk of -43.795 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: pinaverium with relative risk of -44.115 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: frovatriptan with relative risk of -44.982 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: montelukast with relative risk of -45.100 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: fesoterodine with relative risk of -45.403 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: cisatracurium with relative risk of -47.653 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: azathioprine with relative risk of -50.105 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: fosinoprilat with relative risk of -51.926 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: sparfloxacin with relative risk of -54.260 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tasimelteon with relative risk of -56.517 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.112\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pirbuterol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó piroxicam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mitoxantrone with relative risk of -11.859 of piroxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ponatinib with relative risk of -11.976 of piroxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: argatroban with relative risk of -12.082 of piroxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pitavastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -9.491 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -9.552 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -10.908 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nalbuphine with relative risk of -11.387 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -25.072 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -27.419 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sulfasalazine with relative risk of -27.924 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: flecainide with relative risk of -28.278 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -29.280 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acebutolol with relative risk of -32.837 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -33.296 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -34.274 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tasimelteon with relative risk of -34.335 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -36.323 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -38.331 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -38.596 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pioglitazone with relative risk of -42.758 of pitavastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 18: idarubicin with relative risk of -44.317 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mifepristone with relative risk of -45.344 of pitavastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 20: delavirdine with relative risk of -46.028 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: frovatriptan with relative risk of -47.216 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: montelukast with relative risk of -47.333 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fesoterodine with relative risk of -47.637 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cisatracurium with relative risk of -49.886 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.03\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó podophyllotoxin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -10.687 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -10.689 of podophyllotoxin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 4: indinavir with relative risk of -11.293 of podophyllotoxin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 5: travoprost with relative risk of -11.668 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nisoldipine with relative risk of -11.679 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: iloprost with relative risk of -11.700 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: valdecoxib with relative risk of -12.056 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: degarelix with relative risk of -12.165 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ambrisentan with relative risk of -12.295 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: reboxetine with relative risk of -12.438 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: vernakalant with relative risk of -21.643 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.188\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pomalidomide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ponatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mitoxantrone with relative risk of -11.859 of ponatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: argatroban with relative risk of -12.082 of ponatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: piroxicam with relative risk of -13.491 of ponatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.545\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó posaconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.058 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -8.384 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etoposide with relative risk of -9.888 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linezolid with relative risk of -10.148 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 6: pravastatin with relative risk of -12.219 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: fenofibrate with relative risk of -12.432 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.077\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pramipexole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pergolide with relative risk of -11.215 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: citalopram with relative risk of -11.586 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dapsone with relative risk of -12.342 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -12.394 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -17.246 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -19.210 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -19.532 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxapine with relative risk of -20.494 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: salmeterol with relative risk of -20.553 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -21.267 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -21.507 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: emedastine with relative risk of -21.624 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: estradiol with relative risk of -22.393 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tegaserod with relative risk of -23.025 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -23.445 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.216\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó prasugrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pentostatin with relative risk of -7.434 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: loperamide with relative risk of -7.644 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: oxcarbazepine with relative risk of -9.421 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: doxercalciferol with relative risk of -10.944 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paclitaxel with relative risk of -23.135 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ropivacaine with relative risk of -36.974 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: desoximetasone with relative risk of -inf of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pravastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -9.441 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acebutolol with relative risk of -9.764 of pravastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: etoposide with relative risk of -11.275 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -11.512 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fenofibrate with relative risk of -13.818 of pravastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypercholesterolemia,Hypertriglyceridemia,Hyperlipidemia, Familial Combined,Familial hypercholesterolemia - heterozygous,endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.307\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó prazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pindolol with relative risk of -8.288 of prazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: tolvaptan with relative risk of -10.668 of prazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: sitagliptin with relative risk of -11.315 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: exenatide with relative risk of -11.402 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinaprilat with relative risk of -12.280 of prazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: amiloride with relative risk of -16.552 of prazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: abiraterone with relative risk of -16.873 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clozapine with relative risk of -32.396 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nimodipine with relative risk of -41.813 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.66\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pregabalin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó progesterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -13.773 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: ruxolitinib with relative risk of -15.356 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: regorafenib with relative risk of -18.452 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.545\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó propafenone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.974 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -11.008 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.918 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -12.178 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -12.198 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.588 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.728 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.781 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -13.115 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acebutolol with relative risk of -15.947 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: budesonide with relative risk of -17.120 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bromocriptine with relative risk of -19.937 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: metoprolol with relative risk of -20.074 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: erlotinib with relative risk of -20.239 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -20.248 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felbamate with relative risk of -20.464 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -20.712 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dabrafenib with relative risk of -21.344 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bisoprolol with relative risk of -21.935 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: cilostazol with relative risk of -22.011 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: famotidine with relative risk of -22.121 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: fluocinonide with relative risk of -23.209 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terazosin with relative risk of -23.326 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó propranolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of propranolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 5: scopolamine with relative risk of -13.221 of propranolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: nicotine with relative risk of -13.313 of propranolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: avanafil with relative risk of -13.329 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of propranolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of propranolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Atrial Fibrillation,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.301\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target prostacyclin not found. Exiting ...\n",
      "\n",
      "Drug target prostaglandin not found. Exiting ...\n",
      "\n",
      "Drug target pyridostigmine not found. Exiting ...\n",
      "\n",
      "Drug target quazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quetiapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -9.013 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olmesartan with relative risk of -10.116 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -10.282 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nateglinide with relative risk of -10.608 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rivastigmine with relative risk of -10.666 of quetiapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sunitinib with relative risk of -10.689 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: linezolid with relative risk of -10.840 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -10.912 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: brinzolamide with relative risk of -11.008 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: metronidazole with relative risk of -11.063 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dolutegravir with relative risk of -11.132 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: linagliptin with relative risk of -11.384 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: metolazone with relative risk of -11.959 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: famotidine with relative risk of -12.066 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: donepezil with relative risk of -12.578 of quetiapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: trametinib with relative risk of -15.911 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dexmedetomidine with relative risk of -16.587 of quetiapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.095\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -9.085 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -9.254 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: rosuvastatin with relative risk of -9.668 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: leflunomide with relative risk of -9.749 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -10.468 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -10.813 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: raltitrexed with relative risk of -18.964 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: acebutolol with relative risk of -22.152 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: sparfloxacin with relative risk of -22.428 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mometasone with relative risk of -22.583 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tasimelteon with relative risk of -22.715 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: teniposide with relative risk of -22.794 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dexmedetomidine with relative risk of -23.809 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -24.231 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -24.237 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: belinostat with relative risk of -24.730 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mirtazapine with relative risk of -25.271 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fosinoprilat with relative risk of -26.409 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: pinaverium with relative risk of -26.413 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nateglinide with relative risk of -27.385 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: axitinib with relative risk of -27.778 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: trandolapril with relative risk of -29.023 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 25: fluoxetine with relative risk of -29.663 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: terbutaline with relative risk of -29.911 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dapagliflozin with relative risk of -30.162 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rofecoxib with relative risk of -31.697 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ramipril with relative risk of -32.150 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.316\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinaprilat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.756 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: prazosin with relative risk of -11.008 of quinaprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: abiraterone with relative risk of -11.723 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nimodipine with relative risk of -11.910 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.24\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clofarabine with relative risk of -11.059 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.786 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: finasteride with relative risk of -13.400 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rabeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -9.423 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: budesonide with relative risk of -10.009 of rabeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 5: metoprolol with relative risk of -10.712 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: erlotinib with relative risk of -10.878 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: flutamide with relative risk of -10.887 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bromocriptine with relative risk of -11.269 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dabrafenib with relative risk of -11.289 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: felbamate with relative risk of -11.508 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -11.701 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: metronidazole with relative risk of -11.756 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cilostazol with relative risk of -11.956 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bisoprolol with relative risk of -12.574 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: famotidine with relative risk of -12.759 of rabeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Duodenal Ulcer,Zollinger-Ellison syndrome,Gastroesophageal reflux disease,gastroenterology\n",
      "Rank 16: ondansetron with relative risk of -12.871 of rabeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 17: propafenone with relative risk of -13.018 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluocinonide with relative risk of -13.154 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: terazosin with relative risk of -13.271 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: darunavir with relative risk of -13.281 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluconazole with relative risk of -13.421 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.104\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target radium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó raloxifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.065 of raloxifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: flumazenil with relative risk of -8.393 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexamethasone with relative risk of -8.790 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nilotinib with relative risk of -8.949 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: risedronate with relative risk of -9.143 of raloxifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Osteoporosis, Postmenopausal,orthopedics\n",
      "Rank 6: pioglitazone with relative risk of -9.273 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -9.277 of raloxifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: bromocriptine with relative risk of -9.478 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nedocromil with relative risk of -9.650 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ropinirole with relative risk of -9.665 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: glimepiride with relative risk of -9.692 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: felbamate with relative risk of -9.717 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: telithromycin with relative risk of -9.797 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: everolimus with relative risk of -9.823 of raloxifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 15: pentoxifylline with relative risk of -9.913 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: aripiprazole with relative risk of -9.932 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: capsaicin with relative risk of -10.167 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: vilazodone with relative risk of -10.243 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: omeprazole with relative risk of -10.288 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: brimonidine with relative risk of -10.410 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: desvenlafaxine with relative risk of -10.630 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: topiramate with relative risk of -10.760 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: carbamazepine with relative risk of -11.005 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rocuronium with relative risk of -11.077 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ranolazine with relative risk of -11.138 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: labetalol with relative risk of -11.181 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: oxybutynin with relative risk of -11.534 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: betaxolol with relative risk of -11.592 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: domperidone with relative risk of -12.149 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: eletriptan with relative risk of -12.318 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fosinopril with relative risk of -12.713 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: varenicline with relative risk of -17.020 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: apixaban with relative risk of -17.062 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: raltitrexed with relative risk of -17.355 of raloxifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 35: meloxicam with relative risk of -19.494 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: glipizide with relative risk of -19.519 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dutasteride with relative risk of -20.686 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: nelarabine with relative risk of -21.244 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: budesonide with relative risk of -21.291 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: rosiglitazone with relative risk of -21.714 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: belinostat with relative risk of -21.736 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: mirtazapine with relative risk of -22.277 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: leflunomide with relative risk of -24.224 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: silodosin with relative risk of -25.280 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: gemfibrozil with relative risk of -25.319 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: acebutolol with relative risk of -25.674 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -26.600 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: teniposide with relative risk of -27.309 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: fosinoprilat with relative risk of -30.539 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: pinaverium with relative risk of -30.671 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dalbavancin with relative risk of -31.535 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: rosuvastatin with relative risk of -31.644 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sparfloxacin with relative risk of -33.296 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tasimelteon with relative risk of -34.335 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: azathioprine with relative risk of -36.323 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: efinaconazole with relative risk of -inf of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.313\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target raltegravir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó raltitrexed *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: risedronate with relative risk of -9.143 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pioglitazone with relative risk of -9.273 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nedocromil with relative risk of -9.650 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ropinirole with relative risk of -9.665 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: glimepiride with relative risk of -9.692 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: felbamate with relative risk of -9.717 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: adenosine with relative risk of -10.123 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: vilazodone with relative risk of -10.243 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: omeprazole with relative risk of -10.288 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: carbamazepine with relative risk of -11.005 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rocuronium with relative risk of -11.077 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dutasteride with relative risk of -11.547 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dexmedetomidine with relative risk of -13.882 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: axitinib with relative risk of -16.402 of raltitrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 15: nateglinide with relative risk of -16.570 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: raloxifene with relative risk of -16.702 of raltitrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 17: telithromycin with relative risk of -16.989 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: silodosin with relative risk of -17.123 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bromocriptine with relative risk of -17.230 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: capsaicin with relative risk of -17.513 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluoxetine with relative risk of -17.594 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trandolapril with relative risk of -17.647 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: terbutaline with relative risk of -17.842 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rofecoxib with relative risk of -18.935 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: everolimus with relative risk of -18.962 of raltitrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 26: ramipril with relative risk of -19.387 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: glipizide with relative risk of -19.519 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: quinapril with relative risk of -20.158 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dalbavancin with relative risk of -23.390 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: flumazenil with relative risk of -23.560 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: leflunomide with relative risk of -24.224 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: apixaban with relative risk of -24.749 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: gemfibrozil with relative risk of -25.319 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: dapagliflozin with relative risk of -27.166 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: rosiglitazone with relative risk of -37.822 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: belinostat with relative risk of -38.348 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: mirtazapine with relative risk of -38.889 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: rosuvastatin with relative risk of -40.669 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: acebutolol with relative risk of -40.897 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: sparfloxacin with relative risk of -41.452 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: mometasone with relative risk of -42.861 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tasimelteon with relative risk of -42.884 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: teniposide with relative risk of -44.645 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azathioprine with relative risk of -45.124 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: budesonide with relative risk of -46.135 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: nelarabine with relative risk of -46.282 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fosinoprilat with relative risk of -47.041 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: pinaverium with relative risk of -47.446 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.039\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ramelteon *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.911 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: aminophylline with relative risk of -9.880 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: apixaban with relative risk of -9.967 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: sorafenib with relative risk of -10.365 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: clomipramine with relative risk of -10.755 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: rilpivirine with relative risk of -11.504 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dihydroergotamine with relative risk of -11.768 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: canagliflozin with relative risk of -11.769 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ixabepilone with relative risk of -16.356 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: orlistat with relative risk of -17.741 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: palonosetron with relative risk of -18.581 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: esomeprazole with relative risk of -19.585 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pergolide with relative risk of -25.978 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fludarabine with relative risk of -34.706 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gemcitabine with relative risk of -38.781 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: balsalazide with relative risk of -42.670 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: paricalcitol with relative risk of -44.258 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bosentan with relative risk of -48.749 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dronedarone with relative risk of -49.759 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.191\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ramipril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -9.085 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -9.254 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: rosuvastatin with relative risk of -9.668 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Cerebrovascular accident,cardiology\n",
      "Rank 4: leflunomide with relative risk of -9.749 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -10.468 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -10.813 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: raltitrexed with relative risk of -18.964 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: acebutolol with relative risk of -22.152 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: sparfloxacin with relative risk of -22.428 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mometasone with relative risk of -22.583 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tasimelteon with relative risk of -22.715 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: teniposide with relative risk of -22.794 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dexmedetomidine with relative risk of -23.809 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azathioprine with relative risk of -24.231 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -24.237 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: belinostat with relative risk of -24.730 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mirtazapine with relative risk of -25.271 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fosinoprilat with relative risk of -26.409 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: pinaverium with relative risk of -26.413 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nateglinide with relative risk of -27.385 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: axitinib with relative risk of -27.778 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: trandolapril with relative risk of -29.023 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 25: fluoxetine with relative risk of -29.663 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: terbutaline with relative risk of -29.911 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dapagliflozin with relative risk of -30.162 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rofecoxib with relative risk of -31.697 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinapril with relative risk of -32.921 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.316\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ramiprilat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ranitidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.326 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indomethacin with relative risk of -8.549 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bicalutamide with relative risk of -8.609 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lubiprostone with relative risk of -8.874 of ranitidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 5: anagrelide with relative risk of -9.148 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cabergoline with relative risk of -9.740 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: penbutolol with relative risk of -10.086 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rivastigmine with relative risk of -10.260 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -10.263 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirabegron with relative risk of -10.354 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trimethoprim with relative risk of -10.507 of ranitidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 12: brinzolamide with relative risk of -10.603 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: metronidazole with relative risk of -10.657 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: moxifloxacin with relative risk of -10.800 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: atosiban with relative risk of -10.922 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nabumetone with relative risk of -10.997 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: iloperidone with relative risk of -11.086 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: exemestane with relative risk of -11.460 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: norfloxacin with relative risk of -11.946 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: hydrochlorothiazide with relative risk of -12.409 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: trametinib with relative risk of -14.813 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: linezolid with relative risk of -27.618 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.092\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ranolazine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -7.827 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -8.550 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tasimelteon with relative risk of -8.749 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: acebutolol with relative risk of -9.073 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: sparfloxacin with relative risk of -9.172 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -9.826 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rosuvastatin with relative risk of -10.073 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: leflunomide with relative risk of -10.154 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raloxifene with relative risk of -10.271 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -10.282 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -10.589 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -10.913 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: pentoxifylline with relative risk of -11.011 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: brimonidine with relative risk of -11.509 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -11.925 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -12.148 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosinoprilat with relative risk of -12.161 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: labetalol with relative risk of -12.280 of ranolazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: oxybutynin with relative risk of -12.633 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -12.691 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eletriptan with relative risk of -13.416 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: efinaconazole with relative risk of -inf of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.181\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rapamycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rasagiline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -10.984 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bezafibrate with relative risk of -12.257 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lurasidone with relative risk of -12.638 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: loxapine with relative risk of -12.863 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: ivermectin with relative risk of -12.960 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: eprosartan with relative risk of -13.238 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nicardipine with relative risk of -13.348 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.225\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rasburicase not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó reboxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -10.417 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -11.380 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -11.382 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vernakalant with relative risk of -11.588 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indinavir with relative risk of -11.986 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -12.361 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nisoldipine with relative risk of -12.372 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: iloprost with relative risk of -12.393 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -12.749 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: degarelix with relative risk of -12.858 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ambrisentan with relative risk of -12.988 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó regadenoson *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.927 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pergolide with relative risk of -11.215 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: venlafaxine with relative risk of -11.392 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: citalopram with relative risk of -11.586 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dapsone with relative risk of -12.342 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: isradipine with relative risk of -12.394 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: captopril with relative risk of -17.246 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -19.210 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -19.532 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxapine with relative risk of -20.494 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: salmeterol with relative risk of -20.553 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capecitabine with relative risk of -21.507 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: emedastine with relative risk of -21.624 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: estradiol with relative risk of -22.393 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pramipexole with relative risk of -22.677 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tegaserod with relative risk of -23.025 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: almotriptan with relative risk of -23.445 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó regorafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -16.074 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ruxolitinib with relative risk of -17.658 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: progesterone with relative risk of -19.659 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target remifentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó repaglinide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trimethoprim with relative risk of -10.507 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nebivolol with relative risk of -13.246 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trametinib with relative risk of -14.813 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dexmedetomidine with relative risk of -15.490 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linagliptin with relative risk of -19.935 of repaglinide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 6: olmesartan with relative risk of -23.956 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: bicalutamide with relative risk of -24.612 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sunitinib with relative risk of -29.007 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rescinnamine not found. Exiting ...\n",
      "\n",
      "Drug target retapamulin not found. Exiting ...\n",
      "\n",
      "Drug target retigabine not found. Exiting ...\n",
      "\n",
      "Drug target retinoic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ribavirin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acebutolol with relative risk of -9.764 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: budesonide with relative risk of -10.009 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metoprolol with relative risk of -10.712 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -10.878 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: flutamide with relative risk of -10.887 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bromocriptine with relative risk of -11.269 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dabrafenib with relative risk of -11.289 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: felbamate with relative risk of -11.508 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: metronidazole with relative risk of -11.756 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: cilostazol with relative risk of -11.956 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bisoprolol with relative risk of -12.574 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: lapatinib with relative risk of -12.612 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: famotidine with relative risk of -12.759 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: propafenone with relative risk of -13.018 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fluocinonide with relative risk of -13.154 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: terazosin with relative risk of -13.271 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tropisetron with relative risk of -13.475 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tolcapone with relative risk of -13.809 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rifabutin not found. Exiting ...\n",
      "\n",
      "Drug target rifaximin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rilpivirine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bosentan with relative risk of -10.044 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dronedarone with relative risk of -11.054 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aminophylline with relative risk of -11.826 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paricalcitol with relative risk of -11.871 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ramelteon with relative risk of -11.876 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pergolide with relative risk of -11.908 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apixaban with relative risk of -11.911 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: palonosetron with relative risk of -12.264 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sorafenib with relative risk of -12.311 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: esomeprazole with relative risk of -12.574 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clomipramine with relative risk of -12.701 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dihydroergotamine with relative risk of -13.714 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: canagliflozin with relative risk of -13.715 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó riluzole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: darifenacin with relative risk of -10.822 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.093 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dantrolene with relative risk of -11.897 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: nelfinavir with relative risk of -12.164 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cetrorelix with relative risk of -12.543 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: toremifene with relative risk of -13.239 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.136\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rimantadine not found. Exiting ...\n",
      "\n",
      "Drug target riociguat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó risedronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -6.911 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flumazenil with relative risk of -8.239 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rosuvastatin with relative risk of -8.823 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: raloxifene with relative risk of -9.019 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Osteoporosis, Postmenopausal,orthopedics\n",
      "Rank 5: dalbavancin with relative risk of -9.032 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gemfibrozil with relative risk of -9.661 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: everolimus with relative risk of -9.669 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: raltitrexed with relative risk of -9.673 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: adenosine with relative risk of -9.969 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: capsaicin with relative risk of -10.013 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -11.291 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loteprednol with relative risk of -12.095 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fosinopril with relative risk of -12.559 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: teniposide with relative risk of -12.589 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pinaverium with relative risk of -16.454 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bromocriptine with relative risk of -16.893 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: aripiprazole with relative risk of -18.040 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dapagliflozin with relative risk of -18.162 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 19: acebutolol with relative risk of -18.605 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: naproxen with relative risk of -18.655 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 21: mometasone with relative risk of -19.032 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: meloxicam with relative risk of -19.158 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: desvenlafaxine with relative risk of -19.432 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: topiramate with relative risk of -19.562 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: azathioprine with relative risk of -20.680 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: nelarabine with relative risk of -20.685 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: budesonide with relative risk of -20.732 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: domperidone with relative risk of -20.951 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: rosiglitazone with relative risk of -21.155 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: belinostat with relative risk of -21.177 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mirtazapine with relative risk of -21.718 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fosinoprilat with relative risk of -22.858 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: dexamethasone with relative risk of -22.859 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 34: pioglitazone with relative risk of -23.881 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 35: varenicline with relative risk of -24.841 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: omeprazole with relative risk of -26.842 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: crizotinib with relative risk of -26.930 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: leflunomide with relative risk of -32.110 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: tasimelteon with relative risk of -33.083 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: sparfloxacin with relative risk of -39.508 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: apixaban with relative risk of -41.072 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ropinirole with relative risk of -43.843 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.226\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó risperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -9.967 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: clonidine with relative risk of -10.545 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: sildenafil with relative risk of -10.808 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dofetilide with relative risk of -11.551 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.72\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ritonavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.755 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: captopril with relative risk of -8.395 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: afatinib with relative risk of -9.489 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glycopyrrolate with relative risk of -9.885 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.360 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: topotecan with relative risk of -10.429 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: telmisartan with relative risk of -10.458 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: salmeterol with relative risk of -10.499 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bromfenac with relative risk of -13.898 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ospemifene with relative risk of -20.896 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cyclophosphamide with relative risk of -28.095 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: torasemide with relative risk of -30.994 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rivaroxaban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vemurafenib with relative risk of -21.369 of rivaroxaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: asenapine with relative risk of -22.595 of rivaroxaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rivastigmine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -7.482 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: indomethacin with relative risk of -7.709 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lubiprostone with relative risk of -8.032 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anagrelide with relative risk of -8.303 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cabergoline with relative risk of -8.895 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dalbavancin with relative risk of -9.032 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: penbutolol with relative risk of -9.241 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: varenicline with relative risk of -9.337 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: nateglinide with relative risk of -9.357 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: gefitinib with relative risk of -9.398 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: estramustine with relative risk of -9.418 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mirabegron with relative risk of -9.509 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: brinzolamide with relative risk of -9.756 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: metronidazole with relative risk of -9.810 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dolutegravir with relative risk of -9.880 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: moxifloxacin with relative risk of -9.954 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: atosiban with relative risk of -10.075 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: nabumetone with relative risk of -10.151 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: iloperidone with relative risk of -10.239 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: quetiapine with relative risk of -10.344 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: ranitidine with relative risk of -10.402 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: metolazone with relative risk of -10.706 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: granisetron with relative risk of -10.754 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: famotidine with relative risk of -10.814 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: norfloxacin with relative risk of -11.100 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: nalbuphine with relative risk of -11.233 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: trametinib with relative risk of -12.871 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: linezolid with relative risk of -16.466 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: acebutolol with relative risk of -18.605 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sparfloxacin with relative risk of -18.880 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -19.032 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: tasimelteon with relative risk of -19.165 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: azathioprine with relative risk of -20.680 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: fosinoprilat with relative risk of -22.858 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pinaverium with relative risk of -22.861 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: idarubicin with relative risk of -23.137 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: pioglitazone with relative risk of -23.881 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: mifepristone with relative risk of -24.165 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: delavirdine with relative risk of -24.849 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: pitavastatin with relative risk of -25.596 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: frovatriptan with relative risk of -26.036 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: montelukast with relative risk of -26.154 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: fesoterodine with relative risk of -26.457 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: disopyramide with relative risk of -26.859 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: sulfasalazine with relative risk of -27.364 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: flecainide with relative risk of -27.719 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cisatracurium with relative risk of -28.706 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: candesartan with relative risk of -28.720 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.314\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rizatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -10.789 of rizatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rocuronium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.668 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.749 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -9.865 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dalbavancin with relative risk of -9.877 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bromocriptine with relative risk of -10.170 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: silodosin with relative risk of -10.468 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: raltitrexed with relative risk of -10.519 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apixaban with relative risk of -10.813 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: glipizide with relative risk of -11.074 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sparfloxacin with relative risk of -15.037 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: flumazenil with relative risk of -17.193 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: felbamate with relative risk of -19.365 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: eliglustat with relative risk of -20.716 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: acebutolol with relative risk of -22.152 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mometasone with relative risk of -22.583 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tasimelteon with relative risk of -22.715 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: teniposide with relative risk of -22.794 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azathioprine with relative risk of -24.231 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nelarabine with relative risk of -24.237 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: budesonide with relative risk of -24.284 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rosiglitazone with relative risk of -24.708 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: belinostat with relative risk of -24.730 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: mirtazapine with relative risk of -25.271 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: fosinoprilat with relative risk of -26.409 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pinaverium with relative risk of -26.413 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telithromycin with relative risk of -27.960 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: gemfibrozil with relative risk of -28.314 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: capsaicin with relative risk of -28.666 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: nedocromil with relative risk of -29.066 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: glimepiride with relative risk of -29.108 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vilazodone with relative risk of -29.659 of rocuronium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.176\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rofecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó roflumilast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: imatinib with relative risk of -8.336 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bumetanide with relative risk of -9.708 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ciclesonide with relative risk of -11.612 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ropinirole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.065 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: raloxifene with relative risk of -9.173 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -9.186 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bromocriptine with relative risk of -9.478 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 5: telithromycin with relative risk of -9.797 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gemfibrozil with relative risk of -9.815 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: everolimus with relative risk of -9.823 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: raltitrexed with relative risk of -9.827 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aripiprazole with relative risk of -9.932 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: adenosine with relative risk of -10.123 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -11.445 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loteprednol with relative risk of -12.249 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fosinopril with relative risk of -12.713 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -14.415 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: belinostat with relative risk of -14.454 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rosiglitazone with relative risk of -14.656 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mirtazapine with relative risk of -14.995 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rosuvastatin with relative risk of -15.812 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: omeprazole with relative risk of -18.327 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dapagliflozin with relative risk of -18.498 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: naproxen with relative risk of -18.992 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: acebutolol with relative risk of -19.162 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: meloxicam with relative risk of -19.494 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: mometasone with relative risk of -19.591 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: desvenlafaxine with relative risk of -19.768 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: teniposide with relative risk of -19.801 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: topiramate with relative risk of -19.898 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: nelarabine with relative risk of -21.244 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: domperidone with relative risk of -21.287 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dexamethasone with relative risk of -23.418 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: pinaverium with relative risk of -23.420 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: leflunomide with relative risk of -24.224 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: pioglitazone with relative risk of -24.441 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: varenicline with relative risk of -25.400 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: crizotinib with relative risk of -27.489 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: azathioprine with relative risk of -28.444 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fosinoprilat with relative risk of -30.539 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: sparfloxacin with relative risk of -41.452 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: apixaban with relative risk of -42.324 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: tasimelteon with relative risk of -42.884 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: risedronate with relative risk of -43.475 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.186\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ropivacaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tizanidine with relative risk of -12.353 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: loperamide with relative risk of -12.632 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -12.876 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: alogliptin with relative risk of -14.066 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: oxcarbazepine with relative risk of -17.632 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pentostatin with relative risk of -20.420 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: doxercalciferol with relative risk of -29.743 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: paclitaxel with relative risk of -30.670 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: prasugrel with relative risk of -38.157 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.424\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rosiglitazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rosuvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: risedronate with relative risk of -8.538 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: pioglitazone with relative risk of -8.669 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: fluoxetine with relative risk of -8.949 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: estramustine with relative risk of -8.968 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nedocromil with relative risk of -9.045 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: glimepiride with relative risk of -9.087 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: felbamate with relative risk of -9.111 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentoxifylline with relative risk of -9.308 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: duloxetine with relative risk of -9.497 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: adenosine with relative risk of -9.517 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: vilazodone with relative risk of -9.638 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: omeprazole with relative risk of -9.682 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: milnacipran with relative risk of -9.691 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: brimonidine with relative risk of -9.804 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rofecoxib with relative risk of -9.884 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: conivaptan with relative risk of -10.220 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: umeclidinium with relative risk of -10.224 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramipril with relative risk of -10.336 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Cerebrovascular accident,cardiology\n",
      "Rank 19: carbamazepine with relative risk of -10.399 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: meloxicam with relative risk of -10.444 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rocuronium with relative risk of -10.471 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ranolazine with relative risk of -10.532 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: labetalol with relative risk of -10.575 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: oxybutynin with relative risk of -10.928 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: betaxolol with relative risk of -10.986 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: quinapril with relative risk of -11.107 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 27: eletriptan with relative risk of -11.712 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dexmedetomidine with relative risk of -12.587 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: flumazenil with relative risk of -14.287 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: axitinib with relative risk of -15.104 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: nateglinide with relative risk of -15.272 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 32: varenicline with relative risk of -15.721 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ropinirole with relative risk of -15.895 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: bromocriptine with relative risk of -15.931 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 35: capsaicin with relative risk of -16.215 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: trandolapril with relative risk of -16.349 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 37: terbutaline with relative risk of -16.543 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dapagliflozin with relative risk of -17.199 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 39: everolimus with relative risk of -17.662 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: glipizide with relative risk of -18.220 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 41: dutasteride with relative risk of -19.387 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: apixaban with relative risk of -22.640 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: telithromycin with relative risk of -22.855 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: leflunomide with relative risk of -29.867 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: gemfibrozil with relative risk of -31.185 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertriglyceridemia,endocrinology,cardiology\n",
      "Rank 46: raloxifene with relative risk of -31.235 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: silodosin with relative risk of -39.765 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: raltitrexed with relative risk of -40.914 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: belinostat with relative risk of -50.174 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: mirtazapine with relative risk of -50.715 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dalbavancin with relative risk of -52.791 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: rosiglitazone with relative risk of -57.488 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: budesonide with relative risk of -64.604 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: acebutolol with relative risk of -72.605 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 55: sparfloxacin with relative risk of -73.674 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: nelarabine with relative risk of -74.353 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: tasimelteon with relative risk of -77.276 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mometasone with relative risk of -77.466 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: azathioprine with relative risk of -80.961 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: fosinoprilat with relative risk of -82.348 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: teniposide with relative risk of -82.529 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: pinaverium with relative risk of -83.570 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: efinaconazole with relative risk of -inf of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.499\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rotigotine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -11.380 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nilutamide with relative risk of -11.672 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trospium with relative risk of -12.809 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: adapalene with relative risk of -13.201 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rufinamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: scopolamine with relative risk of -13.221 of rufinamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: propranolol with relative risk of -13.246 of rufinamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nicotine with relative risk of -13.313 of rufinamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: avanafil with relative risk of -13.329 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.18\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ruxolitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: oxcarbazepine with relative risk of -9.967 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -13.042 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: progesterone with relative risk of -15.653 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: regorafenib with relative risk of -16.748 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lidocaine with relative risk of -18.669 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 6: pentostatin with relative risk of -21.641 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 7: etravirine with relative risk of -24.070 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loperamide with relative risk of -25.409 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: paclitaxel with relative risk of -32.915 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tizanidine with relative risk of -42.695 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: alogliptin with relative risk of -64.161 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: doxercalciferol with relative risk of -74.047 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.118\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target salbutamol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó salmeterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -8.235 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -8.391 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: afatinib with relative risk of -9.201 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glycopyrrolate with relative risk of -9.598 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: topotecan with relative risk of -10.141 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pergolide with relative risk of -10.522 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dabigatran with relative risk of -10.543 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: venlafaxine with relative risk of -10.698 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: citalopram with relative risk of -10.893 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ritonavir with relative risk of -11.098 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: torasemide with relative risk of -11.290 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dapsone with relative risk of -11.649 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: isradipine with relative risk of -11.701 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: aclidinium with relative risk of -12.176 of salmeterol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 15: bromfenac with relative risk of -13.611 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: amoxapine with relative risk of -18.702 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -19.475 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: capecitabine with relative risk of -19.715 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: emedastine with relative risk of -19.832 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: estradiol with relative risk of -20.601 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pramipexole with relative risk of -20.885 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: tegaserod with relative risk of -21.233 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: almotriptan with relative risk of -21.653 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: telmisartan with relative risk of -26.255 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: captopril with relative risk of -33.079 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: desloratadine with relative risk of -35.043 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.019\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target salmon not found. Exiting ...\n",
      "\n",
      "Drug target samarium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó saquinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -9.724 of saquinavir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 2: colchicine with relative risk of -10.687 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vernakalant with relative risk of -10.895 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indinavir with relative risk of -11.293 of saquinavir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: nisoldipine with relative risk of -11.679 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: iloprost with relative risk of -11.700 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: degarelix with relative risk of -12.165 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ambrisentan with relative risk of -12.295 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: reboxetine with relative risk of -12.438 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: travoprost with relative risk of -21.723 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: valdecoxib with relative risk of -22.804 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.414\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó scopolamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -10.799 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -11.897 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: deferasirox with relative risk of -12.436 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -12.919 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: propranolol with relative risk of -13.246 of scopolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: nicotine with relative risk of -13.313 of scopolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: avanafil with relative risk of -13.329 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -13.344 of scopolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: dipyridamole with relative risk of -13.960 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.174\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sertraline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acamprosate with relative risk of -11.280 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sevelamer not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sildenafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olmesartan with relative risk of -8.871 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: risperidone with relative risk of -11.021 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: verapamil with relative risk of -20.281 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: doxepin with relative risk of -26.002 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: clonidine with relative risk of -30.257 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dofetilide with relative risk of -36.368 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó silodosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -7.482 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flumazenil with relative risk of -8.239 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: verapamil with relative risk of -8.411 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: axitinib with relative risk of -8.719 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: leflunomide with relative risk of -8.903 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bromocriptine with relative risk of -9.324 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nateglinide with relative risk of -9.357 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fluoxetine with relative risk of -9.400 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nedocromil with relative risk of -9.496 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: glimepiride with relative risk of -9.538 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: felbamate with relative risk of -9.563 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: telithromycin with relative risk of -9.643 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: terbutaline with relative risk of -9.648 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: everolimus with relative risk of -9.669 of silodosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 15: trandolapril with relative risk of -9.965 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: apixaban with relative risk of -9.967 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: capsaicin with relative risk of -10.013 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: vilazodone with relative risk of -10.090 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rofecoxib with relative risk of -10.335 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dapagliflozin with relative risk of -10.592 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ramipril with relative risk of -10.788 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: carbamazepine with relative risk of -10.851 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rocuronium with relative risk of -10.923 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: quinapril with relative risk of -11.559 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gemfibrozil with relative risk of -16.825 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: raltitrexed with relative risk of -17.019 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: glipizide with relative risk of -19.183 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dutasteride with relative risk of -20.349 of silodosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 29: raloxifene with relative risk of -24.523 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: rosuvastatin with relative risk of -39.416 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: teniposide with relative risk of -42.700 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: acebutolol with relative risk of -47.190 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: sparfloxacin with relative risk of -47.843 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: dalbavancin with relative risk of -48.381 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tasimelteon with relative risk of -49.681 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: mometasone with relative risk of -49.697 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: azathioprine with relative risk of -52.183 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: budesonide with relative risk of -53.551 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nelarabine with relative risk of -53.772 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fosinoprilat with relative risk of -54.005 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: pinaverium with relative risk of -54.556 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: rosiglitazone with relative risk of -54.840 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: belinostat with relative risk of -55.972 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: mirtazapine with relative risk of -56.513 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.025\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó simvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: citalopram with relative risk of -10.334 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 2: amlexanox with relative risk of -10.647 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: isradipine with relative risk of -11.141 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: indomethacin with relative risk of -32.327 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cyclobenzaprine with relative risk of -33.196 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: amlodipine with relative risk of -33.682 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Cerebrovascular accident,Hypertensive disease,cardiology\n",
      "Rank 7: lubiprostone with relative risk of -49.802 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.656\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sitagliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pindolol with relative risk of -10.581 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: clozapine with relative risk of -10.756 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: prazosin with relative risk of -11.008 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sitaxsentan not found. Exiting ...\n",
      "\n",
      "Drug target sodium not found. Exiting ...\n",
      "\n",
      "Drug target sofosbuvir not found. Exiting ...\n",
      "\n",
      "Drug target solifenacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sorafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.852 of sorafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: gemcitabine with relative risk of -9.620 of sorafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 3: bosentan with relative risk of -10.044 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ixabepilone with relative risk of -10.731 of sorafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: dronedarone with relative risk of -11.054 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fludarabine with relative risk of -11.275 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: balsalazide with relative risk of -11.381 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: orlistat with relative risk of -11.423 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aminophylline with relative risk of -11.826 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paricalcitol with relative risk of -11.871 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ramelteon with relative risk of -11.876 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pergolide with relative risk of -11.908 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apixaban with relative risk of -11.911 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: palonosetron with relative risk of -12.264 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: esomeprazole with relative risk of -12.574 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clomipramine with relative risk of -12.701 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rilpivirine with relative risk of -13.450 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dihydroergotamine with relative risk of -13.714 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: canagliflozin with relative risk of -13.715 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.493\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sotalol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: eplerenone with relative risk of -19.509 of sotalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sparfloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target spinosad not found. Exiting ...\n",
      "\n",
      "Drug target stavudine not found. Exiting ...\n",
      "\n",
      "Drug target streptozotocin not found. Exiting ...\n",
      "\n",
      "Drug target sufentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sulfasalazine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: varenicline with relative risk of -10.183 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gefitinib with relative risk of -10.245 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: granisetron with relative risk of -11.601 of sulfasalazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 4: nalbuphine with relative risk of -12.081 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acebutolol with relative risk of -22.152 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sparfloxacin with relative risk of -22.428 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mometasone with relative risk of -22.583 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tasimelteon with relative risk of -22.715 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: azathioprine with relative risk of -24.231 of sulfasalazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 10: fosinoprilat with relative risk of -26.409 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pinaverium with relative risk of -26.413 of sulfasalazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 12: idarubicin with relative risk of -26.692 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pioglitazone with relative risk of -27.436 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mifepristone with relative risk of -27.720 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rivastigmine with relative risk of -28.067 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: delavirdine with relative risk of -28.404 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pitavastatin with relative risk of -29.151 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: frovatriptan with relative risk of -29.591 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: montelukast with relative risk of -29.709 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fesoterodine with relative risk of -30.012 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: disopyramide with relative risk of -30.415 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flecainide with relative risk of -31.274 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: cisatracurium with relative risk of -32.261 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: candesartan with relative risk of -32.275 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.142\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sulindac not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sumatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: liraglutide with relative risk of -11.172 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -11.432 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: macitentan with relative risk of -12.333 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: etodolac with relative risk of -12.358 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -12.652 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ketorolac with relative risk of -13.050 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of -13.107 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: empagliflozin with relative risk of -13.142 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lamotrigine with relative risk of -13.180 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pimozide with relative risk of -13.452 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: alendronate with relative risk of -13.888 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.202\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sunitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: quetiapine with relative risk of -10.680 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: donepezil with relative risk of -11.662 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nebivolol with relative risk of -12.735 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trimethoprim with relative risk of -26.417 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: trametinib with relative risk of -28.577 of sunitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: repaglinide with relative risk of -29.149 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dexmedetomidine with relative risk of -29.483 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: olmesartan with relative risk of -37.230 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: linagliptin with relative risk of -38.840 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: bicalutamide with relative risk of -39.839 of sunitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target suvorexant not found. Exiting ...\n",
      "\n",
      "Drug target tacrolimus not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tadalafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: docetaxel with relative risk of -12.046 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tafluprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiloride with relative risk of -10.708 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: doxorubicin with relative risk of -10.856 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irinotecan with relative risk of -11.317 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: letrozole with relative risk of -12.110 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: galantamine with relative risk of -13.150 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: zileuton with relative risk of -20.056 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tamoxifen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trimetrexate with relative risk of -10.688 of tamoxifen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trospium with relative risk of -11.711 of tamoxifen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tamsulosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dabigatran with relative risk of -11.236 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atorvastatin with relative risk of -20.483 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tapentadol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tasimelteon *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -5.413 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -6.921 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metoprolol with relative risk of -7.249 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nilotinib with relative risk of -7.280 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: erlotinib with relative risk of -7.414 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: flutamide with relative risk of -7.424 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: etoposide with relative risk of -7.809 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dabrafenib with relative risk of -7.824 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: posaconazole with relative risk of -8.050 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: trimethoprim with relative risk of -8.146 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: brinzolamide with relative risk of -8.241 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pentoxifylline with relative risk of -8.245 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aripiprazole with relative risk of -8.260 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: metronidazole with relative risk of -8.294 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: adenosine with relative risk of -8.449 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: cilostazol with relative risk of -8.492 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tazarotene with relative risk of -8.617 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: brimonidine with relative risk of -8.736 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bisoprolol with relative risk of -9.111 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: amlexanox with relative risk of -9.129 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: granisetron with relative risk of -9.234 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: famotidine with relative risk of -9.296 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: carbamazepine with relative risk of -9.331 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: ondansetron with relative risk of -9.405 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rabeprazole with relative risk of -9.425 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ranolazine with relative risk of -9.465 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: labetalol with relative risk of -9.508 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: triamcinolone with relative risk of -9.548 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: propafenone with relative risk of -9.553 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fluocinonide with relative risk of -9.690 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: nalbuphine with relative risk of -9.713 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: nevirapine with relative risk of -9.771 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: terazosin with relative risk of -9.807 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: darunavir with relative risk of -9.816 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: oxybutynin with relative risk of -9.860 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: betaxolol with relative risk of -9.918 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fluconazole with relative risk of -9.956 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: pravastatin with relative risk of -10.139 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: tolterodine with relative risk of -10.306 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fenofibrate with relative risk of -10.352 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: diltiazem with relative risk of -10.394 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ziprasidone with relative risk of -10.487 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: loteprednol with relative risk of -10.575 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: eletriptan with relative risk of -10.644 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: fosinopril with relative risk of -11.039 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: estramustine with relative risk of -12.739 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: gefitinib with relative risk of -14.500 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: omeprazole with relative risk of -14.831 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: duloxetine with relative risk of -15.050 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: milnacipran with relative risk of -15.245 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: everolimus with relative risk of -15.463 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: naproxen with relative risk of -15.493 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 53: eliglustat with relative risk of -15.608 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: conivaptan with relative risk of -15.774 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: umeclidinium with relative risk of -15.778 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: glipizide with relative risk of -16.021 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: desvenlafaxine with relative risk of -16.270 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: topiramate with relative risk of -16.399 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 59: dutasteride with relative risk of -17.187 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: domperidone with relative risk of -17.789 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: dexamethasone with relative risk of -17.913 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 62: rivastigmine with relative risk of -19.563 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 63: bromocriptine with relative risk of -20.387 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 64: fluoxetine with relative risk of -21.155 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 65: felbamate with relative risk of -21.318 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 66: disopyramide with relative risk of -21.905 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: crizotinib with relative risk of -21.976 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: sulfasalazine with relative risk of -22.410 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: flecainide with relative risk of -22.765 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: rofecoxib with relative risk of -23.188 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: ramipril with relative risk of -23.640 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: meloxicam with relative risk of -23.748 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: candesartan with relative risk of -23.766 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: rocuronium with relative risk of -23.776 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: quinapril with relative risk of -24.412 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: nedocromil with relative risk of -27.939 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: glimepiride with relative risk of -27.981 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: vilazodone with relative risk of -28.532 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 79: terbutaline with relative risk of -29.476 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: nateglinide with relative risk of -31.886 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: dexmedetomidine with relative risk of -32.151 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 82: risedronate with relative risk of -33.056 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: axitinib with relative risk of -33.884 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: idarubicin with relative risk of -33.895 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: capsaicin with relative risk of -34.080 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 86: raloxifene with relative risk of -34.184 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: mifepristone with relative risk of -34.923 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: trandolapril with relative risk of -35.129 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: pitavastatin with relative risk of -35.257 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: delavirdine with relative risk of -35.607 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: frovatriptan with relative risk of -36.794 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 92: montelukast with relative risk of -36.912 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: fesoterodine with relative risk of -37.216 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: dapagliflozin with relative risk of -37.365 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: flumazenil with relative risk of -38.910 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 96: cisatracurium with relative risk of -39.465 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 97: varenicline with relative risk of -43.051 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 98: ropinirole with relative risk of -43.225 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 99: raltitrexed with relative risk of -43.387 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: leflunomide with relative risk of -47.623 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: telithromycin with relative risk of -48.363 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: silodosin with relative risk of -50.287 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: gemfibrozil with relative risk of -50.326 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: dalbavancin with relative risk of -50.870 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: pioglitazone with relative risk of -56.753 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: apixaban with relative risk of -62.399 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 107: rosuvastatin with relative risk of -77.534 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: belinostat with relative risk of -88.109 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: mirtazapine with relative risk of -88.650 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 110: rosiglitazone with relative risk of -100.713 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: budesonide with relative risk of -113.183 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: nelarabine with relative risk of -114.870 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: teniposide with relative risk of -120.830 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: sparfloxacin with relative risk of -170.147 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: pinaverium with relative risk of -184.109 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: acebutolol with relative risk of -184.440 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: fosinoprilat with relative risk of -186.633 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: mometasone with relative risk of -186.963 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: azathioprine with relative risk of -190.158 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: efinaconazole with relative risk of -inf of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.094\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tazarotene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -8.550 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.073 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -9.172 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -9.826 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nilotinib with relative risk of -10.047 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -10.650 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -10.912 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlexanox with relative risk of -11.899 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pinaverium with relative risk of -11.925 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fosinoprilat with relative risk of -12.161 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: triamcinolone with relative risk of -12.320 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 13: tolterodine with relative risk of -13.078 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: diltiazem with relative risk of -13.166 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ziprasidone with relative risk of -13.260 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.326\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target technetium-99m not found. Exiting ...\n",
      "\n",
      "Drug target teduglutide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tegaserod *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target telavancin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó telithromycin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: leflunomide with relative risk of -8.770 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: raloxifene with relative risk of -8.886 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dalbavancin with relative risk of -8.899 of telithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 4: bromocriptine with relative risk of -9.190 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ropinirole with relative risk of -9.378 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: silodosin with relative risk of -9.489 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apixaban with relative risk of -9.834 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: glipizide with relative risk of -10.093 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raltitrexed with relative risk of -16.732 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: felbamate with relative risk of -17.132 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: eliglustat with relative risk of -18.482 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rosiglitazone with relative risk of -20.686 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: belinostat with relative risk of -20.707 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mirtazapine with relative risk of -21.248 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rosuvastatin with relative risk of -22.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sparfloxacin with relative risk of -24.504 of telithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Mycoplasma pneumonia,Moraxella catarrhalis pneumonia,Haemophilus influenzae pneumonia,Chlamydial pneumonia\n",
      "Rank 17: budesonide with relative risk of -27.260 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rocuronium with relative risk of -28.260 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: gemfibrozil with relative risk of -32.735 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nelarabine with relative risk of -34.843 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: flumazenil with relative risk of -39.644 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azathioprine with relative risk of -41.794 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pinaverium with relative risk of -44.115 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nedocromil with relative risk of -44.457 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: glimepiride with relative risk of -44.499 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: vilazodone with relative risk of -45.050 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tasimelteon with relative risk of -47.603 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: teniposide with relative risk of -49.982 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: fosinoprilat with relative risk of -51.926 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: capsaicin with relative risk of -52.320 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: acebutolol with relative risk of -53.507 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -56.574 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.098\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó telmisartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gemcitabine with relative risk of -7.426 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -7.581 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: afatinib with relative risk of -8.391 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glycopyrrolate with relative risk of -8.787 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pergolide with relative risk of -9.712 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: perindopril with relative risk of -9.732 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: metaproterenol with relative risk of -9.869 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: venlafaxine with relative risk of -9.888 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: citalopram with relative risk of -10.083 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ritonavir with relative risk of -10.288 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: torasemide with relative risk of -10.479 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: dapsone with relative risk of -10.838 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: isradipine with relative risk of -10.890 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: bromfenac with relative risk of -12.800 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: amoxapine with relative risk of -16.911 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: topotecan with relative risk of -17.306 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -17.683 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: capecitabine with relative risk of -17.923 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: emedastine with relative risk of -18.040 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: estradiol with relative risk of -18.810 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pramipexole with relative risk of -19.093 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: tegaserod with relative risk of -19.441 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: almotriptan with relative risk of -19.862 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: salmeterol with relative risk of -25.484 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: captopril with relative risk of -28.244 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 26: desloratadine with relative risk of -30.209 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.097\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target temazepam not found. Exiting ...\n",
      "\n",
      "Drug target temozolomide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó temsirolimus *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -9.713 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: caffeine with relative risk of -29.381 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: zafirlukast with relative risk of -30.451 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vardenafil with relative risk of -31.611 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó teniposide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.377 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: erlotinib with relative risk of -7.883 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pioglitazone with relative risk of -8.074 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pentoxifylline with relative risk of -8.712 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: adenosine with relative risk of -8.919 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: brimonidine with relative risk of -9.206 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: carbamazepine with relative risk of -9.801 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: meloxicam with relative risk of -9.846 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranolazine with relative risk of -9.935 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: labetalol with relative risk of -9.978 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: oxybutynin with relative risk of -10.330 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: betaxolol with relative risk of -10.388 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eletriptan with relative risk of -11.114 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -13.953 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: varenicline with relative risk of -14.483 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bromocriptine with relative risk of -14.692 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: felbamate with relative risk of -15.218 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: omeprazole with relative risk of -15.790 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: everolimus with relative risk of -16.423 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: eliglustat with relative risk of -16.567 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: glipizide with relative risk of -16.980 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: dutasteride with relative risk of -18.147 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: estramustine with relative risk of -19.556 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ropinirole with relative risk of -21.533 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: fluoxetine with relative risk of -22.625 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: duloxetine with relative risk of -24.271 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: milnacipran with relative risk of -24.466 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: rofecoxib with relative risk of -24.659 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: conivaptan with relative risk of -24.995 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: umeclidinium with relative risk of -24.999 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ramipril with relative risk of -25.111 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: rocuronium with relative risk of -25.246 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: quinapril with relative risk of -25.882 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: raloxifene with relative risk of -28.550 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: terbutaline with relative risk of -31.480 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dexmedetomidine with relative risk of -35.296 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: nedocromil with relative risk of -38.834 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: glimepiride with relative risk of -38.876 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: vilazodone with relative risk of -39.427 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: dapagliflozin with relative risk of -39.929 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: apixaban with relative risk of -41.998 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: nateglinide with relative risk of -42.199 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: leflunomide with relative risk of -42.725 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: silodosin with relative risk of -44.697 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: capsaicin with relative risk of -45.088 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: axitinib with relative risk of -45.586 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: raltitrexed with relative risk of -46.539 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: trandolapril with relative risk of -46.831 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dalbavancin with relative risk of -47.334 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: flumazenil with relative risk of -50.729 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: telithromycin with relative risk of -52.133 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: gemfibrozil with relative risk of -54.097 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: rosuvastatin with relative risk of -84.178 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: belinostat with relative risk of -86.670 of teniposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 55: mirtazapine with relative risk of -87.211 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: sparfloxacin with relative risk of -106.274 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: rosiglitazone with relative risk of -111.217 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: budesonide with relative risk of -116.182 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: acebutolol with relative risk of -121.735 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: tasimelteon with relative risk of -122.222 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: nelarabine with relative risk of -127.984 of teniposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 62: azathioprine with relative risk of -128.801 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: pinaverium with relative risk of -132.039 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: mometasone with relative risk of -143.122 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: fosinoprilat with relative risk of -149.937 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: efinaconazole with relative risk of -inf of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.007\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tenofovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó terazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -8.731 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -8.749 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ribavirin with relative risk of -10.974 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brinzolamide with relative risk of -11.008 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lapatinib with relative risk of -11.918 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ondansetron with relative risk of -12.178 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rabeprazole with relative risk of -12.198 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -12.588 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluconazole with relative risk of -12.728 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tropisetron with relative risk of -12.781 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tolcapone with relative risk of -13.115 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acebutolol with relative risk of -15.947 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: budesonide with relative risk of -17.120 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bromocriptine with relative risk of -19.937 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: metoprolol with relative risk of -20.074 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: erlotinib with relative risk of -20.239 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -20.248 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felbamate with relative risk of -20.464 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: metronidazole with relative risk of -20.712 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dabrafenib with relative risk of -21.344 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bisoprolol with relative risk of -21.935 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 22: cilostazol with relative risk of -22.011 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: famotidine with relative risk of -22.121 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: propafenone with relative risk of -23.073 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 25: fluocinonide with relative risk of -23.209 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.075\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target terbinafine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó terbutaline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.797 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -8.967 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: varenicline with relative risk of -9.896 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: estramustine with relative risk of -9.976 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -10.181 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: duloxetine with relative risk of -10.508 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: milnacipran with relative risk of -10.702 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: conivaptan with relative risk of -11.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: umeclidinium with relative risk of -11.235 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 10: rosuvastatin with relative risk of -16.728 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: leflunomide with relative risk of -17.165 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: apixaban with relative risk of -17.977 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: raltitrexed with relative risk of -18.271 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: belinostat with relative risk of -23.344 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mirtazapine with relative risk of -23.885 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluoxetine with relative risk of -28.277 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: acebutolol with relative risk of -28.378 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sparfloxacin with relative risk of -28.745 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dapagliflozin with relative risk of -28.775 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -29.306 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 21: tasimelteon with relative risk of -29.403 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: teniposide with relative risk of -30.016 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rofecoxib with relative risk of -30.311 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ramipril with relative risk of -30.763 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: dexmedetomidine with relative risk of -31.091 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: azathioprine with relative risk of -31.150 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: budesonide with relative risk of -31.506 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 28: nelarabine with relative risk of -31.520 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinapril with relative risk of -31.535 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: rosiglitazone with relative risk of -32.124 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fosinoprilat with relative risk of -33.245 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: pinaverium with relative risk of -33.377 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nateglinide with relative risk of -35.648 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: axitinib with relative risk of -36.734 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: trandolapril with relative risk of -37.980 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.048\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target terconazole not found. Exiting ...\n",
      "\n",
      "Drug target tesamorelin not found. Exiting ...\n",
      "\n",
      "Drug target testosterone not found. Exiting ...\n",
      "\n",
      "Drug target tetrabenazine not found. Exiting ...\n",
      "\n",
      "Drug target tetrahydrobiopterin not found. Exiting ...\n",
      "\n",
      "Drug target tetrofosmin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó thalidomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxepin with relative risk of -9.967 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -10.350 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clonidine with relative risk of -10.545 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pindolol with relative risk of -10.581 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bupivacaine with relative risk of -11.939 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: benazepril with relative risk of -12.485 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target theophylline not found. Exiting ...\n",
      "\n",
      "Drug target thymidine not found. Exiting ...\n",
      "\n",
      "Drug target tiagabine not found. Exiting ...\n",
      "\n",
      "Drug target tiaprofenic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ticagrelor *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -30.332 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tigecycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó timolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mitotane with relative risk of -21.036 of timolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ketoconazole with relative risk of -22.324 of timolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tinidazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tiotropium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: medroxyprogesterone with relative risk of -12.814 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tipranavir not found. Exiting ...\n",
      "\n",
      "Drug target tirofiban not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tizanidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ifosfamide with relative risk of -7.527 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: oxcarbazepine with relative risk of -9.880 of tizanidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: lidocaine with relative risk of -10.831 of tizanidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ropivacaine with relative risk of -12.861 of tizanidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: loperamide with relative risk of -18.897 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: etravirine with relative risk of -23.782 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pentostatin with relative risk of -28.987 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: paclitaxel with relative risk of -32.376 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ruxolitinib with relative risk of -43.035 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: doxercalciferol with relative risk of -46.506 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: alogliptin with relative risk of -63.062 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.359\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tobramycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tofacitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -9.658 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: clonidine with relative risk of -9.852 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pindolol with relative risk of -9.889 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: allopurinol with relative risk of -11.108 of tofacitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 5: bupivacaine with relative risk of -11.246 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amiodarone with relative risk of -11.656 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -11.770 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: doxepin with relative risk of -16.467 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.092\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolcapone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolmetin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -10.073 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: olopatadine with relative risk of -12.936 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levocabastine with relative risk of -13.051 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: misoprostol with relative risk of -14.493 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolterodine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -9.242 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -9.864 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -10.518 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nilotinib with relative risk of -10.740 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -11.343 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -11.605 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tazarotene with relative risk of -12.082 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amlexanox with relative risk of -12.592 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pinaverium with relative risk of -12.617 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fosinoprilat with relative risk of -12.853 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: triamcinolone with relative risk of -13.013 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: diltiazem with relative risk of -13.859 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ziprasidone with relative risk of -13.953 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolvaptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: prazosin with relative risk of -11.008 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: exenatide with relative risk of -13.705 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó topiramate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -8.160 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azathioprine with relative risk of -9.826 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: leflunomide with relative risk of -10.154 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -10.271 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: naproxen with relative risk of -10.952 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: aripiprazole with relative risk of -11.030 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: fosinoprilat with relative risk of -12.161 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -12.543 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: domperidone with relative risk of -13.247 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: loteprednol with relative risk of -13.347 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fosinopril with relative risk of -13.812 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tasimelteon with relative risk of -16.062 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sparfloxacin with relative risk of -16.134 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexamethasone with relative risk of -18.438 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: pioglitazone with relative risk of -19.173 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -19.197 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: varenicline with relative risk of -19.727 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: apixaban with relative risk of -19.769 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of -19.901 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: crizotinib with relative risk of -20.430 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: meloxicam with relative risk of -22.202 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: desvenlafaxine with relative risk of -22.476 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.199\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó topotecan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.395 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -8.679 of topotecan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Neuroblastoma,oncology\n",
      "Rank 3: afatinib with relative risk of -9.489 of topotecan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: glycopyrrolate with relative risk of -9.885 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.360 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: salmeterol with relative risk of -10.499 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: perindopril with relative risk of -10.830 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: metaproterenol with relative risk of -10.967 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: argatroban with relative risk of -10.983 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ritonavir with relative risk of -11.386 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: torasemide with relative risk of -11.577 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bromfenac with relative risk of -13.898 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: telmisartan with relative risk of -18.433 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.262\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó torasemide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.468 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: captopril with relative risk of -8.108 of torasemide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: afatinib with relative risk of -9.201 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glycopyrrolate with relative risk of -9.598 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.073 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: topotecan with relative risk of -10.141 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: telmisartan with relative risk of -10.171 of torasemide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: salmeterol with relative risk of -10.211 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bromfenac with relative risk of -13.611 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ospemifene with relative risk of -20.203 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ritonavir with relative risk of -30.515 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: cyclophosphamide with relative risk of -38.150 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.207\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó toremifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: darifenacin with relative risk of -11.515 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimetrexate with relative risk of -11.786 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dantrolene with relative risk of -12.590 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nelfinavir with relative risk of -12.857 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: riluzole with relative risk of -13.110 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cetrorelix with relative risk of -13.236 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target trabectedin not found. Exiting ...\n",
      "\n",
      "Drug target tramadol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trametinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tasimelteon with relative risk of -6.423 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: gemcitabine with relative risk of -6.583 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: indomethacin with relative risk of -6.634 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cyclophosphamide with relative risk of -6.735 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: sparfloxacin with relative risk of -6.857 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bosentan with relative risk of -7.008 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: anagrelide with relative risk of -7.209 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: azathioprine with relative risk of -7.495 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dexamethasone with relative risk of -7.543 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ixabepilone with relative risk of -7.690 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 11: cabergoline with relative risk of -7.802 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: leflunomide with relative risk of -7.809 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: risedronate with relative risk of -7.894 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: raloxifene with relative risk of -7.923 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 15: dronedarone with relative risk of -8.017 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pioglitazone with relative risk of -8.025 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: crizotinib with relative risk of -8.026 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 18: penbutolol with relative risk of -8.151 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fludarabine with relative risk of -8.234 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: varenicline with relative risk of -8.241 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nateglinide with relative risk of -8.263 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: estramustine with relative risk of -8.327 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 23: balsalazide with relative risk of -8.342 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: orlistat with relative risk of -8.380 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mirabegron with relative risk of -8.415 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ropinirole with relative risk of -8.416 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: posaconazole with relative risk of -8.470 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: aripiprazole with relative risk of -8.680 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: metronidazole with relative risk of -8.714 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: aminophylline with relative risk of -8.781 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dolutegravir with relative risk of -8.783 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: paricalcitol with relative risk of -8.830 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ramelteon with relative risk of -8.837 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: moxifloxacin with relative risk of -8.861 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pergolide with relative risk of -8.867 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: atosiban with relative risk of -8.977 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: nabumetone with relative risk of -9.058 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: iloperidone with relative risk of -9.142 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: gonadorelin with relative risk of -9.185 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: palonosetron with relative risk of -9.221 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: caffeine with relative risk of -9.227 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: sorafenib with relative risk of -9.266 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 43: desvenlafaxine with relative risk of -9.378 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ritonavir with relative risk of -9.441 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: topiramate with relative risk of -9.507 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: esomeprazole with relative risk of -9.531 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ospemifene with relative risk of -9.590 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: metolazone with relative risk of -9.608 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: torasemide with relative risk of -9.634 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clomipramine with relative risk of -9.657 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: famotidine with relative risk of -9.716 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: meloxicam with relative risk of -9.798 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: norfloxacin with relative risk of -10.002 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: donepezil with relative risk of -10.227 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: rilpivirine with relative risk of -10.405 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dihydroergotamine with relative risk of -10.669 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: canagliflozin with relative risk of -10.671 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: trovafloxacin with relative risk of -10.719 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: domperidone with relative risk of -10.897 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: fosinopril with relative risk of -11.461 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: rivastigmine with relative risk of -14.279 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: apixaban with relative risk of -14.428 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: trimethoprim with relative risk of -14.707 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: brinzolamide with relative risk of -15.025 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: lubiprostone with relative risk of -15.948 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: repaglinide with relative risk of -16.050 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ranitidine with relative risk of -16.363 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: quetiapine with relative risk of -16.997 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: dalbavancin with relative risk of -19.198 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: linezolid with relative risk of -27.187 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: sunitinib with relative risk of -29.672 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 72: bicalutamide with relative risk of -29.925 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 73: linagliptin with relative risk of -31.753 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: dexmedetomidine with relative risk of -55.984 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: olmesartan with relative risk of -72.244 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.22\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trandolapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -8.393 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -8.564 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: erlotinib with relative risk of -9.086 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -9.491 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: silodosin with relative risk of -9.776 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rosuvastatin with relative risk of -15.812 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: leflunomide with relative risk of -16.249 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: raltitrexed with relative risk of -17.355 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: belinostat with relative risk of -21.736 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: mirtazapine with relative risk of -22.277 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: estramustine with relative risk of -23.593 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: apixaban with relative risk of -24.749 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: fluoxetine with relative risk of -26.668 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dapagliflozin with relative risk of -27.166 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: duloxetine with relative risk of -28.314 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: milnacipran with relative risk of -28.509 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rofecoxib with relative risk of -28.702 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: conivaptan with relative risk of -29.038 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: umeclidinium with relative risk of -29.042 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramipril with relative risk of -29.154 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 21: quinapril with relative risk of -29.925 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "Rank 22: acebutolol with relative risk of -32.837 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 23: tasimelteon with relative risk of -34.335 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: azathioprine with relative risk of -36.323 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terbutaline with relative risk of -37.258 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: pinaverium with relative risk of -38.596 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sparfloxacin with relative risk of -41.452 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: mometasone with relative risk of -42.861 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: teniposide with relative risk of -44.645 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dexmedetomidine with relative risk of -45.854 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: budesonide with relative risk of -46.135 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: nelarabine with relative risk of -46.282 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fosinoprilat with relative risk of -47.041 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: rosiglitazone with relative risk of -47.184 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: nateglinide with relative risk of -52.762 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: axitinib with relative risk of -56.151 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.221\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target trandolaprilat not found. Exiting ...\n",
      "\n",
      "Drug target tranexamic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó travoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -9.319 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -10.281 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vernakalant with relative risk of -10.489 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indinavir with relative risk of -10.888 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nisoldipine with relative risk of -11.274 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: iloprost with relative risk of -11.294 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: degarelix with relative risk of -11.759 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ambrisentan with relative risk of -11.889 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: entacapone with relative risk of -11.901 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: reboxetine with relative risk of -12.033 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: saquinavir with relative risk of -20.339 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: valdecoxib with relative risk of -21.705 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ticagrelor with relative risk of -30.202 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó treprostinil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acamprosate with relative risk of -11.280 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pemetrexed with relative risk of -11.724 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vinorelbine with relative risk of -11.812 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gabapentin with relative risk of -12.644 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó triamcinolone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -9.242 of triamcinolone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pruritus of genital organs,Lymphoma, T-Cell, Cutaneous,Lichen Simplex Chronicus,Seborrheic dermatitis,Asthma,Scalp psoriasis,Chronic small plaque psoriasis,Pruritus Ani,Allergic rhinitis (disorder),Exanthema,Contact Dermatitis,Granuloma Annulare,Lupus Erythematosus, Discoid,dermatology\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -9.764 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -9.864 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -10.518 of triamcinolone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 6: nilotinib with relative risk of -10.740 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -11.343 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -11.605 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tazarotene with relative risk of -12.082 of triamcinolone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 10: amlexanox with relative risk of -12.592 of triamcinolone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Aphthous Stomatitis\n",
      "Rank 11: pinaverium with relative risk of -12.617 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fosinoprilat with relative risk of -12.853 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tolterodine with relative risk of -13.771 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: diltiazem with relative risk of -13.859 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ziprasidone with relative risk of -13.953 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.425\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target triazolam not found. Exiting ...\n",
      "\n",
      "Drug target trifluorothymidine not found. Exiting ...\n",
      "\n",
      "Drug target triiodothyronine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trimethoprim *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -7.456 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -7.656 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acebutolol with relative risk of -7.982 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -8.081 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -8.732 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nilotinib with relative risk of -8.949 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -9.552 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: linezolid with relative risk of -9.743 of trimethoprim | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 9: metronidazole with relative risk of -9.964 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: repaglinide with relative risk of -10.243 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tazarotene with relative risk of -10.290 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: quetiapine with relative risk of -10.498 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ranitidine with relative risk of -10.556 of trimethoprim | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: exemestane with relative risk of -10.767 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: amlexanox with relative risk of -10.801 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pinaverium with relative risk of -10.830 of trimethoprim | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 17: fosinoprilat with relative risk of -11.068 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: triamcinolone with relative risk of -11.222 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -11.480 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: hydrochlorothiazide with relative risk of -11.716 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: tolterodine with relative risk of -11.980 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: diltiazem with relative risk of -12.068 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ziprasidone with relative risk of -12.161 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nebivolol with relative risk of -12.553 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: trametinib with relative risk of -13.206 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: linagliptin with relative risk of -18.326 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dexmedetomidine with relative risk of -20.815 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sunitinib with relative risk of -26.011 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: olmesartan with relative risk of -27.871 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: bicalutamide with relative risk of -29.475 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.066\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trimetrexate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tropisetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acebutolol with relative risk of -9.764 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: budesonide with relative risk of -10.009 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 3: metoprolol with relative risk of -10.712 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: erlotinib with relative risk of -10.878 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: flutamide with relative risk of -10.887 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bromocriptine with relative risk of -11.269 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dabrafenib with relative risk of -11.289 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: felbamate with relative risk of -11.508 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ribavirin with relative risk of -11.667 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: metronidazole with relative risk of -11.756 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilostazol with relative risk of -11.956 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bisoprolol with relative risk of -12.574 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lapatinib with relative risk of -12.612 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: famotidine with relative risk of -12.759 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 15: propafenone with relative risk of -13.018 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluocinonide with relative risk of -13.154 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: terazosin with relative risk of -13.271 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tolcapone with relative risk of -13.809 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.163\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trospium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tamoxifen with relative risk of -10.671 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -10.687 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nilutamide with relative risk of -10.979 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trimetrexate with relative risk of -11.093 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: adapalene with relative risk of -12.508 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rotigotine with relative risk of -12.650 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trovafloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ulipristal *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acitretin with relative risk of -10.511 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: deferasirox with relative risk of -11.050 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nifedipine with relative risk of -11.533 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: scopolamine with relative risk of -11.834 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: propranolol with relative risk of -11.859 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicotine with relative risk of -11.927 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: avanafil with relative risk of -11.942 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rufinamide with relative risk of -11.958 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dipyridamole with relative risk of -12.574 of ulipristal | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó umeclidinium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.668 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.749 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: erlotinib with relative risk of -9.779 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -10.183 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: terbutaline with relative risk of -10.495 of umeclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 6: acebutolol with relative risk of -14.851 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tasimelteon with relative risk of -14.964 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: azathioprine with relative risk of -16.257 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pinaverium with relative risk of -18.396 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apixaban with relative risk of -18.670 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sparfloxacin with relative risk of -22.428 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -22.583 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: teniposide with relative risk of -22.794 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dexmedetomidine with relative risk of -23.809 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nelarabine with relative risk of -24.237 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -24.284 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rosiglitazone with relative risk of -24.708 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -26.409 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: estramustine with relative risk of -26.588 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nateglinide with relative risk of -27.385 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: axitinib with relative risk of -27.778 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trandolapril with relative risk of -29.023 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: duloxetine with relative risk of -31.310 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: milnacipran with relative risk of -31.505 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: conivaptan with relative risk of -32.034 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.052\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ustekinumab not found. Exiting ...\n",
      "\n",
      "Drug target v not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó valdecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target valganciclovir not found. Exiting ...\n",
      "\n",
      "Drug target valproate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó valsartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -11.183 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vandetanib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -10.810 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pemetrexed with relative risk of -11.724 of vandetanib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: indinavir with relative risk of -11.986 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.273\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vardenafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -9.713 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: caffeine with relative risk of -29.381 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: zafirlukast with relative risk of -30.451 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: temsirolimus with relative risk of -32.048 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó varenicline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trametinib with relative risk of -7.065 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: idarubicin with relative risk of -7.276 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexmedetomidine with relative risk of -7.635 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: nelarabine with relative risk of -8.063 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: budesonide with relative risk of -8.222 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rosiglitazone with relative risk of -8.291 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mifepristone with relative risk of -8.304 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: axitinib with relative risk of -8.873 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: delavirdine with relative risk of -8.988 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dalbavancin with relative risk of -9.186 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: disopyramide with relative risk of -9.207 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nateglinide with relative risk of -9.511 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rivastigmine with relative risk of -9.568 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: estramustine with relative risk of -9.572 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sulfasalazine with relative risk of -9.712 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: terbutaline with relative risk of -9.802 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gemfibrozil with relative risk of -9.815 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -9.913 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: aripiprazole with relative risk of -9.932 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: flecainide with relative risk of -10.066 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: duloxetine with relative risk of -10.102 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: trandolapril with relative risk of -10.119 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: frovatriptan with relative risk of -10.175 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: pitavastatin with relative risk of -10.246 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: montelukast with relative risk of -10.293 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: milnacipran with relative risk of -10.297 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: brimonidine with relative risk of -10.410 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fesoterodine with relative risk of -10.596 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: conivaptan with relative risk of -10.826 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: umeclidinium with relative risk of -10.830 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: granisetron with relative risk of -10.908 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: candesartan with relative risk of -11.067 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ranolazine with relative risk of -11.138 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: labetalol with relative risk of -11.181 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: nevirapine with relative risk of -11.445 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: oxybutynin with relative risk of -11.534 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: betaxolol with relative risk of -11.592 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: loteprednol with relative risk of -12.249 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: eletriptan with relative risk of -12.318 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: fosinopril with relative risk of -12.713 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: cisatracurium with relative risk of -12.846 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: teniposide with relative risk of -12.925 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: rosuvastatin with relative risk of -15.812 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: raloxifene with relative risk of -16.702 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: naproxen with relative risk of -18.992 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: acebutolol with relative risk of -19.162 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: mometasone with relative risk of -19.591 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: desvenlafaxine with relative risk of -19.768 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: topiramate with relative risk of -19.898 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: domperidone with relative risk of -21.287 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dexamethasone with relative risk of -23.418 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: pinaverium with relative risk of -23.420 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: leflunomide with relative risk of -24.224 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: pioglitazone with relative risk of -24.441 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: risedronate with relative risk of -24.647 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ropinirole with relative risk of -25.574 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: crizotinib with relative risk of -27.489 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: azathioprine with relative risk of -28.444 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: meloxicam with relative risk of -29.261 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: fosinoprilat with relative risk of -30.539 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: apixaban with relative risk of -33.145 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 62: sparfloxacin with relative risk of -41.452 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: tasimelteon with relative risk of -42.884 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 64: efinaconazole with relative risk of -inf of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.155\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vemurafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: asenapine with relative risk of -22.595 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rivaroxaban with relative risk of -23.182 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó venlafaxine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amoxapine with relative risk of -10.439 of venlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: regadenoson with relative risk of -10.518 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: capecitabine with relative risk of -10.759 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.765 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: telmisartan with relative risk of -10.863 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: emedastine with relative risk of -10.876 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: salmeterol with relative risk of -10.904 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: citalopram with relative risk of -11.586 of venlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 10: estradiol with relative risk of -11.645 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pramipexole with relative risk of -11.929 of venlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: tegaserod with relative risk of -12.277 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dapsone with relative risk of -12.342 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: isradipine with relative risk of -12.394 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: almotriptan with relative risk of -12.697 of venlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.232\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó verapamil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -5.175 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -5.911 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dexmedetomidine with relative risk of -6.077 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tasimelteon with relative risk of -6.111 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: belinostat with relative risk of -6.319 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acebutolol with relative risk of -6.454 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: nelarabine with relative risk of -6.505 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sparfloxacin with relative risk of -6.549 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: budesonide with relative risk of -6.665 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rosiglitazone with relative risk of -6.731 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mirtazapine with relative risk of -6.860 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: azathioprine with relative risk of -7.181 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: axitinib with relative risk of -7.303 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: olmesartan with relative risk of -7.481 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: nateglinide with relative risk of -7.943 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluoxetine with relative risk of -7.982 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: silodosin with relative risk of -8.206 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: terbutaline with relative risk of -8.230 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trandolapril with relative risk of -8.548 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 20: ivacaftor with relative risk of -8.820 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rofecoxib with relative risk of -8.916 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: thalidomide with relative risk of -9.047 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: didanosine with relative risk of -9.096 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: dapagliflozin with relative risk of -9.174 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pinaverium with relative risk of -9.278 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ramipril with relative risk of -9.368 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 27: fosinoprilat with relative risk of -9.519 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 28: tofacitinib with relative risk of -9.542 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: bupropion with relative risk of -9.755 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: quinapril with relative risk of -10.140 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 31: benazepril with relative risk of -16.534 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 32: sildenafil with relative risk of -19.317 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: allopurinol with relative risk of -21.225 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: dofetilide with relative risk of -21.666 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: amiodarone with relative risk of -23.562 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 36: ifosfamide with relative risk of -24.755 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dasatinib with relative risk of -29.289 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: loratadine with relative risk of -30.076 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: bupivacaine with relative risk of -30.237 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: clonidine with relative risk of -67.417 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 41: doxepin with relative risk of -148.514 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pindolol with relative risk of -164.617 of verapamil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.118\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vernakalant *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.800 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: colchicine with relative risk of -10.687 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: saquinavir with relative risk of -10.689 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: indinavir with relative risk of -11.293 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: travoprost with relative risk of -11.668 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nisoldipine with relative risk of -11.679 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: iloprost with relative risk of -11.700 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: valdecoxib with relative risk of -12.056 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: degarelix with relative risk of -12.165 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ambrisentan with relative risk of -12.295 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: reboxetine with relative risk of -12.438 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: podophyllotoxin with relative risk of -20.472 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.376\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vigabatrin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vilazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rosuvastatin with relative risk of -9.158 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: leflunomide with relative risk of -9.239 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -9.355 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dalbavancin with relative risk of -9.368 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bromocriptine with relative risk of -9.660 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: silodosin with relative risk of -9.958 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: raltitrexed with relative risk of -10.009 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apixaban with relative risk of -10.303 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: glipizide with relative risk of -10.563 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sparfloxacin with relative risk of -13.837 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: felbamate with relative risk of -18.162 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: eliglustat with relative risk of -19.512 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nelarabine with relative risk of -21.936 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -21.983 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rosiglitazone with relative risk of -22.407 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: belinostat with relative risk of -22.429 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: mirtazapine with relative risk of -22.969 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 18: tasimelteon with relative risk of -27.795 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: azathioprine with relative risk of -29.542 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rocuronium with relative risk of -29.982 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: pinaverium with relative risk of -31.768 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flumazenil with relative risk of -33.391 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: acebutolol with relative risk of -34.626 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gemfibrozil with relative risk of -35.373 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mometasone with relative risk of -36.065 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: teniposide with relative risk of -37.298 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -40.122 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telithromycin with relative risk of -45.073 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: capsaicin with relative risk of -46.291 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: nedocromil with relative risk of -48.483 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: glimepiride with relative risk of -48.524 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.172\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vincristine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fosphenytoin with relative risk of -11.297 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: irbesartan with relative risk of -12.010 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: phentolamine with relative risk of -12.074 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vinflunine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vinorelbine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: acamprosate with relative risk of -11.280 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pemetrexed with relative risk of -11.724 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 3: treprostinil with relative risk of -12.093 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gabapentin with relative risk of -12.644 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.24\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vismodegib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: atropine with relative risk of -10.837 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cabozantinib with relative risk of -11.689 of vismodegib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: rizatriptan with relative risk of -12.615 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pantoprazole with relative risk of -12.828 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: calcipotriol with relative risk of -inf of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.219\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vorapaxar not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó voriconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluvastatin with relative risk of -13.769 of voriconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zafirlukast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: danazol with relative risk of -9.425 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: caffeine with relative risk of -27.995 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vardenafil with relative risk of -30.224 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: temsirolimus with relative risk of -30.661 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zaleplon not found. Exiting ...\n",
      "\n",
      "Drug target zanamivir not found. Exiting ...\n",
      "\n",
      "Drug target ziconotide not found. Exiting ...\n",
      "\n",
      "Drug target zidovudine not found. Exiting ...\n",
      "\n",
      "Drug target zidovudine/lamivudine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zileuton *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiloride with relative risk of -10.015 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: doxorubicin with relative risk of -10.163 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irinotecan with relative risk of -10.623 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: letrozole with relative risk of -11.417 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: galantamine with relative risk of -12.457 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: tafluprost with relative risk of -21.085 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ziprasidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -9.242 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tasimelteon with relative risk of -9.441 of ziprasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: acebutolol with relative risk of -9.764 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -9.864 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -10.518 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nilotinib with relative risk of -10.740 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gefitinib with relative risk of -11.343 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trimethoprim with relative risk of -11.605 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tazarotene with relative risk of -12.082 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amlexanox with relative risk of -12.592 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pinaverium with relative risk of -12.617 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fosinoprilat with relative risk of -12.853 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: triamcinolone with relative risk of -13.013 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tolterodine with relative risk of -13.771 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: diltiazem with relative risk of -13.859 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.151\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zoledronic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zolmitriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clarithromycin with relative risk of -11.894 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nefazodone with relative risk of -13.498 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pazopanib with relative risk of -16.279 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: maprotiline with relative risk of -17.528 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: nizatidine with relative risk of -17.589 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: levetiracetam with relative risk of -17.673 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nalmefene with relative risk of -17.881 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: liraglutide with relative risk of -20.128 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.153\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zolpidem not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zonisamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: beclomethasone with relative risk of -12.638 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zopiclone not found. Exiting ...\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[0.0,\n",
       " 0.19708029197080293,\n",
       " 0.3082312277706778,\n",
       " 0.0,\n",
       " 0.15999999999999998,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.10893494406704092,\n",
       " 0.31457434812429513,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.05690285869123425,\n",
       " 0.2168402222160895,\n",
       " 0.04267714401842569,\n",
       " 0.04139240959969419,\n",
       " 0.07713498622589533,\n",
       " 0.23489134318391827,\n",
       " 0.29785370127025845,\n",
       " 0.0,\n",
       " 0.01635013508967069,\n",
       " 0.5518305512694627,\n",
       " 0.20608015860957307,\n",
       " 0.0,\n",
       " 0.5454545454545455,\n",
       " 0.06599893494351243,\n",
       " 0.38567493112947665,\n",
       " 0.3281788618867061,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.25146600357238436,\n",
       " 0.3333333333333333,\n",
       " 0.19706815777542694,\n",
       " 0.27272727272727276,\n",
       " 0.1767349051688595,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.13156896293724862,\n",
       " 0.09483988667446171,\n",
       " 0.0,\n",
       " 0.43795620437956206,\n",
       " 0.04301642684306217,\n",
       " 0.0,\n",
       " 0.014622202834900096,\n",
       " 0.3197278911564625,\n",
       " 0.10134897785844875,\n",
       " 0.5474452554744526,\n",
       " 0.14141414141414144,\n",
       " 0.33374482678878586,\n",
       " 0.16069788797061524,\n",
       " 0.06188616791533069,\n",
       " 0.09265076550813388,\n",
       " 0.0,\n",
       " 0.013547149804194658,\n",
       " 0.0,\n",
       " 0.628198396017809,\n",
       " 0.08219369986010104,\n",
       " 0.5169452043339585,\n",
       " 0.09145102289662647,\n",
       " 0.0,\n",
       " 0.6666666666666666,\n",
       " 0.0,\n",
       " 0.033473551710916004,\n",
       " 0.4800000000000001,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.06342066265965794,\n",
       " 0.10357564625392512,\n",
       " 0.31150231443652127,\n",
       " 0.22843884596603783,\n",
       " 0.21245628502657177,\n",
       " 0.15526318126921845,\n",
       " 0.5610885117127227,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.13605442176870747,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.06713476941677032,\n",
       " 0.07366362402171234,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.4164181774155939,\n",
       " 0.24190921719809577,\n",
       " 0.27272727272727276,\n",
       " 0.04599211563731932,\n",
       " 0.0,\n",
       " 0.06296621087680794,\n",
       " 0.3471311271262806,\n",
       " 1.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.2751602483804331,\n",
       " 0.33867874510486645,\n",
       " 0.46280991735537197,\n",
       " 0.48337033980074634,\n",
       " 0.0,\n",
       " 0.10204081632653063,\n",
       " 0.08420520206039867,\n",
       " 0.057466446179734336,\n",
       " 0.14435964542280397,\n",
       " 0.18367346938775508,\n",
       " 0.20016221546880866,\n",
       " 0.027396870768893678,\n",
       " 0.0,\n",
       " 0.013062925071497748,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.027652994039255748,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.1988433797766934,\n",
       " 0.5045865992742444,\n",
       " 0.1660420312486546,\n",
       " 0.6666666666666666,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.06388735339909782,\n",
       " 0.125568991024096,\n",
       " 0.14728573432458972,\n",
       " 0.10252264296834152,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.1879773543669569,\n",
       " 0.0,\n",
       " 0.22996057818659657,\n",
       " 0.0,\n",
       " 0.10507884063815104,\n",
       " 0.1834304398019883,\n",
       " 0.15999999999999998,\n",
       " 0.06948807413110042,\n",
       " 0.15926903462895822,\n",
       " 0.10090577907058737,\n",
       " 0.0,\n",
       " 0.027094299608389317,\n",
       " 0.11494551349013646,\n",
       " 0.0,\n",
       " 0.03634193668426081,\n",
       " 0.42966252426733004,\n",
       " 0.0,\n",
       " 1.0,\n",
       " 0.2571166207529844,\n",
       " 0.11378437280269808,\n",
       " 0.7272727272727273,\n",
       " 0.03362655018211884,\n",
       " 0.49354036212090663,\n",
       " 0.29032122790252995,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.6400746625810226,\n",
       " 0.1928374655647383,\n",
       " 0.3333333333333333,\n",
       " 0.06670820989389277,\n",
       " 0.0,\n",
       " 0.3890171678191632,\n",
       " 0.0,\n",
       " 0.08759124087591241,\n",
       " 0.0,\n",
       " 0.3333333333333333,\n",
       " 0.0,\n",
       " 0.10309587552617401,\n",
       " 0.013062925071497748,\n",
       " 0.0,\n",
       " 0.4177467702125522,\n",
       " 0.0,\n",
       " 0.013792493653154544,\n",
       " 0.3501392308159459,\n",
       " 0.08654500009084454,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.3668608796039767,\n",
       " 0.0,\n",
       " 0.02043672751471333,\n",
       " 0.3018412363686278,\n",
       " 0.0,\n",
       " 0.41541502043938705,\n",
       " 0.4800000000000001,\n",
       " 0.0,\n",
       " 0.24457064026903105,\n",
       " 0.38400848118295067,\n",
       " 0.5313064172220978,\n",
       " 0.33590648498648173,\n",
       " 0.14748707040582754,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0351019266181562,\n",
       " 0.6666666666666666,\n",
       " 0.034939131390854916,\n",
       " 0.039707470932057384,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.08607086855854892,\n",
       " 0.03311392767975535,\n",
       " 0.3679369250985546,\n",
       " 0.0,\n",
       " 0.18793388545075249,\n",
       " 0.3844305827351453,\n",
       " 0.009125805317863247,\n",
       " 0.0,\n",
       " 0.18181818181818182,\n",
       " 0.0,\n",
       " 0.3554852215067329,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.34763918791219917,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.2264679554992386,\n",
       " 0.19439960502976825,\n",
       " 0.20154380906987826,\n",
       " 0.12264564169951817,\n",
       " 0.1696248383721206,\n",
       " 0.0,\n",
       " 0.12998144195087702,\n",
       " 0.0,\n",
       " 0.08759124087591241,\n",
       " 0.15999999999999998,\n",
       " 0.10621866955697061,\n",
       " 0.64,\n",
       " 0.0,\n",
       " 0.3976714826763922,\n",
       " 0.08837144059475383,\n",
       " 0.12683800204710097,\n",
       " 0.16985973676491214,\n",
       " 0.0,\n",
       " 0.5102040816326531,\n",
       " 0.0,\n",
       " 0.1004551928192768,\n",
       " 0.5431449846692948,\n",
       " 0.18365472910927455,\n",
       " 0.018678765070636143,\n",
       " 0.18365472910927455,\n",
       " 0.36252775485055977,\n",
       " 0.0,\n",
       " 0.17520805957074023,\n",
       " 0.0,\n",
       " 0.0608340420438379,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.061449405616314144,\n",
       " 0.07617245821408689,\n",
       " 1.0,\n",
       " 0.029517039943870078,\n",
       " 0.07194059439455104,\n",
       " 0.17517966123599002,\n",
       " 0.0,\n",
       " 0.022578583006991094,\n",
       " 0.3119446957445691,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.5454545454545455,\n",
       " 0.18181818181818182,\n",
       " 0.04971773898013827,\n",
       " 0.022069453476551006,\n",
       " 0.10386148183215906,\n",
       " 0.018062866405592876,\n",
       " 1.0,\n",
       " 0.14903609967936063,\n",
       " 0.09198423127463864,\n",
       " 0.3333333333333333,\n",
       " 0.7642449864747786,\n",
       " 0.0,\n",
       " 0.031671011459567695,\n",
       " 0.21897810218978103,\n",
       " 0.19961836860772747,\n",
       " 0.0085649878757813,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.2571166207529844,\n",
       " 0.17379716650301588,\n",
       " 0.10997334829569368,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.08278481919938838,\n",
       " 0.0,\n",
       " 0.09570043326855349,\n",
       " 0.0,\n",
       " 0.24750141265040917,\n",
       " 0.3741496598639456,\n",
       " 0.025069627887555297,\n",
       " 0.10401354088180084,\n",
       " 0.11958104743908567,\n",
       " 0.0,\n",
       " 0.42049934296977665,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07358738501971092,\n",
       " 0.03529552971738434,\n",
       " 0.08759124087591241,\n",
       " 0.0,\n",
       " 0.09475646472422786,\n",
       " 0.04877387887820079,\n",
       " 0.29579419172693944,\n",
       " 0.18365472910927455,\n",
       " 0.20578223703664872,\n",
       " 0.05690285869123425,\n",
       " 0.17488446180992573,\n",
       " 0.21897810218978103,\n",
       " 0.18181818181818182,\n",
       " 0.19706815777542694,\n",
       " 1.0,\n",
       " 0.20154380906987826,\n",
       " 0.10221351984147153,\n",
       " 0.26263472380516945,\n",
       " 0.11203231510003715,\n",
       " 0.0,\n",
       " 0.029517039943870078,\n",
       " 0.18797735436695687,\n",
       " 0.5454545454545455,\n",
       " 0.07713498622589533,\n",
       " 0.21577134172537593,\n",
       " 0.0,\n",
       " 0.30656934306569344,\n",
       " 0.6598400897741619,\n",
       " 0.5454545454545455,\n",
       " 0.0741815239810205,\n",
       " 0.3014448029176603,\n",
       " 0.09463155277783993,\n",
       " 0.315814932150154,\n",
       " 0.24000000000000005,\n",
       " 0.0,\n",
       " 0.10401354088180084,\n",
       " 0.31306669695075096,\n",
       " 0.0390079576620505,\n",
       " 0.19059754704066514,\n",
       " 0.315814932150154,\n",
       " 0.0923669304831454,\n",
       " 0.18085245522557358,\n",
       " 0.22497704315886133,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07358738501971092,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.13605442176870747,\n",
       " 0.2259830071392403,\n",
       " 0.7200000000000001,\n",
       " 0.0,\n",
       " 0.3333333333333333,\n",
       " 0.3143972312325763,\n",
       " 0.0,\n",
       " 0.17572205307116587,\n",
       " 0.0,\n",
       " 0.18611350422519285,\n",
       " 0.4241829148548183,\n",
       " 0.4989349039886565,\n",
       " 0.0,\n",
       " 0.180109412259784,\n",
       " 0.11815719417351578,\n",
       " 0.018531601820134084,\n",
       " 0.4139240959969419,\n",
       " 0.17379716650301588,\n",
       " 1.0,\n",
       " 0.0,\n",
       " 0.024502532231967963,\n",
       " 0.6556473829201103,\n",
       " 0.0,\n",
       " 0.49327182068622855,\n",
       " 1.0,\n",
       " 0.14177951930390342,\n",
       " 0.20154380906987826,\n",
       " 0.10242514564422167,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.09448718538255026,\n",
       " 0.32647937666264965,\n",
       " 0.09753204433466346,\n",
       " 0.09716088596251371,\n",
       " 0.0,\n",
       " 0.007312282896163851,\n",
       " 0.07461828628003707,\n",
       " 0.04778360085232708,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.35873421653068294,\n",
       " 0.09198423127463864,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 1.0,\n",
       " 0.1988433797766934,\n",
       " 0.26204348543141187,\n",
       " 0.20715871705746267,\n",
       " 0.0,\n",
       " 0.21983501040383982,\n",
       " 0.22119140724740993,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.425260316268272,\n",
       " 0.06618871807533394,\n",
       " 0.16349382011770663,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.05241147588198727,\n",
       " 1.0,\n",
       " 0.27272727272727276,\n",
       " 0.0,\n",
       " 0.15540233650213106,\n",
       " 0.0,\n",
       " 0.23165576283475653,\n",
       " 0.11768615920252516,\n",
       " 0.37595470873391384,\n",
       " 0.17221668401787082,\n",
       " 0.0,\n",
       " 0.24000000000000005,\n",
       " 0.21897810218978103,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.1506827892289152,\n",
       " 0.1533070521243977,\n",
       " 0.0]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# runs calc_relative_risk for every drug on our dataset \n",
    "precisions = []\n",
    "for drug_name in drugs:\n",
    "    \n",
    "    try:\n",
    "        prec = main(drug_name)\n",
    "        precisions.append(prec)\n",
    "    except:\n",
    "        print('')\n",
    "\n",
    "precisions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.16117359670736595"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.mean(precisions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "425"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(precisions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.20856583300647946"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.std(precisions)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Check ln(scaled risk score) distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Admin\\AppData\\Local\\Temp/ipykernel_26080/1880836188.py:3: RuntimeWarning: divide by zero encountered in log\n",
      "  ddr['scaled_risk_score_log'] = np.log(ddr.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug_a</th>\n",
       "      <th>clinical_phase_a</th>\n",
       "      <th>moa_a</th>\n",
       "      <th>target_a</th>\n",
       "      <th>disease_area_a</th>\n",
       "      <th>indication_a</th>\n",
       "      <th>risk_score_a</th>\n",
       "      <th>scaled_risk_score</th>\n",
       "      <th>total_overlaps</th>\n",
       "      <th>drug_b</th>\n",
       "      <th>clinical_phase_b</th>\n",
       "      <th>moa_b</th>\n",
       "      <th>target_b</th>\n",
       "      <th>disease_area_b</th>\n",
       "      <th>indication_b</th>\n",
       "      <th>risk_score_b</th>\n",
       "      <th>gene</th>\n",
       "      <th>scaled_risk_score_log</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>abiraterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>androgen biosynthesis inhibitor</td>\n",
       "      <td>CYP11B1|CYP17A1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>0.047161</td>\n",
       "      <td>5.104514e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>mitotane</td>\n",
       "      <td>Launched</td>\n",
       "      <td>antineoplastic agent</td>\n",
       "      <td>CYP11A1|CYP11B1|ESR1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>adrenal cortical carcinoma</td>\n",
       "      <td>0.197996</td>\n",
       "      <td>CYP11B1</td>\n",
       "      <td>-9.882800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>abiraterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>androgen biosynthesis inhibitor</td>\n",
       "      <td>CYP11B1|CYP17A1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>0.047161</td>\n",
       "      <td>6.741792e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>progesterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>progesterone receptor agonist</td>\n",
       "      <td>CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ES...</td>\n",
       "      <td>obstetrics/gynecology|endocrinology</td>\n",
       "      <td>infertility|amenorrhea</td>\n",
       "      <td>0.078474</td>\n",
       "      <td>CYP17A1</td>\n",
       "      <td>-9.604600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA1</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA2</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA3</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18737</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>1.245444e-35</td>\n",
       "      <td>15</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>carbonic anhydrase inhibitor|glutamate recepto...</td>\n",
       "      <td>CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>epilepsy|migraine headache</td>\n",
       "      <td>0.041200</td>\n",
       "      <td>SCN9A</td>\n",
       "      <td>-80.370986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18738</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.864365e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>valdecoxib</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>cyclooxygenase inhibitor</td>\n",
       "      <td>CA12|PTGS2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.033806</td>\n",
       "      <td>CA12</td>\n",
       "      <td>-9.223997</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18739</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>CACNA1G</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18740</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>CACNA1I</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18741</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>SCN5A</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>18742 rows √ó 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            drug_a clinical_phase_a  \\\n",
       "0      abiraterone         Launched   \n",
       "1      abiraterone         Launched   \n",
       "2      acamprosate         Launched   \n",
       "3      acamprosate         Launched   \n",
       "4      acamprosate         Launched   \n",
       "...            ...              ...   \n",
       "18737   zonisamide         Launched   \n",
       "18738   zonisamide         Launched   \n",
       "18739   zonisamide         Launched   \n",
       "18740   zonisamide         Launched   \n",
       "18741   zonisamide         Launched   \n",
       "\n",
       "                                                   moa_a  \\\n",
       "0                        androgen biosynthesis inhibitor   \n",
       "1                        androgen biosynthesis inhibitor   \n",
       "2                          glutamate receptor antagonist   \n",
       "3                          glutamate receptor antagonist   \n",
       "4                          glutamate receptor antagonist   \n",
       "...                                                  ...   \n",
       "18737  sodium channel blocker|T-type calcium channel ...   \n",
       "18738  sodium channel blocker|T-type calcium channel ...   \n",
       "18739  sodium channel blocker|T-type calcium channel ...   \n",
       "18740  sodium channel blocker|T-type calcium channel ...   \n",
       "18741  sodium channel blocker|T-type calcium channel ...   \n",
       "\n",
       "                                                target_a  \\\n",
       "0                                        CYP11B1|CYP17A1   \n",
       "1                                        CYP11B1|CYP17A1   \n",
       "2      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "3      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "4      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "...                                                  ...   \n",
       "18737  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18738  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18739  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18740  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18741  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "\n",
       "             disease_area_a             indication_a  risk_score_a  \\\n",
       "0                  oncology          prostate cancer      0.047161   \n",
       "1                  oncology          prostate cancer      0.047161   \n",
       "2      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "3      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "4      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "...                     ...                      ...           ...   \n",
       "18737  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18738  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18739  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18740  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18741  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "\n",
       "       scaled_risk_score  total_overlaps        drug_b clinical_phase_b  \\\n",
       "0           5.104514e-05               1      mitotane         Launched   \n",
       "1           6.741792e-05               1  progesterone         Launched   \n",
       "2           1.519970e-40              16     amoxapine         Launched   \n",
       "3           1.519970e-40              16     amoxapine         Launched   \n",
       "4           1.519970e-40              16     amoxapine         Launched   \n",
       "...                  ...             ...           ...              ...   \n",
       "18737       1.245444e-35              15    topiramate         Launched   \n",
       "18738       9.864365e-05               1    valdecoxib        Withdrawn   \n",
       "18739       9.500548e-08               3     verapamil         Launched   \n",
       "18740       9.500548e-08               3     verapamil         Launched   \n",
       "18741       9.500548e-08               3     verapamil         Launched   \n",
       "\n",
       "                                                   moa_b  \\\n",
       "0                                   antineoplastic agent   \n",
       "1                          progesterone receptor agonist   \n",
       "2                      norepinephrine reputake inhibitor   \n",
       "3                      norepinephrine reputake inhibitor   \n",
       "4                      norepinephrine reputake inhibitor   \n",
       "...                                                  ...   \n",
       "18737  carbonic anhydrase inhibitor|glutamate recepto...   \n",
       "18738                           cyclooxygenase inhibitor   \n",
       "18739                            calcium channel blocker   \n",
       "18740                            calcium channel blocker   \n",
       "18741                            calcium channel blocker   \n",
       "\n",
       "                                                target_b  \\\n",
       "0                                   CYP11A1|CYP11B1|ESR1   \n",
       "1      CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ES...   \n",
       "2      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "3      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "4      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "...                                                  ...   \n",
       "18737  CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABR...   \n",
       "18738                                         CA12|PTGS2   \n",
       "18739  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "18740  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "18741  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "\n",
       "                            disease_area_b                indication_b  \\\n",
       "0                                 oncology  adrenal cortical carcinoma   \n",
       "1      obstetrics/gynecology|endocrinology      infertility|amenorrhea   \n",
       "2                     neurology/psychiatry                  depression   \n",
       "3                     neurology/psychiatry                  depression   \n",
       "4                     neurology/psychiatry                  depression   \n",
       "...                                    ...                         ...   \n",
       "18737                 neurology/psychiatry  epilepsy|migraine headache   \n",
       "18738                                  NaN                         NaN   \n",
       "18739                           cardiology                hypertension   \n",
       "18740                           cardiology                hypertension   \n",
       "18741                           cardiology                hypertension   \n",
       "\n",
       "       risk_score_b     gene  scaled_risk_score_log  \n",
       "0          0.197996  CYP11B1              -9.882800  \n",
       "1          0.078474  CYP17A1              -9.604600  \n",
       "2          0.113536   GABRA1             -91.684713  \n",
       "3          0.113536   GABRA2             -91.684713  \n",
       "4          0.113536   GABRA3             -91.684713  \n",
       "...             ...      ...                    ...  \n",
       "18737      0.041200    SCN9A             -80.370986  \n",
       "18738      0.033806     CA12              -9.223997  \n",
       "18739      0.025678  CACNA1G             -16.169331  \n",
       "18740      0.025678  CACNA1I             -16.169331  \n",
       "18741      0.025678    SCN5A             -16.169331  \n",
       "\n",
       "[18742 rows x 18 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddr = pd.read_csv('validation data/DDR_full_net_risk_fixed.csv')\n",
    "\n",
    "ddr['scaled_risk_score_log'] = np.log(ddr.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n",
    "\n",
    "ddr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAYsAAAEXCAYAAABcRGizAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjQuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/MnkTPAAAACXBIWXMAAAsTAAALEwEAmpwYAAAm40lEQVR4nO3debxVZdn/8c9XnAccElERx8gkTUVSGzR9SENzLBPMAc0ey7Iey+oxG9Bs0Kx+j0NaVuSQQw6pOJSampZpiiYqjjggIKLigCAZyPX7474PLg5777UPnD0czvf9eu3X2ede07XXXntd677vNSgiMDMzq2WZVgdgZmbtz8nCzMxKOVmYmVkpJwszMyvlZGFmZqWcLMzMrJSTRYtI+qWk73bTvDaUNEtSn/z/XyV9rjvmnef3J0mjumt+XVjuDyS9LOmFJi3vWUkfa+a0kk6Q9Js6xuvW77SVJJ0o6fctWO7+kibn38q2zV5+T7dsqwNYGkl6FugPzAPeBh4BLgDOjYj5ABHxhS7M63MR8Zdq40TEc8CqSxb1guWdCLw7Ig4pzH+P7ph3F+PYEDgO2CgiXmz28pslIn7U6hh6kZ8Cx0TENZUGSgrgTSCAt4AHSL/ZPzQtwjbmmkXj7B0RqwEbAacA/wv8trsXImlpTfgbAjOW5kTR07+7jppsD7IRMKFknK0jYlVgc+A84CxJoyuNqKTX7EN7zQdtlYh4PSLGAiOAUZK2BJB0nqQf5PdrS7pO0muSXpH0N0nLSLqQtNO8NledvylpY0kh6UhJzwG3FsqKO5/NJN0jaaakayStlZe1i6QpxRg7mlAkDQdOAEbk5Y3Pwxc0geS4viNpkqQXJV0gafU8rCOOUZKey01I3662biStnqd/Kc/vO3n+HwNuBtbPcZxXYdqK6ywPGyjpj3m+MySdlcs3k3RrLntZ0kWS1qgS2zKSjpf0VB7/so51mIcfmmOeUeszdprniZKukPR7STOBw4tNMpJWzMNm5M91r6T+FeaznqQHJX2jZHmHS3pa0huSnpF0cGHYf0t6NA97RNKQXL5F/r5fkzRB0j6Fac6TdI6kGyTNBnaVtL6kK/O6fkbSV+pZF53i3Ccv67W87C0Kw4ZI+leO83JJf1D+3VSYT8VtU9IKkmYBfYDxkp4qiykiXo6IC4GjgW9Jeldexl8l/VDSnaRayKbq1ASpTs1skg4rbCvfLY4vaXtJ45R+p9Ml/byr669ZnCyaJCLuAaYAO1UYfFwe1o/UfHVCmiQOBZ4j1VJWjYifFKb5KLAF8PEqizwM+CywHqk57Iw6Yvwz8CPgD3l5W1cY7fD82hXYlNT8dVancT5COjIbBnyv+OPv5Exg9Tyfj+aYj8hNbnsAz+c4Dq8wbcV1pnS0ex0wCdgYGABcmqcR8GNgfdK6GwicWCW2LwP75bjWB14FfgEgaTBwDnBoHvYuYIMq8+lsX+AKYA3gok7DRpHWx8A8zy8Ac4ojSNoEuB04KyJOq7YQSauQvvM9cg33Q6RmFSR9mvS5DwP6AvsAMyQtB1wL3ASsk9fBRZI2L8z6M8APgdWAf+Txx5PW8zDgWEnVtslKcb4HuAQ4lvRd3kA6OFpe0vLAVaQj/LXyePvXmN3hVNg2I+KtXFuAVHPYrN74gGtIzfXbF8oOBY4irYNJtSbO28rZwMGk3+LqpHXV4XTg9IjoC2wGXNaF2JrKyaK5nidt9J3NJW1IG0XE3Ij4W5TftOvEiJgdEXOqDL8wIh6OiNnAd4ED1T3NBgcDP4+IpyNiFvAtYKQWrtWcFBFzImI8aUeySNLJsYwEvhURb0TEs8DPSD/EelRbZ9uTduDfyOvn3xHxd4CImBgRN+edx0vAz0nJoJIvAN+OiCkR8RZp53pA/pwHANdFxB152HeB+XXGfVdEXB0R8yt8d3NJSeLdEfF2RNwXETMLwwcDtwGjI+LcOpY1H9hS0koRMS0iOppgPgf8JCLujWRiREwCdiTtYE+JiP9ExK2kxHtQYZ7XRMSdue9tK6BfRHw/j/808GvS91qvEcD1+XuZS+pXWImU3HYk7ajPyN/xH4F7asyrnm2zS3JML7Pw7/a8iJgQEfPy8FoOAK6NiL9HxH+A75H6RDrMBd4tae2ImBURdy9urI3mZNFcA4BXKpSfBkwEbsrNBsfXMa/JXRg+CVgOWLuuKGtbn4WPpiaRftDF5pLi2UtvUrnzfe0cU+d5DagwbiXV1tlAYFJEzOs8gaT+ki6VNDU3A/2e6utkI+Cq3DTyGvAo6WSF/qR1sGD95oQ8o864a31vFwI3ApdKel7ST/LRfoeDgamkmklNOaYRpKQ3TdL1kt6bBw8EKjXFrA9M7jgJI+v8nRTj34jUVPhaYT2dwMLbQpmFtqe87Ml5mesDUzsdONVaf/Vsm12S138/Fv7dlv32OsdU3FbeZOFt5UjgPcBjudlxr8WNtdGcLJpE0gdIP4C/dx6Wj6yPi4hNSU0CX5M0rGNwlVmW1TwGFt5vSDqCeRmYDaxciKsP6cdQ73yfJ+0kivOeB0wvma6zl3NMnec1tZ6Ja6yzycCGVY4mf0T6fFvlav8hpKapSiaTmnDWKLxWjIipwDQK61fSyqQaQV2h1/hMcyPipIgYTDqy3ovUVNThRNJ6u7ieWmJE3BgRu5FqYI+Rjvo7PlulppjngYFauNO283fSecf9TKd1tFpE7FkWW6dlLtgGJIm0bjvW84Bc1mEg1XXXtlm0b55HsUbT+Ttc6DcFrFt4P41CE6WklShsKxHxZEQcRGr2OxW4Ijchth0niwaT1DcfLVwK/D4iHqowzl6S3p1/FK+TjmA7ju6mk9pfu+oQSYPzjuz7wBUR8TbwBLCipE/ko6bvACsUppsObKzqZ3lcAnxV0iaSVuWdPo5FjuRrybFcBvxQ0mqSNgK+RjraL1Vjnd1D+oGeImkVpU7jD+fJVgNmAa9LGgDU6iD+ZY5to7y8fpL2zcOuAPaS9JHcrv59uuG3JGlXSVvlRDCTlEyLR/lzgU8DqwAX1PiOOmpR++Ydz1ukz90xr98AX5e0nZJ358/5T1JN8JuSlpO0C7A37/T5dHYP8Iak/5W0kqQ+krbMB0b1ugz4hKRheXs8Lsf7D+Au0vd6jKRl8/rfvvqsumfbBJC0ltIJAb8ATo2IWjXHB0jNXctJGkpqeupwBbC3pA/lbeVECgcokg6R1C/XqF7LxfU2aTaVk0XjXCvpDdLR17dJ7eNHVBl3EPAX0g/6LuDsiLgtD/sx8J1czf96F5Z/Ialj8AVgReArkM7OAr5I2mFMJR0VFc+Oujz/nSHp/grzHZPnfQfwDPBvUkfo4vhyXv7TpBrXxXn+9ai4znIS2ht4N+nkgCmk5hiAk4AhpORyPfDHGvM/HRhLauZ6A7gb2AEgt/1/Kcc7jdT5PaXKfLpiXdLOZSap2et20rpeILd7f5LUtDKmRsJYhpR8nyc1oXyUdGYPEXE5qZP6YuAN4GpgrTzvvUknF7xM6pg9LCIeq7SAvK73ArYhbQsvk7ar1ev9wBHxOKmGd2aefm/SCR3/KXzWI0k70kNIfShvVZldd2yb45XOnJpI6tv5akR8r2Sa75Jqaq+StrGLC59vQo7hUtK2Mgt4sfAZhgMT8jJPB0bW6IdsKZX3o5qZtQdJ/wR+GRG/a3UsiyPXeF4DBkXEMy0Op0tcszCztiXpo5LWzc1Qo4D3A39udVxdIWlvSSvnJsGfAg8Bz7Y2qq5zsjDrRkr30ZpV4XVCg5ZXaVmzJFW6nqdpunE9bE46/fo1Un/GARExrbvjbbB9Sc2Bz5OaT0fWcWp823EzlJmZlXLNwszMSvXoG5lVs/baa8fGG2/c6jDMzHqU++677+WI6Fdp2FKZLDbeeGPGjRvX6jDMzHoUSVXvdeVmKDMzK+VkYWZmpZwszMyslJOFmZmVcrIwM7NSThZmZlbKycLMzEo5WZiZWSknCzMzK7VUXsFtZtYT6KTKT/WN0e13g1fXLMzMrJSThZmZlXKyMDOzUk4WZmZWysnCzMxKOVmYmVkpJwszMyvlZGFmZqWcLMzMrJSThZmZlXKyMDOzUk4WZmZWysnCzMxKOVmYmVkpJwszMyvlZGFmZqUaliwkDZR0m6RHJE2Q9D+5fC1JN0t6Mv9dM5dL0hmSJkp6UNKQwrxG5fGflDSqUTGbmVlljaxZzAOOi4jBwI7AlyQNBo4HbomIQcAt+X+APYBB+XUUcA6k5AKMBnYAtgdGdyQYMzNrjoYli4iYFhH35/dvAI8CA4B9gfPzaOcD++X3+wIXRHI3sIak9YCPAzdHxCsR8SpwMzC8UXGbmdmimtJnIWljYFvgn0D/iJiWB70A9M/vBwCTC5NNyWXVyjsv4yhJ4ySNe+mll7r3A5iZ9XINTxaSVgWuBI6NiJnFYRERQLc8mTwizo2IoRExtF+/ft0xSzMzyxqaLCQtR0oUF0XEH3Px9Ny8RP77Yi6fCgwsTL5BLqtWbmZmTdLIs6EE/BZ4NCJ+Xhg0Fug4o2kUcE2h/LB8VtSOwOu5uepGYHdJa+aO7d1zmZmZNcmyDZz3h4FDgYckPZDLTgBOAS6TdCQwCTgwD7sB2BOYCLwJHAEQEa9IOhm4N4/3/Yh4pYFxm5lZJw1LFhHxd0BVBg+rMH4AX6oyrzHAmO6LzszMusJXcJuZWSknCzMzK+VkYWZmpZwszMyslJOFmZmVcrIwM7NSThZmZlbKycLMzEo5WZiZWSknCzMzK+VkYWZmpZwszMyslJOFmZmVcrIwM7NSThZmZlbKycLMzEo5WZiZWSknCzMzK+VkYWZmpZwszMyslJOFmZmVcrIwM7NSThZmZlbKycLMzEo5WZiZWSknCzMzK+VkYWZmpZwszMyslJOFmZmVcrIwM7NSThZmZlaqS8lC0jKS+jYqGDMza0+lyULSxZL6SloFeBh4RNI3Gh+amZm1i3pqFoMjYiawH/AnYBPg0EYGZWZm7aWeZLGcpOVIyWJsRMwFoqFRmZlZW6knWfwKeBZYBbhD0kbAzEYGZWZm7WXZshEi4gzgjELRJEm7Ni4kMzNrN6XJQtLXKhS/Lum+iHig+0MyM+vddJIWKYvRrW39r6cZaijwBWBAfn0eGA78WtI3q00kaYykFyU9XCg7UdJUSQ/k156FYd+SNFHS45I+XigfnssmSjp+MT6jmZktoXqSxQbAkIg4LiKOA7YD1gF2Bg6vMd15pKTS2f+LiG3y6wYASYOBkcD78jRnS+ojqQ/wC2APYDBwUB7XzMyaqJ5ksQ7wVuH/uUD/iJjTqXwhEXEH8EqdcewLXBoRb0XEM8BEYPv8mhgRT0fEf4BL87hmZtZE9SSLi4B/ShotaTRwJ3BxvkjvkcVY5jGSHszNVGvmsgHA5MI4U3in2atS+SIkHSVpnKRxL7300mKEZWZm1ZQmi4g4GTgKeC2/vhAR34+I2RFxcBeXdw6wGbANMA34WRenrxXnuRExNCKG9uvXr7tma2Zm1Hc21IbAi8BVxbKIeK6rC4uI6YV5/Bq4Lv87FRhYGHWDXEaNcjMza5LSZAFczztXbK9Eut3H46TO6C6RtF5ETMv/7k+61xTAWFLT1s+B9YFBwD2AgEGSNiEliZHAZ7q6XDMzWzL1XJS3VfF/SUOAL5ZNJ+kSYBdgbUlTgNHALpK2ISWfZ0mn4RIREyRdRuoDmQd8KSLezvM5BrgR6AOMiYgJdX42M7OGa8drIhqhnprFQiLifkk71DHeQRWKf1tj/B8CP6xQfgNwQ5eCNDOzbtXVK7iXAYYAzzcsIjMzazv11CxWK7yfR+rDuLIx4ZiZWTuqmSzyFdSrRcTXmxSPmZm1oZrXWeRO5g83KRYzM2tT9TRDPSBpLHA5MLujMCL+2LCozMysrdSTLFYEZgD/VSgLwMnCzKyXqOc6iyOaEYiZmbWvmn0WknaVdKWkCfl1haRdmhOamZm1i6rJQtIngDGk+zd9BjiYdHHcmOJDi8zMbOlXqxnqG8B+ETG+UPaApHHAmfiqajOzXqNWM9S6nRIFABHxINC/cSGZmVm7qZUsZi/mMDMzW8rUaobaLF9f0ZmATRsUj5mZtaFayaLWs65/2t2BmJlZ+6qaLCLi9mYGYmZm7av0GdxmZmZOFmZmVqrWRXkX5r//07xwzMysHdWqWWwnaX3gs5LWlLRW8dWsAM3MrPVqnQ31S+AW0mmy95FOme0Q+PRZM7Neo2rNIiLOiIgtgDERsWlEbFJ4OVGYmfUi9dyi/GhJWwM75aI78i0/zMyslyg9G0rSV4CLgHXy6yJJX250YGZm1j7qeVLe54AdImI2gKRTgbtId541M7NeoJ7rLAS8Xfj/bRbu7DYzs6VcPTWL3wH/lHRV/n8/4LcNi8jMzNpOPR3cP5f0V+AjueiIiPhXQ6MyM7O2Uk/Ngoi4H7i/wbGYmVmb8r2hzMyslJOFmZmVcrIwM7NSpX0Wkj4JnEq6IE/5FRHRt8GxmZn1SDpp0asLYnS0IJLuU08H90+AvSPi0UYHY2Zm7ameZqjpThRmZr1bPTWLcZL+AFwNvNVRGBF/bFRQZmbWXupJFn2BN4HdC2UBOFmYmfUS9VzBfUQzAjEzaydLYyf1kqjnFuUbSLpK0ov5daWkDeqYbkwe/+FC2VqSbpb0ZP67Zi6XpDMkTZT0oKQhhWlG5fGflDRqcT+omZktvno6uH8HjAXWz69rc1mZ84DhncqOB26JiEGkR7Yen8v3AAbl11HAOZCSCzAa2AHYHhjdkWDMzKx56kkW/SLidxExL7/OA/qVTRQRdwCvdCreFzg/vz+fdAfbjvILIrkbWEPSesDHgZsj4pWIeBW4mUUTkJmZNVg9yWKGpEMk9cmvQ4AZi7m8/hExLb9/Aeif3w8AJhfGm5LLqpWbmVkT1ZMsPgscSNq5TwMOAJa40zsignRWVbeQdJSkcZLGvfTSS901WzMzo76zoSYB+3TT8qZLWi8ipuVmphdz+VRgYGG8DXLZVGCXTuV/rRLnucC5AEOHDu29pyyYWcNUOkOqt6iaLCR9MyJ+IulMKtQAIuIri7G8scAo4JT895pC+TGSLiV1Zr+eE8qNwI8Kndq7A99ajOWamfl02CVQq2bRcYuPcYszY0mXkGoFa0uaQjqr6RTgMklHApNIzVsANwB7AhNJFwAeARARr0g6Gbg3j/f9iOjcaW5mZg1WNVlExLX57ZsRcXlxmKRPl804Ig6qMmhYhXED+FKV+YwBxpQtz8zMGqeeDu5KzT5uCjIz60Vq9VnsQWoaGiDpjMKgvsC8RgdmZmbto1afxfOk/op9gPsK5W8AX21kUGZm1l5q9VmMB8ZLugqYHRFvA0jqA6zQpPjMzKwN1NNncROwUuH/lYC/NCYcMzNrR/U8z2LFiJjV8U9EzJK0cgNjMjNb6vT0C/rqqVnM7nTL8O2AOY0LyczM2k09NYtjgcslPQ8IWBcY0cigzMysvdRzb6h7Jb0X2DwXPR4RcxsblpmZtZN6ahaQEsVgYEVgiCQi4oLGhWVmZu2kNFlIGk26x9Ng0j2c9gD+DjhZmJn1EvV0cB9Aup/TCxFxBLA1sHpDozIzs7ZST7KYExHzgXmS+pKeQTGwZBozM1uK1NNnMU7SGsCvSbf9mAXc1cigzMysvdRMFpIE/DgiXgN+KenPQN+IeLAZwZmZWXuomSwiIiTdAGyV/3+2GUGZmVl7qafP4n5JH2h4JGZm1rbq6bPYAThE0rPAbNJV3BER729kYGZm1j5qPfxow4h4Dvh4E+MxM7M2VKtmcTUwJCImSboyIj7VpJjMzKzN1OqzKN5Pd9NGB2JmZu2rVrKIKu/NzKyXqdUMtbWkmaQaxkr5PbzTwd234dGZmVlbqPUM7j7NDMTMzNpXPddZmJlZL+dkYWZmpZwszMysVL1PyjMzWyrpJC30/22jbmtRJO3NNQszMyvlZGFmZqXcDGVmbatzExFAjPY1wq3gZGFmPYoTSGs4WZiZFfzgjh+0OoS25GRhZj1ed9Y2bnnmliUNZ6nkDm4zs4Kt+2/N1v23bnUYbcc1CzNbKlWqbdTj/4b/HwC7nr9rN0bT87lmYWZmpZwszMysVEuShaRnJT0k6QFJ43LZWpJulvRk/rtmLpekMyRNlPSgpCGtiNnMrDdrZc1i14jYJiKG5v+PB26JiEHALfl/gD2AQfl1FHBO0yM1M+vl2qmDe19gl/z+fOCvwP/m8gsiIoC7Ja0hab2ImNaSKM1sqXbCLSe0OoS21KpkEcBNkgL4VUScC/QvJIAXgP75/QBgcmHaKblsoWQh6ShSzYMNN9ywgaGb2dLsril3tTqEttSqZPGRiJgqaR3gZkmPFQdGROREUreccM4FGDp0qK/9N7PF8sENPgg4aXTWkmQREVPz3xclXQVsD0zvaF6StB7wYh59KjCwMPkGuczMrNv9aNiPAF9n0VnTO7glrSJptY73wO7Aw8BYYFQebRRwTX4/FjgsnxW1I/C6+yvMzJqrFTWL/sBVkjqWf3FE/FnSvcBlko4EJgEH5vFvAPYEJgJvAkc0P2Qzs96t6ckiIp4GFrnxSkTMAIZVKA/gS00IzczMqvAV3GZmVqqdrrMwM2u5Y/98bKtDaEtOFmbWcot7h9hGGD99fKtDaEtuhjIzKxi2yTCGbbJI92mv55qFmVnBd3b+DuAn5nXmmoWZmZVysjAzs1JOFmZmVsrJwszMSrmD28ys4PPXfb7VIbQlJwszs4InZjzR6hDakpuhzMwK9nrPXuz1nr1aHUbbcc3CzKzguA8eB8B1T1zX4kjai5OF9RqVbikRo/1QRbN6OFmY9QBLkuicJK07uM/CzMxKOVmYmVkpN0OZmRUcetWhrQ6hLTlZmJkVTJk5pdUhtCU3Q5mZFRz4vgM58H0HtjqMtuOahZlZwdFDjwbgsgmXtTiS9uJk0QQ+ddHMejonC7Ml4AMB6y2cLJZy3pktHq83s4U5WZi1mUqJqhnTmtXiZGG9Wld2rt4Rd492X48HXHZAq0NoS04WZmYFM+bMaHUIbcnJwno89y80Vm9bv6O2HgXA+ePPb3Ek7cXJwpZK7d7UYe3r8G0OB5wsOnOy6Gb17qSqjdeMI7ZGLLu3HX22AydEayYnC7Nu1pMTpxOQVeNkYT1KT92Z9eQEUkm930NP/oy2MCcLM7MS+2y+DyfvejLzYz7z5s/j2D8fy52T7wTgTwf/iR032JG/P/d39r5k74rTL99neS7Y7wK2W387Zrw5gxFXjGDS65P4zFaf4Rsf+saC8d7f//0M+dUQxk8fz8gtR3LCR04gCJ5/4/mmfM5anCysbfXUWkRP0Kx12xO/wz0v2nORsluevoWxj48FYKt1tuKyT1/GFr/YAoDT/nEaKy+3Mp/f7vNV53nktkfy6r9fZdCZgxjxvhGc+rFTGXnlSC5+6GIufuhiALZcZ0uuHnE146ePp4/6cPrw0xn8i8HMmDODUz92KsPfPbwBn7Z+ThZ1WtqaEcyssjnz5ixSNnvu7AXvV1l+FSLe+e3f+sytfHSjj9ac576b78uJt58IwBWPXMFZe561yDgHbXkQl064FABJCLHK8qswY84M+q7Qd3E+SrdysjAzK+i4Rfk5485ZqHy/9+7Hj4f9mHVWWYdPXPyJLs1zQN8BTH59MgBvx9u8/u/XeddK71roAsAR7xvBvpfuC8C8+fM4+vqjeejoh5j9n9k8+cqTS/KRuoWTxRJotyp2I+Jxjcp6m44HH3VOFlc/djVXP3Y1O224EyfvejK7Xbhbty1z+wHb8+bcN5nw0gQAll1mWY4eejTb/mpbnn71ac7c40x23mjnblve4nCysIZxorGe7Isf+CL/PeS/gdSPMW3WNAD+9tzf2HTNTRepGdQydeZUBq4+kKlvTKWP+rD6iqsvNO3ILUdyycOXLPh/m3W3AeDpV58G0oOYNl1z00VqNM38PfWYZCFpOHA60Af4TUSc0uKQbDG0W23MrJqz7z2bs+89G4DN1txsQfm2627LCn1W6NI9pMY+MZZRW4/i7il3c8DgA7j1mVsXDBPiwMEHstPvdlpQNnXmVAb3G8zaK6/Ny2++zG6b7cajLz/aDZ9q8fWIZCGpD/ALYDdgCnCvpLER8UhrI+t+rTwa9468uby+e45PDf4Uh73/MObOn8ucuXMYccWIBcPuOPwO3rv2e1l1+VWZ/NXJHDn2SG566iZO2uUkxj0/jmufuJbf3v9bLtz/Qp788pO8MucVRl4xcsH0O2+0M5NnTuaZ155ZUDZt1jROuv0k7jj8DubOn8uk1yZx+DWHN/MjL0LFXv12JemDwIkR8fH8/7cAIuLHlcYfOnRojBs3rntjaOEPu95k0awYK8XjHZ8tLW4bdRsAu56/a4sjKdfdB5KS7ouIoRWH9ZBkcQAwPCI+l/8/FNghIo4pjHMUcFT+d3Pg8SVY5NrAy0swfaM4rq5xXF3juLpmaYxro4joV2lAj2iGqkdEnAuc2x3zkjSuWnZtJcfVNY6raxxX1/S2uJbp7hk2yFRgYOH/DXKZmZk1QU9JFvcCgyRtIml5YCQwtsUxmZn1Gj2iGSoi5kk6BriRdOrsmIiY0MBFdktzVgM4rq5xXF3juLqmV8XVIzq4zcystXpKM5SZmbWQk4WZmZXq1clC0mmSHpP0oKSrJK1RGPYtSRMlPS7p44Xy4blsoqTjGxTXpyVNkDRf0tBC+cGSHii85kvaJg/7a46rY9g6TYxrY0lzCsv+ZWHYdpIeyuvrDEndfvVejbh2k3RfXv59kv6rMKxl6ysPa9n21SmOPxTWwbOSHsjlVb/TZpF0oqSphRj2LAyruP6aFFfF/UabrLPGbT8R0WtfwO7Asvn9qcCp+f1gYDywArAJ8BSpY71Pfr8psHweZ3AD4tqCdGHhX4GhVcbZCniq8H/VcRsdF7Ax8HCVae4BdgQE/AnYo4lxbQusn99vCUxtk/XV0u2rRrw/A75X9p02MZ4Tga9XKK+4/poYV7X9RkvXWaO3n15ds4iImyJiXv73btL1GwD7ApdGxFsR8QwwEdg+vyZGxNMR8R/g0jxud8f1aESUXYF+UF5+09QZ1wKS1gP6RsTdkbbmC4D9mhVXRPwrIjqeRzkBWEnSCt29/K7GRYu3r0pyje9A4JKycdtAtfXXFDX2G63W0O2nVyeLTj5LOvIFGABMLgybksuqlbfCCBb9Yf8uV3+/24jmnhKbSPqXpNslddw+cwBpHXVo5fr6FHB/RLxVKGvV+mrH7WsnYHpEFJ+yU+k7bbZjcnPPGElr5rJ2+h0W9xvQ2nXW0PXSI66zWBKS/gKsW2HQtyPimjzOt4F5wEXtFFeNaXcA3oyIhwvFB0fEVEmrAVcCh5KO5JsR1zRgw4iYIWk74GpJ7+vqshsQV8e07yM1F+xeKG7l+mqqOmM8iIUPPip+pxExs1mxAecAJwOR//6MtHNuuMXcbzRlnbXKUp8sIuJjtYZLOhzYCxiWm0qg9u1FuuW2I2VxlRhJp1pFREzNf9+QdDGpStrlnd/ixJWP1t/K7++T9BTwHtK6KVbRm76+JG0AXAUcFhFPFebXsvVFE7avojp+A8sCnwS2K0xT7Tvt1ts517v+JP0auC7/2/Db/yzOfqNZ66yGhq6XXt0MpfRApW8C+0TEm4VBY4GRklaQtAkwiNRR2/LbjkhahtS2fGmhbFlJa+f3y5E24ocrz6EhMfVTeuYIkjYlra+nI2IaMFPSjrmZ5zCgaUfb+SyV64HjI+LOQnlL1xftt319DHgsIhY0GVb7TpsQywK5z6vD/rzzHVVbf82Kq+J+ow3WWWO3n1b13LfDi9QxNhl4IL9+WRj2bdKZBY9TOIMH2BN4Ig/7doPi2p/U3vgWMB24sTBsF+DuTuOvAtwHPEjqyD2dBpwdUi0uUn/AhLwO7wf2LkwzlPQjfwo4i3zXgCbF9R1gduH7fQBYp9Xrq9XbV4U4zwO+0Kms6nfarBdwIfBQ/p7GAuuVrb8mxVVxv9Em66xh249v92FmZqV6dTOUmZnVx8nCzMxKOVmYmVkpJwszMyvlZGFmZqWcLMzMrJSThS3V8m2ju3TBnaTzJB3QhfG/L6nqFb9dnV8rSZrV6hisPS31t/swayRJfSLie62Oo5J81bwiYn6rY7GezzULa2uSVpF0vaTxkh6WNELSByT9I5fdI2m1XIP4m6T78+tDFebVR+nBNffmO5l+PpdL0llKD435C+kq71oxPSvpVEn3A58u1hwknSLpkTz/n1aY9uQ8fp8q815kekn9lR6yMz6/PpTLv5bXycOSjs1lG+fPcQHpyvmBkr5R+Mwn1bneldfVw0oPjxqRy5eRdLbSw39ulnRDT6k12ZJxzcLa3XDg+Yj4BICk1YF/ASMi4l5JfYE5wIvAbhHxb0mDSDdaHNppXkcCr0fEB5Sea3GnpJtID0nanPRQnf7AI8CYkrhmRMSQHNPw/PddpFt8vDciQoUnL+bhpwGrAUdEhVsn1Jj+DOD2iNg/J5lVle5qegSwA+nBUv+UdDvwKumeRKMi4m5Ju+f/t8/jjZW0c0TcUfL5PglsA2wNrA3cK+kO4MOkh/wMJiXVR+tYV7YUcM3C2t1DwG75SH4nYENgWkTcCxARMyM9iGY54NeSHgIuJ+3MOtsdOEzp0aH/BN5F2pHuDFwSEW9HeljSrXXE9YcKZa8D/wZ+K+mTQPHmlN8FVo+IL1RKFCXT/xfpdt3kGF8HPgJcFRGzI2IW8EfSMykAJkXE3YXPvDspwd4PvDd/5jIf4Z11Mh24HfhALr88IuZHxAvAbXXMy5YCrllYW4uIJyQNId0g7QdU35F/lXSzvq1JB0H/rjCOgC9HxI0LFRae7dwFsyvEOk/S9sAw4ADgGNKOHtIdQbeTtFZEvFJphiXTL25sAn4cEb9ajPmYLeCahbU1SeuTHvT0e+A0UrPLepI+kIevpvQ8htVJNY75pAcZVeoTuBE4Wum25Eh6j6RVgDuAEblPYz1g18WMdVVS7eEGUvLaujD4z8ApwPVKD1zqyvS3AEfncfrkpri/AftJWjl/hv1zWaXP/Nk8byQNkFSzTyb7G++sk36k2tc9wJ3Ap3LfRX/SXZCtF3DNwtrdVsBpkuYDc0k7TQFnSlqJ1F/xMeBs4EpJh5F2zIsc+QO/IbW33y9JwEukZ4JfRTqCfwR4DrhrMWNdDbhG0oo5xq8VB0bE5TlRjJW0Z0TMqXP6/wHOlXQk8DZwdETcJek83nmOw28i4l+SNu60zJskbQHclT4ys4BDSH08tVwFfBAYT3pS3Tcj4gVJV5JqPo+QbtN9P6n5zJZyvkW5mXWJpFUjYlbukL8H+HDuv7ClmGsWZtZV1+UztZYHTnai6B1cszCrQtJVwCadiv+3cwd5u827jmW/i9QP0tmwiJjR6OVbz+RkYWZmpXw2lJmZlXKyMDOzUk4WZmZWysnCzMxK/X8rgbbZ3oue1gAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "thr = round(np.percentile(ddr['scaled_risk_score_log'], 50),3)\n",
    "\n",
    "_ = plt.hist(ddr['scaled_risk_score_log'], bins='auto', range=(-200,0),  color ='green')\n",
    "plt.title('Distribution of scaled_risk_score_log of Drugs')\n",
    "plt.xlabel('scaled_risk_score_log')\n",
    "plt.ylabel('Fraction of Drugs')\n",
    "\n",
    "plt.axvline(thr, 0, 0.35, color = 'white', ls = '--')\n",
    "plt.text(thr+0.2,20,thr,fontdict=dict(color='white', size=10))\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "_ = plt.hist(ddr['scaled_risk_score_log'], bins='auto', range=(-200,0),  color ='purple')\n",
    "plt.title('Distribution of scaled_risk_score_log of Drugs on Log Scale')\n",
    "plt.xlabel('scaled_risk_score_log')\n",
    "plt.ylabel('log(Fraction of Drugs)')\n",
    "\n",
    "plt.axvline(thr, 0, 0.8, color = 'white', ls = '--')\n",
    "plt.text(thr+0.2,13,thr,fontdict=dict(color='white', size=10))\n",
    "\n",
    "plt.yscale('log')\n",
    "\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "interpreter": {
   "hash": "dcacb0086e9a4f4eabd41c33bf4faac5ea0a3337ed3f5eff0680afa930572c04"
  },
  "kernelspec": {
   "display_name": "Python 3.9.7 64-bit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
